

CURRICULUM VITAE

Yu Shyr, Ph.D.

PRESENT POSITION

October 1, 2021

Chair

Department of Biostatistics
Vanderbilt University Medical Center

Harold L. Moses Chair in Cancer Research

Vanderbilt University Medical Center

Director

Center for Quantitative Sciences
Vanderbilt University Medical Center

Director

Vanderbilt Technologies for Advanced Genomics Analysis and
Research Design
Vanderbilt University Medical Center

Associate Director for Quantitative Sciences

Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center

Professor

Department of Biostatistics
Vanderbilt University Medical Center

Department of Biomedical Informatics
Vanderbilt University Medical Center

Department of Health Policy
Vanderbilt University Medical Center

Associate Editor for Statistics

JAMA Oncology

Address:

Department of Biostatistics
2525 West End Avenue, Suite 1100
Vanderbilt University School of Medicine
Nashville, TN 37203

Telephone:

(615) 936-6760

Fax:

(615) 343-4924

E-mail:

yu.shyr@vumc.org

EDUCATION

1981 – 1985

B.B., Statistics
Tamkang University (Taiwan)

1987 – 1989

M.S., Statistics
Michigan State University

1989 – 1994

Ph.D., Biostatistics
University of Michigan, Ann Arbor
Dissertation: Some Aspects of Canonical Correlation Analysis

EXPERIENCE

- 1988 – 1989 **Graduate Student Teaching Assistant (GSTA)**
Department of Statistics
Michigan State University
- 1989 – 1994 **Graduate Student Research Assistant (GSRA)**
Department of Biostatistics
University of Michigan
- 1990 **Research Associate**
Institute of Gerontology
University of Michigan
- 1991 – 1992 **Research Associate**
Department of Periodontics/Prevention/Geriatrics
School of Dentistry
University of Michigan
- 1993 – 1994 **Adjunct Lecturer**
Department of Biostatistics
University of Michigan
- 1994 – 1998 **Chief Biostatistician**
Vanderbilt-Ingram Cancer Center
Vanderbilt University School of Medicine
- 1994 – 1999 **Assistant Professor of Biostatistics**
Department of Preventive Medicine
Vanderbilt University School of Medicine
- 1997 – 1998 **Consultant**
Lexicon Genetics, Incorporated
- 1997 – 2000 **Consultant**
Applied Medical Research, Incorporated
- 1998 – 2014 **Director, Biostatistics Shared Resource**
Vanderbilt-Ingram Cancer Center
Vanderbilt University School of Medicine
- 1999 – 2002 **Associate Professor of Biostatistics**
Department of Preventive Medicine
Vanderbilt University School of Medicine
- 2000 **Acting Director, Division of Biostatistics**
Department of Preventive Medicine
Vanderbilt University School of Medicine
- 2001 – 2013 **Faculty**
Center for Technology-Guided Therapy
Vanderbilt University School of Engineering
Vanderbilt University Medical Center
- 2001 – 2012 **Director, Biostatistics Core**
Lung Cancer SPORE
Vanderbilt University School of Medicine
- 2001 – present **Co-Director, Biostatistics and Bioinformatics Core**
Meharry/Vanderbilt Cancer Center Alliance Grant
Vanderbilt University Medical Center
Meharry Medical College
- 2002 – present **Director, Biostatistics and Bioinformatics Core**
GI Cancer SPORE

2003 – present
Director, Biostatistics Core
Breast Cancer SPORE
Vanderbilt University Medical Center

2003 – 2013
Professor of Biostatistics
Department of Preventive Medicine
Vanderbilt University School of Medicine

2003 – present
Professor
Department of Biostatistics
Vanderbilt University Medical Center

2003 – 2013
Ingram Professor of Cancer Research
Vanderbilt University School of Medicine

2004 – 2006
Consultant
CooperSurgical, Incorporated

2005 – 2012
Adjunct Professor
School of Medicine
Tokai University, Japan

2006 – 2017
Chief
Division of Cancer Biostatistics
Department of Biostatistics
Vanderbilt University Medical Center

2006 – 2018
Invited Professorship
Shanghai Center for Bioinformatics Technology, China

2006 – 2014
Affiliate Professor
Department of Statistics
National Chen Kung University, Taiwan

2007 – 2011
Director
Cancer Biostatistics Center
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center

2007 – 2009
Consultant
Westat, Incorporated
Rockville, MD

2009 – present
Associate Director for Quantitative Sciences
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center

2009 – 2012
Director
Statistical Center
Sentinel Node Oncology Foundation (SNOF)

2009 – 2014
Voting Member
United States Food and Drug Administration (FDA)
Anti-infective Drugs Advisory Committee: Voting member

2010 – present
Consultant
GlaxoSmithKline Oncology

2011 – 2017
Visiting Chair Professor
Department of Bioinformatics and Biostatistics
Shanghai Jiao Tong University, China

2011 – present
Director
Center for Quantitative Sciences

Vanderbilt University Medical Center

2011 – 2017 **Professor**
 Department of Cancer Biology
 Vanderbilt University School of Medicine

2011 – present **Professor**
 Department of Biomedical Informatics
 Vanderbilt University Medical Center

2012 – present **Director**
 Vanderbilt Technologies for Advanced Genomics Analysis and
 Research Design
 Vanderbilt University Medical Center

2013 – present **Harold L. Moses Chair in Cancer Research**
 Vanderbilt University Medical Center

2013 – present **Professor**
 Department of Health Policy
 Vanderbilt University Medical Center

2014 – 2019 **Director, Quantitative Sciences Shared Resource**
 Vanderbilt-Ingram Cancer Center
 Vanderbilt University Medical Center

2014 – present **Visiting Distinguished Chair Professor**
 Department of Statistics
 National Cheng Kung University, Taiwan

2014 – present **Consultant**
 Janssen Pharmaceuticals (Johnson & Johnson), Inc.

2014 – present **Consultant**
 Roche U.S. Pharmaceuticals, Inc.

2014 – 2015 **Consultant**
 ACR Biologics, LLC

2015 – present **Consultant**
 Novartis Pharmaceuticals Corporation

2015 – present **Steering Committee Member**
 Advanced Computing Center for Research Education (ACCRE)
 Vanderbilt University

2016 – present **Consultant**
 Center for Drug Evaluation and Research (CDER)
 United States Food & Drug Administration (FDA)

2017 – present **Chair**
 Department of Biostatistics
 Vanderbilt University Medical Center

2018 – present **Training Faculty Member**
 Cancer Biology Department
 Vanderbilt University School of Medicine

2019 – present **Director, Data Science Shared Resource**
 Vanderbilt-Ingram Cancer Center
 Vanderbilt University Medical Center

2020 – present **Consultant**
 Mustang Bio, Inc.

2021 – present **Chair Professor of Health Data Science**
 Taipei Medical University, Taiwan

HONORS

1. American Statistical Association Chapter Service Recognition Award, 2000.
2. Invited Keynote Speaker of Taiwan Biotechnology Symposiums, 2000.
3. Chair Professor of Statistics at Tamkang University, 2000.
4. Vanderbilt University School of Medicine Master of Science in Clinical Investigation Program Excellence in Teaching Award, 2002, 2003, 2004.
5. Endowed Professorship: Ingram Professor of Cancer Research, 2003.
6. Invited Keynote Speaker of 2003 Meeting of the Louisiana Chapter of the American Statistical Association.
7. Invited Keynote Speaker of 2008 Biostatistics and Bioinformatics Workshop in High-Dimensional Data Analysis, Taipei, Taiwan.
8. Distinguished Alumni Award of Department of Statistics, Tamkang University, 2008.
9. American Statistical Association, Fellow, 2010.
10. Invited Keynote Speaker, Japan Symposium on Innovation in Medical Research and Ethical Challenges, Tokyo, Japan, 2010.
11. Highest Rated Lecture, AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2010, 2012, 2013, 2014, 2016.
12. Invited Keynote Speaker, International Conference on Applied Statistics, Taipei, Taiwan, 2011.
13. Scientific Review Committee Award for Exceptional Service and Dedication, Vanderbilt-Ingram Cancer Center, 2011.
14. Jacek Hawiger Award for Teaching Graduate Students and Postdoctoral Fellows in the Classroom, Lecture, or SmallGroup Setting, Vanderbilt University, 2012.
15. Academy for Excellence in Teaching: Member, Vanderbilt University, 2013.
16. Harold L. Moses Chair in Cancer Research, 2013.
17. Gold Eagle Distinguished Alumni Award, Tamkang University, 2015.
18. Merrill J. Egoring Outstanding Mentor Award, AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2016.
19. American Association for the Advancement of Science (AAAS), Elected Fellow, 2016.
20. Outstanding Reviewer of *Cancer* (top 2% of reviewers), 2015-2018.
21. Outstanding Biostatistician Mentor Award, ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research, Zeist, Netherlands, 2018, 2019.
22. Mr. Chang Wen Bao Honor Lecture Award, 2018.
23. Invited Keynote Speaker, The 111th Formosan Medical Association - Taiwan Medical Week, Taipei, Taiwan, 2018.
24. Honorary Doctoral Degree, National Cheng Kung University, Tainan, Taiwan, 2018.
25. Invited Keynote Speaker, Supercomputing Asia 2019 Conference, Singapore, 2019.
26. Invited Keynote Speaker, Chinese Society of Therapeutic Radiation Oncology (CSTRO) 16th Annual Meeting, Shenzhen, China, 2019.
27. Invited Keynote Speaker, Multiomics and Precision Medicine Conference, Tainan, Taiwan, 2019.
28. Co-chairs of the North American Biostatistics Chairs Executive Committee, 2020-2021.
29. Invited Keynote Speaker, 2020 International Symposium on Application of Big Data in Prevention and Treatment of Cancer, Taiwan, 2020.

30. Invited Keynote Speaker, 2020 Annual Meeting of Taiwan Biobank Association, Taiwan, 2020.
31. Invited Keynote Speaker, The International Conference on Recent Advances in Precision Medicine and Public-Private Partnership, Taiwan, 2021.
32. Invited Plenary Sessions Speaker, AACR Annual Meeting, New Orleans, Louisiana, USA 2022.

PROFESSIONAL SOCIETIES

1. American Statistical Association (ASA)
2. American Association for the Advancement of Science (AAAS)
3. American Association for Cancer Research (AACR)
4. American Society for Clinical Oncology (ASCO)
5. European Society for Medical Oncology (ESMO)
6. International Biometrics Society (IBS)
7. Institute of Mathematical Statistics (IMS)
8. Royal Society of Medicine (RMS)
9. Society for Clinical Trials (SCT)
10. Society for Epidemiologic Research (SER)
11. International Chinese Statistical Association (ICSA)
12. International Association for the Study of Lung Cancer (IASLC)

TEACHING, WORKSHOPS, AND SEMINARS

A. At Vanderbilt

Cancer Center Seminars

1. "Statistical Power and Sample Size Calculations," 1995
2. "The Analysis of Lifetime Data," 1995
3. "Analysis of Epidemiologic and Clinical Data," 1995
4. "Fundamentals of Clinical Trials," 1995

Department of Preventive Medicine

Lectures

5. "Statistics and Epidemiology," 1995 – 1999
6. "Clinical Trials," 1998 – 2008
7. "Statistics in Medical Literature," 1999 – 2000

Seminars

8. "Statistical Issues and Analyses of a Study of the Use of Condoms in Urban, Low-Income, Minority Youth," 1994
9. "Longitudinal Analysis of Sinusoidity of Time-Qualified Data," 1996
10. "Statistical Issues and Analyses of a Study of the Risk Factors for Hospitalization in Well-Dialyzed Chronic Hemodialysis Patients," 1997
11. "Sample Size Determination for the Two-stage Design of a Phase II Cancer Clinical Trial with Correlated Unbalanced Binary Endpoints," 1998
12. "Dose Modification in a Phase II Clinical Trial with Toxicity Endpoints: Statistical Strategies for Analysis," 2000
13. "Randomized Controlled Trials," 2009, 2011 – 2012

Cancer Biostatistics Workshop, 1996 – 2001

Master of Public Health Program

Courses

14. "Clinical Trials" (MSCI 514-5504) 1996, 1998, 2000 – 2010
15. "Biostatistics I" (MPH 544-5502) 2012 – 2019

Department of Biomedical Informatics

Lectures

16. "Cluster Analysis," 2002
17. "Statistical Methods for Genomic/Proteomic Pattern studies," 2002

Seminars

18. "Analysis of RNA Expression Patterns in Human Lung Cancer Using Flexible Compound Covariate Method," 2002

Master of Science in Clinical Investigation Program

Courses

19. "Clinical Trials" (MSCI-5145504) 2003 – 2008, 2010 – present
20. "Big Data in Biomedical Research" (MSCI-5033) 2015 – present

Lectures

21. "Bioinformatics & Biostatistics in Clinical Proteomics Research," 2008

Department of Biostatistics

Seminars

22. "Weighted Flexible Compound Covariate Method for Microarray and MALDI-TOF-MS Data Analysis," 2004
23. "On Mass Spectrometry Data Preprocessing Using Mathematical Tools and Statistical Techniques," 2004
24. "Biostatistics for Regulators and Politicians: Why Statisticians Need to Be Activists?" 2010
25. "How to Consult Efficiently with Investigators – A Case Study of Clinical Trials," 2007
26. "Challenges and Opportunities for Biostatisticians: Why Biostatisticians Need to Be Activists!" 2011
27. "Emerging Methods in Biostatistics and Data Science: Prospects for the Future of Precision Medicine," 2016
28. "Analytical Challenges and Tasks for Big Data in Biomedical Research," Lightning Round Talks, 2016
29. "Stretching the Limits of Statistics: Integrative Data Science for the Precision Medicine Era," 2017
30. "Big Data, Smart Data, and Actionable Data in Precision Medicine," 2018
31. "A novel adjustment method for Cox proportional hazards model in data with long-term survival," 2019

Interdisciplinary Graduate Program

Courses

32. "Statistical Analysis for High Dimensional Data," 2005
33. "Clinical Trials," 2012 – 2013

CRC Research Skills Workshop

Seminars

34. "Clinical Trial Design," 2006, 2009 – 2010

35. "Interim Analysis in Clinical Trials," 2006
36. "Randomization in Clinical Trials," 2006

Eskind Biomedical Library Training Program

Courses

37. "Clinical Trials," 2008
38. "Advanced Data Analysis with Case Studies," 2011
39. "Advanced Statistical Bioinformatics for Omics Research," 2012
40. "Meta-Analysis," 2013

Other

41. "Using and Understanding Medical Statistics," in Department of Surgery Resident Training, 1997.
42. "Understanding, Applying, and Not Misusing the Survival Analysis Techniques in Clinical Trials," Medical Oncology Division Seminar, 1997
43. "Statistical Methods for the Analysis of Biomedical Data," Nephrology Clinical Journal Club, 1997
44. "Statistical Issues in Clinical Research," in Department of Surgery Resident Training, 2000.
45. "Statistical Cluster Analysis for Gene-Expression Profiles," in Bioinformatics Gene Expression/Proteomics Analysis Seminar, 2001
46. "An Introduction to Cluster Analysis," in Statistical Genomics: Making Sense of all the Data Workshop, 2001
47. "Statistical Class-prediction Model," in Vanderbilt-Ingram Cancer Center Seminar, 2001
48. "Statistical Methods for Health Sciences," in Nephrology Clinical Conference, 2001
49. "Fundamentals of Clinical Trials," in Nephrology Clinical Conference, 2001
50. "Statistical Issues in Data Safety and Monitoring Committee," in General Clinical Research Center (GCRC), 2001
51. "Applying Cluster Analysis in Proteomics Research," in Vanderbilt Proteomics Conference Workshop, 2002.
52. "Design, Analysis and Interpretation of Microarray Data," in Vanderbilt Clinical Pharmacology Grand Rounds, 2002.
53. "Statistical Methods for the Analysis of Microarray Data," in Nephrology Clinical Conference, 2003.
54. "Data Reduction Approaches for High Dimensional Data Derived from High Throughput Assays" in Meharry Medical College/Vanderbilt-Ingram Cancer Center 5th Annual Retreat & Mini Symposium, 2004.
55. "Data and Safety Monitoring: A Consumer's Guide," in Clinical Pharmacology Grand Rounds, 2005.
56. "A Software Package for MALDI-TOF / Microarray Data Analysis," in Cancer Proteomics & Genomics Program Seminar, Vanderbilt-Ingram Cancer Center, 2005.
57. "On Actuarial Models and Survival Analysis for Cancer Patients," in Math Club Seminar, 2005.
58. "Recent Development of Mass Spectrometry Data Processing Using Mathematical Tools and Statistical Techniques," in VICC and UABCC Spring 2005 Inter-SPORE Biostatistics/Bioinformatics Workshop, 2005.
59. "A Software Package for MALDI-TOF MS Data Preprocessing and Statistical Analysis," in Mass Spectrometry Research Center Seminar, 2005.
60. "On Mass Spectrometry Data Preprocessing in Cancer Study," in Biomath Study Group Seminar, 2005.
61. "Some Statistical Aspects of Oncology Phase II Trials," in Vanderbilt Department of Medicine Seminar, 2006.
62. "Novel Statistical Methods for Omics Research," in Lung Cancer Program Retreat, 2007.
63. "Biomathematics & Bioinformatics in Tumor Micro-Environment Research," in Vanderbilt University Tumor Micro-Environment Network (VUTMEN) Seminar, 2007.
64. "Statistical Issues in Clinical Trials," in Division of Hematology/Oncology Seminar, 2007.
65. "Randomized Clinical Trials," in Internal Medicine resident course: Taught, 2012.

66. "Bioinformatics," CQS Summer Institute: Course Director, 2014.
67. "Big Data in Biomedical Research," CQS Summer Institute: Course Director, 2015 - present.
68. "Randomized Clinical Trials," Vanderbilt Department of Medicine Clinical Investigator Toolbox, 2016.
69. "Emerging Methods in Data Science: Prospects of Precision Medicine," in Pulmonary Grand Rounds, 2017.
70. "FDA Review of Human Clinical Trials," in Introduction to Clinical and Translational Research VICTR course, 2017.
71. "Stretching the Limits of Statistics: Integrative Data Science for the Precision Medicine Era," in Biostatistics Seminar Series, 2017.
72. Statistics tutorial in the SyBBURE-Searle program, 2017.
73. Chair for Lightning Round, Vanderbilt Data Science Visions Working Group, Data Science Symposium 2018.
74. "Big Data, Smart Data, Actionable Data in Precision Medicine," in Vanderbilt University Section of Surgical Sciences, March 2018
75. "Big Data, Smart Data, Actionable Data in Precision Medicine," in Vanderbilt Diabetes Research & Training Center, March 2018
76. "Data Science and Biomedical Research," in Department of Radiology and Radiological Sciences, June 2019
77. "Overview of Dose Finding Designs for Phase I Clinical Trials," in Division of Division of Hematology and Oncology Journal Club, September, 2021.

B. At Other Universities and Institutions (Invited Talks)

1. "Computer Packages" (BIOS 511, University of Michigan). Taught, Ann Arbor, MI, 1993, 1994.
2. "Longitudinal Categorical Data Analysis Using Generalized Linear Models," Seminar given at the University of Pennsylvania, Philadelphia, PA, 1994.
3. "Some Aspects of Canonical Correlation Analysis," Seminar given at Syntex Labs, 1994.
4. "Incomplete Longitudinal Data Analysis Using Generalized Linear Models," Seminar given at Middle Tennessee State University (The Middle Tennessee Chapter of American Statistical Association), Murfreesboro, TN, 1995.
5. "Redundancy Analysis and Its Application to Canonical Analysis of More than Two Vector Variables," Seminar given at the Tamkang University, Taipei, Taiwan, 1995.
6. "The Role of the Statistician in the Medical Research," Seminar given at the Tzu Chi Medical College, and National Tung Hua University, Hualien, Taiwan, 1995.
7. "A Formula for a Missing Plot in a General Incomplete Block Design, When Recovery of Inter-block Information is Used," Seminar given at the National Cheng Kung University, Tainan, Taiwan, 1995.
8. "Statistical Strategies for Modeling the Quasi-Sinusoidality for Time-Qualified Data," Presented at the Technical University, Graz, Austria, 1999.
9. "Weighted Three-Stage Cosigner Analysis of Quasi-Sinusoidality of Time-Qualified Data," Seminar given at the Tamkang University, Taipei, Taiwan, 1999.
10. "Study Design and Statistical Issues in Clinical Trials," Clinical Trials Protocol Training Course for Bristol-Myers Squibb Inc., Princeton, Wallingford, and Brussels, 2000.
11. "Statistics with Applications to the Clinical Trials," lecture given at the Tamkang University, Taipei, Taiwan, 2000.
12. "Statistics in Modern Molecular Biology: Protein and RNA Analysis," lecture given at the Tamkang University, Taipei, Taiwan, 2000.
13. "Statistical Methods in Longitudinal Data Analysis," lecture given at the Tamkang University, Taipei, Taiwan, 2000.
14. "Clustering Methods for the Analysis of Microarray and Protein Expression Data," workshop given at the University of Alabama Comprehensive Cancer Center, Birmingham, AL, 2001.

15. "Analysis of cDNA Microarray Expression Data in Human Lung Cancer Using Statistical Class-Prediction Model," lecture given at the University of Alabama Comprehensive Cancer Center, Birmingham, AL, 2001.
16. "Statistical Methods for Analyzing the Microarray and Protein Expression Profile Data in Lung Cancer" lecture given at the University of Colorado (Lung SPORE meeting), Denver, CO, 2002.
17. "Analysis and Interpretation of Array Data," lecture given at Educational Session in 93rd American Association for Cancer Research Annual Meeting, San Francisco, CA, 2002.
18. "Analysis of RNA Expression Patterns in Human Lung Cancer Using Flexible Compound Covariate Method," lecture given at Department of Biostatistics, School of Public Health, University of Alabama, Birmingham, AL, 2002.
19. "Analysis and Interpretation of Microarray Data," lecture given at British Columbia Cancer Research Center, Vancouver, Canada, 2002.
20. "Weighted Flexible Compound Covariate Method for Classifying Microarray Data," lecture given at National Health Research Institutes, Taipei, Taiwan, 2002.
21. "Design, Analysis and Interpretation of Microarray/MALDI-TOF Data," lecture given at Taipei Veterans General Hospital, Taipei, Taiwan, 2002.
22. "Quality Filtering: Critical Appraisal and Synthesis of Biomedical Literature" continuing education lecture given at Medical Library Association annual meeting, San Diego, CA, 2003.
23. "Statistical Methods for Genomic/Proteomic Pattern Studies," lecture given at the 10th World Conference on Lung Cancer, Vancouver, Canada, 2003.
24. "Tumor Proteomic/Genomic Patterns Predict Classification and Tumor Behavior in Human Non-small Cell Lung Cancer", seminar given at Pennington Biomedical Research Center, Baton Rouge, LA, 2003.
25. "Statistical Issues in the Era of Proteomics and Genomics Research," lecture given at GI/Pancreas Inter-SPORE Meeting, Nashville, TN, 2004
26. "Statistical Issues in the Combinations of the Targeted Therapies in Lung Cancer" lecture given at Targeted Therapies for the Treatment of Lung Cancer Investigators' Meeting, San Diego, CA, 2004.
27. "Bioinformatics Tools for High Dimensional Data Analysis," seminar given at the Division of Biostatistics of the National Health Research Institutes, Taiwan, 2004.
28. "Analysis of Complex, Multivariate laboratory Data in Epidemiologic Research," lecture given at the International Epidemiology Institute Course on Molecular Epidemiology, Nashville, TN, 2004.
29. "Biostatistical Analyses of Proteomic and Microarray Data," lecture given at the International Epidemiology Institute Course on Molecular Epidemiology, Nashville, TN, 2004.
30. "Misclassification, Multiple Comparisons, and Sample Size Requirements," lecture given at the International Epidemiology Institute Course on Molecular Epidemiology, Nashville, TN, 2004.
31. "The Challenges of the Statistical Design, Analysis, and Interpretation for High Dimensional Data," lecture given at the Joint NCI-FDA Workshop on Research Strategies, Study Design and Statistical Approaches to Biomarkers Validation for Cancer Diagnosis and Detection, Washington DC, 2004.
32. "Clinical Trials," AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2004, 2005, 2006, 2007.
33. "Data Reduction Approaches for High Dimensional Data Derived from High Throughput Assays," lecture given at the International Society for Biological Therapy of Cancer 19th Annual Meeting, San Francisco, CA, 2004.
34. "Design and Analysis of Phase II Clinical Trials," lecture given at the Meharry Medical College MPH Program, Nashville, TN, 2005.
35. Recent Development of Computational Research in Quantitative Biomedical Science, A Software Package for MS MALDI-TOF Data Processing, seminar given at the EPSCOR Mini-symposium, Murfreesboro, TN, 2005.

36. "Mass Spectrometry Data Processing using wavelets," lecture given at the 2005 AMS Spring Southeastern Sectional Meeting, Bowling Green, KY, 2005.
37. "Bioinformatics Tools for Analyzing the Genomic/Proteomic Data," lecture given at the Mouse Models of Human Cancers Consortium Annual Meeting, Nashville, TN, 2005.
38. "Bioinformatics, Biostatistics and Biomarkers," lecture given at the Mathematical Biosciences Institute (MBI) Workshop - Genomics, Proteomics, and Bioinformatics - Biomarkers in Cancer Research, Columbus, OH, 2005
39. "The Statistical Challenges for Genomic/Proteomic Data Analysis," lecture given at the ICSA 2005 Applied Statistics Symposium, Washington DC, 2005.
40. "Bioinformatics/Statistics/Mathematics and High Dimensional Data - From Genomic to Proteomic Research" lecture given at Shanghai Cancer Research Center, Shanghai, China, 2005.
41. "Science of Doing Science Biostatistics/Bioinformatics," seminar given at UT Southwestern Medical Center, Dallas, TX, 2005.
42. "Conquering Colorectal Disparities: Molecular Techniques & Examples of How They Can Be Used to Address Cancer Disparities," lecture given at Meharry-Vanderbilt Alliance, Franklin, TN, 2005.
43. "MALDI TOF MS Data Processing Using Wavelets, Splines, and Statistical Techniques", AMS Sectional Meeting, Western Kentucky University, Bowling Green, Kentucky, 2005.
44. "Biostatistical and Bioinformatics Approaches in High Dimensional Data Derived from High Throughput Assays: A Consumer Guide", tutorial given at The Fourth Asia Pacific Bioinformatics Conference, National Taiwan University, Taipei, Taiwan, 2006.
45. "Statistical Challenges for Case-Cohort Study", seminar given at Danish Cancer Society, Copenhagen, Denmark, 2006.
46. "Statistical Challenges in Genomic and Proteomic Cancer Research," lecture given at the Radiation Therapy Oncology Group (RTOG) Annual Meeting, Miami, FL, 2006.
47. "Biological outcome measures in clinical trials," education session lecture given at the American Society Clinical Oncology (ASCO) Annual Meeting, Atlanta, GA, 2006.
48. "The Statistical Issues in Proteomics Data Analysis," seminar given at The University of Texas MD Anderson Cancer Center (MDACC) Bioinformatics Workshop, Houston, TX, 2006.
49. "Adaptive Trial Design and Data Analysis", seminar given at Tokai University, Japan, 2006.
50. "Clinical Trials" taught at Tokai University, Japan, 2006.
51. "A Lesson We Learn from the High Dimensional Data Generated from High Throughput Assays", seminar given at Mayo Clinic, Rochester, MN, 2006.
52. "The Statistical Challenges for Clinical Trials Design in High Dimensional Biomarkers" seminar given at Duke University, Durham, NC, 2006.
53. "The Wavelet-Based Algorithm for MALDI-TOF MS Data Pre-processing" seminar given at Department of Statistics, National Cheng Kung University, Tainan, Taiwan, 2006.
54. "Recent Development of Mass Spectrometry Data Processing Using Mathematical Tools and Statistical Techniques" seminar given at Department of Statistics, Tamkang University, Taipei, Taiwan, 2006.
55. "Multiscale Analysis and Proteomic Data Processing", (Joint Presentation w/ Dr. Don Hong), First International Conference on Computational Systems Biology, FuDan University, Shanghai, China, 2006.
56. "Introduction to Wavelets and Multiscaling Analysis", (Joint Presentation w/ Dr. Don Hong), Seminar given at the College of Sciences, Ningbo University, Ningbo, Zhejiang, China, 2006.
57. "Introduction to Wavelets and Applications in Data Analysis", (Joint Presentation w/ Dr. Don Hong), Seminar given at the Department of Mathematical Sciences, Guangxi University of Nationalities, Nanning, Guangxi, China, 2006.

58. "Wavelets and Applications in Proteomic Data Analysis", (Joint Presentation w/ Dr. Don Hong), Seminar given at the Department of Computer Informatics Science and Mathematics, Guilin University of Technology, Guilin, Guangxi, China, 2006.
59. "Multiscaling Techniques and PCA/ICA/EMD for Proteomic Data Processing and Biomarkers Discovery", (Joint Presentation w/ Dr. Don Hong), Seminar given at the Center of Artificial Intelligence and Applications, Beihang University, Beijing, China, 2006.
60. "Proteomic Data Analysis Using Wavelets and Splines", (Joint Presentation w/ Dr. Don Hong), Seminar given at the Department of Mathematics, Central Florida University, Orlando, Florida, 2006.
61. "Phase II Trial Design and Analysis" lecture given at Meharry Medical College CRECD/MSCI Program, Nashville, TN, 2006.
62. "Clinical Trials" taught at Tokai University, Isehara, Japan, 2007.
63. "Statistical Challenges in Omic Data Analysis" seminar given at Shanghai Jiaotong University Cancer Research Institute, Shanghai, China, 2007.
64. "Biomarkers Clinical Trials Design and Analysis for High-Dimensional Data," seminar given at Bioinformatics Center of Shanghai Institute of Biological Sciences (SIBS) & Chinese Academy of Sciences (CAS), Shanghai, China, 2007.
65. "Missing Data Analysis — A Case Study of Denmark Childhood Cancer Survivors Cohort," lecture given at 3rd GCCT Investigators Meeting, Nashville, TN, 2007.
66. "Wavelet Methods in Tumor Finger Prints Research", Seminar given at National Cheng Kung University, Taiwan, 2007.
67. "High Dimensional Data Analysis," taught at Tokai University, Isehara, Japan, 2007.
68. "Science of Doing Science – Bioinformatics & Biostatistics: A Lesson We Learned from Omics Research" Seminar at China Medical University School of Medicine, Taichung, Taiwan, 2008.
69. "Biostatistical and Bioinformatics Approaches in High Dimensional Data Derived from High Throughput Assays" Seminar at China Medical University Biostatistics Center, Taichung, Taiwan, 2008.
70. "Missing Data Analysis Workshop" lecture given at China Medical University Biostatistics Center, Taichung, Taiwan, 2008.
71. "Clinical Trials Workshop" lecture given at China Medical University Biostatistics Center, Taichung, Taiwan, 2008.
72. "Strategy of Multivariate Data Analysis Workshop" lecture given at China Medical University Biostatistics Center, Taichung, Taiwan, 2008.
73. "Advanced Clinical Trials Design and Analysis," taught at Tokai University, Isehara, Japan, 2008.
74. "The Challenges and Approaches in MALDI-TOF Experiment Design and Preprocessing Procedures," seminar given at Nagoya University School of Medicine, Nagoya, Japan, 2008.
75. "Novel Phase II Clinical Trials Design," lecture given at AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2008, 2009, 2010, 2011, 2012, 2013.
76. "Advanced Statistical Considerations: Things you think you can do, but..." lecture given at ASCO 44th Annual Meeting, Educational Section of Advanced Concepts in Clinical Trial Design and Methodology, Chicago, IL, May 2008.
77. "Design and Analysis of Clinical Trials — Concepts and Methodologies," seminar given at Tokai University, Isehara City, Japan, 2008.
78. "Are We Ready to be the New Sheriffs in Town? Some issues of High Dimensional Data Analysis," seminar given at Tamkang University, Taiwan, 2008.
79. "Innovative Trial Design for Biomarkers Research," seminar given at NCI Translational Science Meeting, Washington, DC, 2008.
80. "High Dimensional Data Analysis," taught at Tokai University, Isehara, Japan, 2008.

81. "Adaptive Design: A Shortcut to Personalized Medicine?" seminar given at Adaptive Design in Clinical Drug Development Conference, London, England, 2009.
82. "Challenges in Biostatistics, Bioinformatics, and Omics Research," seminar given at National Cheng Kung University, Tainan City, Taiwan, 2009.
83. "Advanced Clinical Trials Design and Analysis," taught at Tokai University, Isehara, Japan, 2009.
84. "Adaptive Design: A Shortcut to Personalized Medicine?" seminar given at Tokai University, Isehara, Japan, 2009.
85. "Advanced Statistical Considerations: Things you think you can do, but...", ASCO 45th Annual Meeting, Educational Section of Advanced Concepts in Clinical Trial Design and Methodology, Orlando, FL, 2009.
86. "Advanced Clinical Trials," two-day workshop given at FDA, 2009.
87. "Adaptive Design: A Shortcut to Personalized Medicine?" lecture given at ADAPT 2009 conference, Washington, DC, 2009.
88. "A Novel Comprehensive Wave-form MS Data Processing Method," seminar given at the 2nd International Congress of Image and Signal Processing (CISP '09)/2nd International Conference on Biomedical Engineering and Informatics (BMEI '09), Tianjin, China, 2009.
89. "Omics Era and Its Impact on Biomedical Research: Are we ready to be the new sheriffs in town?" seminar given at Shanghai Center for Bioinformation Technology, Shanghai, China, and Shanghai Jiao Tong University, Shanghai, China, 2009.
90. "High Dimensional Data Analysis," taught at Tokai University, Isehara, Japan, 2009.
91. "A Shortcut to Personalized Medicine? The power of adaptive designs," seminar given at Adaptive Design in Clinical Drug Development Conference, London, England, 2010.
92. "Adaptive Clinical Trials in the Era of Personalized Medicine," seminar given at Tsukuba University, Ibaraki, Japan, 2010.
93. "Omics Biomarkers Research: From Experimental Design to Data Analysis," lecture given at 2nd Niagara Lung Cancer Symposium, Niagara-on-the-Lake, Ontario, Canada, 2010.
94. "Quantitative Sciences Integration: Future Direction of Biomedical Research in the USA," lecture given at Tokai University School of Medicine, Isehara, Japan, 2010.
95. "High-throughput Biomarker Adaptive Design — A Shortcut to Personalized Medicine?" lecture given at Adaptive Clinical Trials Conference, Washington DC, 2010.
96. "Advanced Statistical Considerations: Things you think you can do, but...", ASCO 46th Annual Meeting, Educational Section of Advanced Concepts in Clinical Trial Design and Methodology, Chicago, IL, May 2010.
97. "Applied Biostatistics and Bioinformatics," 5-day workshop taught at Shanghai Jiao Tong University, Shanghai, China, 2010.
98. "Biostatistical Challenges in Omics Research," seminar given at National Cheng Kung University, Tainan, Taiwan, 2011.
99. "Teaching Biostatistics with Tangible and Interesting Examples," seminar given at National Cheng Kung University, Tainan, Taiwan, 2011.
100. "Design and Analysis of Translational Research," in Creating Collaborative Research Ethics Education with Costa Rica: Taught, 2011.
101. "Advanced Biostatistics," 3-day workshop taught at Kitasato University, Tokyo, Japan, 2011.
102. "US FDA case study" special lecture series at International Program for Clinical Research at Kitasato University, Tokyo, Japan, 2011.
103. "Quantitative Sciences Integration in the Era of Personalized Medicine Research," seminar given at the International Conference on Applied Statistics, Taipei, Taiwan, 2011

104. "Rigorous Quantitative Sciences Integration — the Foundation of the High-Dimensional Genomic Research," seminar given at 4th International Symposium on Cancer Metastasis and the Lymphovascular System: Basis for Rational Therapy, New York, 2011.
105. "Rigorous Trial Design and the Ethics of Drug Development — Case Studies from US FDA and Duke Medical Center," lecture given at National Yang-Ming University, Taipei, Taiwan, 2011.
106. "Rigorous Quantitative Sciences Integration — the Foundation of the Drug Approval in the Personal Genome Era," seminar given at Emerging Information and Technology Conference (EITC), University of Chicago, Chicago, IL, 2011.
107. "A Study of the Effect of Radiation Therapy on Mitochondrial DNA Mutation Using Next Generation Sequencing," seminar given at the 9th International Bioinformatics Workshop (IBW2011), Fourth Military Medical School, Xi'an, China, 2011.
108. "Advanced Biostatistics," 3-day workshop taught at Shanghai Jiao Tong University, Shanghai, China, 2011.
109. "Early Phase Cancer Clinical Trials Workshop — A Road Map for Investigator Initiated Studies," symposium and 3-day workshop taught at University of Malaya, Kuala Lumpur, Malaysia, 2011.
110. "The Use of Next-Generation Sequencing Technology to Study the Effect of Radiation Therapy on Mitochondrial DNA Mutation," seminar given at Tamkang University, Taipei, Taiwan, 2011.
111. "Rigorous Trial Design and Ethics of Drug Development," seminar given at National Tsing Hua University, Hsinchu, Taiwan, 2011.
112. "Sample Size Calculation for Differential Expression Analysis of RNA-seq Data Under Poisson Distribution," seminar given at National Cheng Kung University, Tainan, Taiwan, 2011.
113. "Advanced Biostatistics," 1-credit course taught at Tamkang University, Taipei, Taiwan, 2011.
114. "Omics Data Analysis: Present & Future — From the Era of Gigabyte Data to the Era of Petabyte Data: Are we ready for the next generation sequencing data?" seminar given at National Cancer Center of Tokyo, Japan, 2012.
115. "Omics Data Analysis: Present & Future — From the Era of Gigabyte Data to the Era of Petabyte Data: Are we ready for the next generation sequencing data?" 12th Annual Targeted Therapy of Lung Cancer Meeting, Santa Monica, CA, 2012.
116. "Methods in Cancer Research," 5-day workshop given at Al-Ahsa, Saudi Arabia, 2012.
117. "The Challenges of the High-Density Biomarker Adaptive Trials," seminar given at Adaptive Designs in Clinical Drug Development, London, England, 2012.
118. "Statistical Bioinformatics Challenges for Clinical Trial Design in the Era of High-Density Data Analysis," seminar given at AACR Annual Meeting, Chicago, IL, 2012.
119. "Advanced Biostatistics," 5-day course given at Beijing University, Beijing, China, 2012.
120. "Sample size calculation for differential expression analysis of RNA-seq data under Poisson distribution," seminar given at Indiana University Bloomington School of Informatics and Computing, Bloomington, IN, 2012.
121. "Emerging Methods of Quantitative Biology," seminar given at the Nordic Neuroendocrine Symposium, Nashville, TN, 2012.
122. "Introduction to Statistical Methods for High-Dimensional Data Analysis," seminar given at the Workshop for Chronic Disease Epidemiology and Prevention, Shanghai, China, 2012.
123. "Recent Developments of the Statistical Bioinformatics Approaches to Designing and Analyzing Sequencing Data," seminar given at the International Workshop on Cancer Systems Biology, Jilin University, Changchun, China, 2012.
124. "Novel Clinical Trial Designs in the Genomic Era," seminar given at the International Congress on Targeted Therapies in Cancer, Washington, DC, 2012.

125. "Advanced Biostatistics with R," 5-day course given at Shanghai Jiao Tong University, Shanghai, China, 2012.
126. "Adaptive Clinical Trial Design in the Era of High-Density Data Analysis," seminar given at ADAPT Congress 2012, Washington, DC. 2012.
127. "Emerging Methods of Quantitative Biology," seminar given at EITA-Bio 2012, Princeton University, Princeton, NJ, 2012.
128. "Emerging Methods of Quantitative Biology," seminar given at Moffitt Cancer Center Grand Rounds, Tampa, FL, 2012.
129. "Bioinformatics in Oncology Clinical Trials" and "Novel Phase II Design," seminars given at Talent in Oncology Programme, Munich, Germany, 2012.
130. "Emerging Methods of Quantitative Biology: What are the Statistical Challenges?" seminar given at National Cheng Kung University, Tainan, Taiwan, 2013.
131. "Novel Trial Design for Sequencing Biomarkers," seminar given at 2013 Biomarkers Summit, London, United Kingdom, 2013.
132. "Emerging Methods of Quantitative Biology" seminar given at FuDan University, Shanghai, China, 2013.
133. "Big data, Genomics, and Precision Medicine", seminar given at Ohio State University Cancer Center, Columbus, OH, 2013.
134. "Advanced Biostatistics," 3-day course given at Beijing University, Beijing, China 2013.
135. "Novel Clinical Trial Designs in the Era of High-Density Biomarker Data" presentation given at Biomarkers Summit, London, UK, 2013.
136. "Novel Phase II Design," seminars given at Talent in Oncology Programme, Amsterdam, Netherlands, 2013.
137. "Advanced Biostatistics with R," 5-day course given at Shanghai Jiao Tong University, Shanghai, China 2013.
138. "Big data and Biomedical Research: Where do we go from here", seminar given at Cancer Research and Biostatistics, Seattle, WA, 2013.
139. "Bioinformatics in Biomarker Discovery", seminar given at Taipei Veterans General Hospital, Taipei, Taiwan, 2013.
140. "Sample Size Estimation for the RNA-sequencing Data", seminar given at University of Pennsylvania, PA, 2013.
141. "Clinical Trial Designs in the Genomic Era," seminar given at 11th Annual International Congress on Targeted Therapies in Cancer, Washington, DC, 2013.
142. "Statistical Bioinformatics Challenges in the Era of Personalized Medicine in Cancer," workshop given at Roswell Park Cancer Institute, Buffalo, NY, 2013.
143. "Advanced Biostatistics," 5-day course given at Tamkang University, Taipei, Taiwan, 2013.
144. "Genomics: From Research Tool to the Lung Cancer Clinic" presentation given at 15th World Conference on Lung Cancer, Sydney, Australia, 2013.
145. "Novel Phase I Trial Designs" presentation given at 14th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2014.
146. "Advanced Biostatistics with R," 3-day course given at National Institute of Biological Sciences, Beijing, China, 2014.
147. "Insights in the Era of Personalized Cancer Therapy and Targeted Therapies: How to Progress Through Well-Conducted Phase I and II Clinical Trials", presentation given at AACR Annual Meeting, San Diego, 2014.

148. "Computational Science: Leveraging Computer Data for Large Data Sets", presentation given at Thirteenth Annual Frontiers in Cancer Prevention Research Conference, New Orleans, LA, 2014.
149. "Bioinformatics in oncology clinical trials" and "Reporting and interpreting statistics in clinical trial research," seminars given at Talent in Oncology Programme, Munich, Germany, 2014.
150. "Big Data, Genomics, and Precision Medicine", presentation given at Peking University (PKU) Big Data Brainstorm Workshop, Beijing, China, 2014.
151. "Big Data for Precision Median and Biomarker Discovery", seminar given at Albert Einstein College of Medicine, New York, NY, 2014.
152. "Emerging Methods of Quantitative Biology", seminar given at the 2nd International Symposium of Gunma University, Gunma, Japan, 2014.
153. "Statistical Challenges and Opportunities with Big Data", seminar given at University of Michigan School of Public Health, Ann Arbor, MI, 2014.
154. "Bioinformatics for Dummies", presentation given at 13th Round Asia Oncology Forum, Hong Kong, 2014.
155. "Basic Statistics", "Phase II Trial Designs", and "Phase III Trial Designs", lectures given at Methods in Clinical Research Workshop for Minority Physicians, Coral Gables, FL, 2014.
156. "Big Data, Genomics, and Precision Medicine", seminar given at Peking University, Beijing, China, 2014.
157. "Novel Phase II Trials" lecture given at AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, CO, 2014.
158. "The Challenges of the high-Density Biomarker Trials Design" presentation given at Smart Trials Conference, London, UK, 2014.
159. "Advanced Biostatistics," 4-day course given at National Cheng Kung University, Tainan, Taiwan, 2014.
160. Fifth International Workshop on Cancer Systems Biology given at Jilin University, Changchun, China, 2015.
161. "Data Science in the Era of the Precision Medicine", presentation given at the 40th Annual Congress Oncology Nursing Society (ONS), Orlando, FL, 2015
162. "Advanced Biostatistics with R," 5-day course given at Shanghai Jiao Tong University, Shanghai, China 2015.
163. "Emerging Methods of Quantitative Biology" presentation given at 12th annual International Bioinformatics Workshop (IBW), Harbin, China, 2015.
164. "Evaluating Well Designed vs Poorly Designed Randomized Trials", "Phase II trial designs in Oncology", and "Biostatistics in Clinical Trials", lectures given at Talent Oncology Program (TOP) workshop, Hong Kong, 2015.
165. "Advanced Biostatistics," 3-day course given at National Institute of Biological Sciences, Beijing, China, 2015.
166. "Big Data Analysis for the Uninitiated", presentation given at AACR Annual Meeting, Philadelphia, PA, 2015.
167. "Big Data in Top Medical Journals: Quantitative Biology for Reproducible Research and Publishing with Integrity", presentation given at Chinese Society of Clinical Oncology (CSCO) Annual Meeting, Xiamen, China, 2015.
168. "Big Challenges of Big Data: Biomedical Science in the Petabyte Era", presentation give at Pacific Rim Cancer Biostatistics Conference, Seattle, WA, 2015.
169. "Data Science in the Era of the Precision Medicine", seminar given at Osaka University School of Medicine, Osaka, Japan, 2015.

170. "Phase III Trials", "Phase II Trials", and "Statistical Considerations in Clinical Trials", lectures given at Methods in Clinical Research Workshop for Minority Physicians, Los Angeles, CA, 2015.
171. "Statistical Considerations in Protocol Development: From Hypothesis to Analysis" lecture given at AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, CO, 2015.
172. "Bioinformatics in Oncology Clinical Trials", and "Biomarkers in Clinical Trials: Statistical Considerations in Design and Evaluation", lectures given at Talent Oncology Program (TOP) workshop, Singapore, 2015.
173. "Data Tsunami as a Limiting Step in Using the All Omics Approach", presentation given at European Society for Medical Oncology (ESMO) Asia Annual Meeting, Singapore, 2015.
174. "Big Data, Genomics and Precision Medicine in Oncology Research," Novel Phase I and Phase II Clinical Trial Designs," Statistics 101," "Important Statistics You Need to Know for Clinical Trials," The Challenges of High-Density Biomarker Adaptive Trials," talks given at the Canadian Oncology Resident Education at the Canadian Lung Cancer Conference, Vancouver, British Columbia, 2016.
175. "Novel Phase I and Phase II Clinical Trial Designs," BC Cancer Agency Research Conference, Vancouver, British Columbia, 2016
176. "Important Statistics You Need to Know for Clinical Trials," Canadian Oncology Resident Education at the Canadian Lung Cancer Conference, Vancouver, British Columbia, 2016.
177. "Big Data, Omics, and Precision Medicine in Cancer Research," Chinese Society of Gynecology Oncology Annual Meeting, Beijing, China, 2016.
178. "Clinical Trials Design Methods," two-part lecture given at the AACR Annual Meeting, New Orleans, LA, 2016.
179. "Basic Biostatistics," "Phase II Clinical Trials," Phase III Clinical Trials," three-day lecture given at the Roswell Park Cancer Institute: Methods in Clinical Research Workshop, 2016.
180. "The BETRNet Virtual Repository: A Key Network Resource for Collaboration," Barrett's Esophagus Translational Research Network (BETRNet) Steering Committee Meeting, Rockville, Maryland, 2016.
181. "Advanced Biostatistics with R," 5-day course given at Shanghai Jiao Tong University, Shanghai, China 2016.
182. "Novel Phase II Trials," lecture given at AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, CO, 2016.
183. "Big Data, Omics, and Precision Medicine in Cancer," keynote lecture at 2nd International Conference on Translational Cancer Research, Tianjin, China, 2016.
184. "Biostatistics in Clinical Trials," presentation given at Ta Talent in Oncology Programme lent in Oncology Programme (TOP) Asia Fundamentals Meetings, Taipei, Taiwan, 2016.
185. "Evaluating Well-Designed vs. Poorly-Designed Randomized Trials," presentation given at Talent in Oncology Programme (TOP) Asia Fundamentals Meetings, Taipei, Taiwan, 2016.
186. "Statistical Aspects of Omics Data Analysis Using the Random Compound Covariate," talk given at the 75th Annual Meeting of Japanese Cancer Association (JCA): Breakthroughs in Cancer Treatment: Collaboration of Basic Translational and Clinical Research, Tokyo, Japan, 2016.
187. "Advanced Biostatistics," five-day lecture given at National Cheng Kung University, Tainan, Taiwan, 2016.
188. "Biostatistics for Young Scientists," lecture given at Roche Young Scientist's Form, Hong Kong, China, 2017
189. "Statistics in Oncology: Navigating Clinical Trials and Putting Data into Practice," lecture given at McGill University Visiting Speakers in Oncology Program, Quebec, Canada, 2017
190. "Should the anti-cancer drugs be approved based on the non-randomized single-arm trials?" lecture given at 17th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, 2017

191. "Big Data, Omics, and Precision Medicine," lecture given at AACR Annual Meeting, Meet-The-Experts Session, Washington, DC, 2017
192. "How to Interpret the Omics Big Data and Apply to the Clinical Practice," lecture given at the Global Breast Cancer Conference, Jeju Island, South Korea, 2017
193. "Advanced Biostatistics," 5-day lecture given at National Cheng Kung University, Tainan, Taiwan, 2017.
194. "Advanced Biostatistics with R," 5-day course given at Shanghai Jiao Tong University, Shanghai, China 2017.
195. "Bioinformatics in oncology: principles and application to trials for targeted agents," presentation given at Talent in Oncology Programme (TOP) Asia Fundamentals Meetings, Guangzhou, China, 2017.
196. "Biostatistics: Statistical Controversies and Challenges in Reporting Clinical Trials," presentation given at Talent in Oncology Programme (TOP) Asia Fundamentals Meetings, Guangzhou, China, 2017.
197. "Big Data, Omics, and Precision Medicine," presentation given at Institute of Genetics and Molecular and Cellular Biology (IGBMC), Strasbourg, Switzerland, 2017.
198. "Common Statistical Errors and Mistakes in Cancer Research: How to Avoid Them," lecture given at American Association for Cancer Research (AACR) Annual Meeting, Chicago, IL, 2018.
199. "Big Data, Smart Data, and Actionable Data in Precision Medicine," lecture given at American Association for Cancer Research (AACR) Annual Meeting, Chicago, IL, 2018.
200. "Big Data, Smart Data, and Actionable Data in Precision Medicine," lecture given at Taiwan Breast Cancer Consortium and German Breast Group Joing Meeting, Taipei, Taiwan, 2018.
201. "Identifying Actional Targets – Bioinformatics," lecture given at European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 2018.
202. "Big Data, Smart Data, and Actionable Data in Precision Medicine," lecture given at Fu Jen Catholic University, Taipei, Taiwan, 2018.
203. "Debate: Which is most important efficacy endpoint in first line trials in advanced NSCLC PFS or OS - Point of View." IASLC 19th World Conference on Lung Cancer. Toronto, ON, 2018.
204. "Shaping the Future of Precision Medicine and Healthcare," lecture given at the 3rd International Symposium on Translational Cancer Research, Tianjin, China, 2018.
205. "Data Science in the Precision Medicine Era: Will Statisticians Lead or Follow?" lecture given at Department of Biostatistics, Columbia University, New York, 2018.
206. "Bayesian 101," and "Bayesian Design - Challenges and prospects," lectures given at Paul Carbone Academy, Taipei, Taiwan, 2018.
207. "REDCap and Open Science," lecture given at Natinal Cheng Kung University, Tainan, 2018.
208. "Power in multiple testing: Sample size calculations for differential expression analysis of RNA-seq data." Lecture given as part of Sample Size and Power Workshop for Basic, Translational, and Clinical Studies, AACR Annual Meeting, Atlanta, GA, 2019.
209. "Data Science: Shaping the Future of Precision Medicine and Healthcare," lecture gibven at Investigators' and Site Coordinators' Opportunity for Research Excellence (I-SCORE) meeting, Rockville, MD, 2019.
210. "Big Dacta, Omics and Precision Medicine," lecture given at Investigators' and Site Coordinators' Opportunity for Research Excellence (I-SCORE) meeting, Rockville, MD, 2019.
211. "Data science in the precision medicine era: Will statisticians lead or follow?" lecture given at 3rd Pacific Rim Cancer Biostatistics Conference, Portland, OR, 2019.
212. "From BioVU to All of Us: Shaping the future of precision medicine and healthcare," lecture given at Beijing Summit on Data Science in Health, Beijing, China, 2019.

213. "Complex Innovative Design," lecture given at 2019 ESMO Targeted Anticancer Therapies Congress, Paris, France, 2019.
214. "AI, Machine Learning, and Novel Statistical Methods in Cancer Research," lecture given at Osaka University, Osaka, Japan, 2019.
215. "Big Data, Smart Data, and Actionable Data: Shaping the Future of Precision Medicine and Healthcare," lecture given at Tokyo University, Tokyo, Japan, 2019.
216. "Clinical Trial Design Workshop 2019," workshop given at Thai Society of Clinical Oncology (TSCO), Phetchaburi, Thailand, 2019.
217. "Biostatistics for the Practicing Oncologist," lecture given at Thai Society of Clinical Oncology (TSCO) annual meeting, Phetchaburi, Thailand, 2019.
218. "AI, Machine Learning, and Novel Statistical Methods in Biomedical Research," lecture given at National Taiwan University, Taipei, Taiwan, 2019.
219. "From All of Us to Amazon Care - The Future of the Precision Medicine," lecture given at 2019 Multiomics and Precision Medicine Conference, Tainan, Taiwan, 2019.
220. "Bioinformatics: The Basics," lecture given at 2019 World Conference on Lung Center (WCLC), Barcelona, Spain, 2019.
221. "Data Science in the Precision Health Era: Will Statisticians Lead or Follow?" lecture given at University of Pennsylvania Department of Biostatistics, Epidemiology and Informatics, virtual seminar, 2020.
222. "scKWARN: Kernel-Weighted-Average Robust Normalization for Single-Cell RNA-seq Data," lecture given at Department of Biostatistics, SUNY at Buffalo, virtual seminar, 2020.
223. "Current Use of RWD for Evidence Generation- Academia Perspectives," lecture given at 2020 Asia Oncology Day, virtual conference, 2020.
224. "RWE generation in 21st Century- opportunities and barriers," lecture given at 2020 Asia Oncology Day, virtual conference, 2020.
225. "Impact of COVID-19 on Data Science and Precision Medicine," lecture given at 2020 International Symposium on Application of Big Data in Prevention and Treatment of Cancer, virtual conference, 2020.
226. "Biobank Data in Digital Healthcare: Lessons Learned from the US, UK, Sweden, and Denmark," lecture given at 2020 Annual Meeting of Taiwan Biobank Association, virtual conference, 2020.
227. International Association for the Study of Lung Cancer (IASLC) Targeted Therapies of Lung Cancer. Santa Monica, CA, virtual conference, 2021.
228. "Current use of RWD for Evidence Generation", lecture given at 2021 Lung Cancer Precision Diagnosis and Treatment Forum, virtual conference, 2021.
229. "The Core Aspects and Challenges in Clinical Trials Design of Precision Immunotherapy", lecture given at 2021 Lung Cancer Precision Diagnosis and Treatment Forum, virtual conference, 2021.
230. "Common Statistical Errors in Medical Manuscript"
231. "A Simple Yet Powerful Method to Correct Misinterpretation of Clinical Trial Results with Long-term Survival", lecture given at Fiona and Stanley Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center 2021.
232. "Immunotherapy Clinical Trials: Design and Endpoints", lecture given at 2021 GOG Foundation Symposium - Cancer Immunotherapy: Successes, Challenges and New Frontiers, virtual conference 2021.
233. "Optimal Strategies for Designing Clinical Trials of Patients with Rare Mutations", lecture given at Diamond Talk, virtual conference, 2021.

234. “The Next Chapter of Precision Health: Leveraging and Integrating Real-World, Clinical, Omics, and Social Behavioral Data”, lecture given at The International Conference on Recent Advances in Precision Medicine and Public-Private Partnership, Taiwan, 2021.

C. Web-Based Courses

1. “Basic Study Design in Clinical Trials,” Bristol-Myers Squibb Protocol Training Course, 2002. <http://www.midicorp.com/extranet/frameset.html>
2. “Bias Reduction in Clinical Trials,” Bristol-Myers Squibb Protocol Training Course, 2002. <http://www.midicorp.com/extranet/frameset.html>
3. “Trial Setup/Monitoring Considerations in Clinical Trials,” Bristol-Myers Squibb Protocol Training Course, 2002. <http://www.midicorp.com/extranet/frameset.html>
4. “Fundamentals of Clinical Trials,” American Society of Clinical Oncology University Course, 2014, 2015. <http://university.asco.org/fundamentals-clinical-trials.html>
5. “Adaptive Clinical Trials,” Henry Steward Talks, Russell House London, United Kingdom, 2016.
6. “Adaptive Clinical Trials: Future Directions,” Henry Steward Talks, Russell House London, United Kingdom, 2016.
7. “Biostatistics,” American Society of Clinical Oncology (ASCO), 2016. <https://registrar.asco.org/Users/ActivityHomePage.aspx?ProductID=5518>

D. Mentoring

1. Ayumi Shintani, Department of Biostatistics, Vanderbilt University School of Medicine, faculty mentor, 2001 – 2007.
2. Dercherg Lo, Department of Economics, Vanderbilt University College of Arts and Sciences. PhD committee, 2003 – 2005.
3. Judith Dexheimer, Department of Bioinformatics, Vanderbilt University School of Medicine, PhD committee, 2006 – 2011.
4. Fei Ye, Department of Biostatistics and Epidemiology, University of South Carolina. MS committee, 2004. PhD committee, 2004 – 2007.
5. Elizabeth Kanter, Department of Biomedical Engineering, Vanderbilt University School of Medicine. PhD committee, 2005 – 2008.
6. Debbie Wujcik, Department of Nursing, University of Utah. PhD committee, 2005 – 2008.
7. Mark Harris, Department of Mathematics and Cancer Biology, Vanderbilt University School of Medicine, PhD committee, 2008 – 2009.
8. Stephen Turner, Division of Human Genetics, Vanderbilt University School of Medicine, PhD committee, 2008 – 2010.
9. Dr. Terri Ni, Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University School of Medicine, faculty mentor, 2003 – 2009.
10. Dr. Andrew Yi, Division of Genetic Medicine, Vanderbilt University School of Medicine, faculty mentor, 2007 – present.
11. Dr. Joshua Smith (M.D.), Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, PhD Committee, 2009 – 2010.
12. Benjamin Grady, Division of Human Genetics, Vanderbilt University School of Medicine, PhD qualifying exam committee, 2009; PhD committee, 2009 – present.
13. Zeqiang Ma, Department of Biomedical Informatics, Vanderbilt University School of Medicine, PhD committee, 2010 – present.

14. Olivia Veatch, Division of Human Genetics, Vanderbilt University School of Medicine, PhD qualifying exam committee, 2010.
15. Emily Holzinger, Division of Human Genetics, Vanderbilt University School of Medicine, PhD qualifying exam committee, 2010.
16. Dr. Mayur Patel (M.D.), Division of Trauma and Surgical Critical Care, Vanderbilt University School of Medicine, fellow mentoring committee, 2011 – 2017.
17. Dr. Bingshan Li, Ph.D., Division of Human Genetics, Vanderbilt University School of Medicine, faculty mentor, 2012 – 2018.
18. Dr. Carlos Lopez, Ph.D., Department of Cancer Biology, Vanderbilt University School of Medicine, faculty mentor, 2012 – present.
19. Dr. Qi Liu, Ph.D., Department of Biomedical Informatics, Vanderbilt University School of Medicine, faculty mentor, 2012 - present.
20. Isaac Pence, Ph.D., Candidate. Department of Biomedical Engineering, Vanderbilt University School of Engineering, dissertation committee, 2013 – present
21. Dr. Yan Guo, Ph.D., Department of Cancer Biology, Vanderbilt University School of Medicine, faculty mentor, 2013 – present.
22. Dr. Michelle Ormseth, M.D., M.S.C.I., Department of Rheumatology, Vanderbilt University School of Medicine, faculty mentor, 2014 – present.
23. Dr. Quanhu Sheng, Ph.D., Department of Cancer Biology, Vanderbilt University School of Medicine, faculty mentor, 2014 – present.
24. Xue Zhong, Department of Biostatistics, Vanderbilt University School of Medicine, MS advisor, 2014 – 2015.
25. Dr. Xiao Dong, Department of Genetics, Cell Biology and Development, University of Minnesota, Twin Cities, K99 mentor, 2014-2020
26. Dr. Alicia K. Morgans, M.D., Division of Hematology/Oncology Vanderbilt University School of Medicine, faculty mentor, 2015 – present
27. Dr. Anthony Daniels, M.D., M.Sc., Department of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, co-mentor, 2016 – present
28. Dr. Danxia Yu, Ph.D., Department of Epidemiology, Vanderbilt University School of Medicine, faculty mentor, 2016-present.
29. Dr. Derek Smith, Ph.D., Department of Biostatistics, Vanderbilt University School of Medicine, Ph.D. advisor, 2017 – present
30. Jun Qian, College of Basic and Applied Sciences, Middle Tennessee State University, MS mentor, 2017.
31. Dr. Ryan Hsi, M.D. Department of Urologic Surgery, Vanderbilt University Medical Center. Faculty mentor 2017 – present

ACADEMIC SERVICE

A. Have refereed papers for the following journals

1. *Science*
2. *New England Journal of Medicine*
3. *Journal of American Statistical Association*
4. *Bioinformatics*
5. *Communications in Statistics*
6. *Biometrical Journal*

7. *American Medical Informatics Association*
8. *Information Sciences: An International Journal*
9. *Cancer* (**Editorial Board Member**)
10. *Cancer Research*
11. *Southern Medical Journal*
12. *Arteriosclerosis, Thrombosis, and Vascular Biology*
13. *International Chinese Journal of Dentistry* (**Editorial Board Member**)
14. *Clinical Pharmacology and Therapeutics*
15. *Journal of Concrete and Applicable Mathematics* (**Guest Editor with Prof. Don Hong**)
16. *BMC Bioinformatics*
17. *Clinical Cancer Research* (**Editorial Board Member**)
18. *Technology in Cancer Research and Treatment*
19. *Proteomics*
20. *Proceedings of the National Academy of Sciences*
21. *Cancer Prevention Research Journal* (**Editorial Board Member**)
22. *Computational Statistics and Data Analysis*
23. *Journal of Applied Statistics*
24. *Biological Procedures Online* (**Editorial Board Member**)
25. *Clinical Trials*
26. *Journal of Clinical Oncology*
27. *Carcinogenesis*
28. *Science Translational Medicine*
29. *Proteomics — Clinical Applications*
30. *Dataset Papers in Medicine*
31. *PLoS ONE* (**Statistical Advisory Board Member**)
32. *Journal of Thoracic Oncology* (**Associate Editor**)
33. *Journal of Computational Systems Biology* (**Editorial Board Member**)
34. *Journal of Nuclear Medicine* (**Editorial Board Member**)
35. *JAMA Oncology* (**Associate Editor**)
36. *Quantitative Biology* (**Editorial Board Member**)
37. *JNCI* (**Editorial Board Member**)
38. *JNCI Cancer Specturm* (**Editorial Board Member**)
39. *Nature Communications*
40. *Translational Cancer Research* (**Editorial Board Member**)

B. American Statistical Association

1. International Science and Engineering Fair (ISEF): Special Awards Judge for American Statistical Association, 1997.
2. Mid-Tennessee Chapter: Council Representative, 1998 – 1999.

3. Mid-Tennessee Chapter: President, 1999.
4. Council of Chapter Office: Vice Chair Candidate, 2001.
5. Council of Chapters Governing Board: Vice Chair, 2002 – 2004.
6. Council of Chapters Nominations Committee: Member, 2004 – 2005.
7. Council of Chapters: Candidate for Chair Elect Position, 2010.

C. Society for Epidemiologic Research

8. Annual Meeting Abstracts Reviewer, 1997.
9. Annual Meeting Abstracts Reviewer, 1998.
10. Annual Meeting Abstracts Reviewer, 1999.

D. National Cancer Institute

11. NCI Study Section Special Emphasis Panel (ZCA1 SRRB-X (CC)): Member, 1999.
12. NCI Subcommittee D-Clinical Studies Review Panel (P01-CA72008-04): Member, 2000.
13. NCI Subcommittee E-Cancer Epidemiology, Prevention & Control Studies Review Panel (P01-CA88961-01): Member, 2000.
14. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (University of Wisconsin, Madison): Member, 2000.
15. NCI Subcommittee E-Cancer Epidemiology, Prevention & Control Studies Review Panel (NCI-E GRB-R(Y)): Member, 2001.
16. NCI Subcommittee C-Basic and Preclinical Review Panel (NCI-C GRP-P (Q2)): Member, 2001.
17. NCI 9th SPORE Investigators' Workshop: Invited Speaker, 2001.
18. NCI Lymphoma Specialized Programs of Research Excellence (SPORE) Review Panel: Member, 2002.
19. NCI Lung SPORE Annual Meeting, Denver, Colorado, Session of Methods of Array Analysis: Chair, 2002.
20. NCI PO1-CA096888-01C4 "Molecular Gene and Radiation Therapies for Cancer" site visit reviewer: Member, 2002.
21. NCI Special Emphasis Panel of Biology and Transplantation of Human Stem Cell (ZCA1 GRB-W(01)): Member, 2002.
22. NCI Subcommittee E-Cancer Epidemiology, Prevention & Control Review Panel (NCI-E GRB-P (K2)): Member, 2002.
23. NCI Subcommittee C — Basic & Preclinical Review Panel (NCI-C GRB-P (K1)): Member, 2002.
24. NCI PO1-CA100336-01 Review Panel "Molecular Targets in Prostate Cancer": Member, 2002.
25. NCI Pancreatic Specialized Programs of Research Excellence (SPORE) Review Panel: Member, 2003.
26. NCI PO1 CA 104668-01 Review Panel "Mechanism-Based Approach for the Management of Prostate Cancer" (NCI-C GRB-P (X8)): Member, 2003.
27. NCI Ovarian & Breast Specialized Programs of Research Excellence (SPORE) Review Panel: Member, 2003.
28. NCI PO1 CA 104106-01 Review Panel "Signaling and Progression in Prostate Cancer" (NCI-C GRB-R (C2)): Member, 2003.

29. NCI Leukemia & Lymphoma Specialized Programs of Research Excellence (SPORE) Review Panel: Member, 2003.
30. NCI Developmental Therapeutics Study Section: Member, 2003 – 2008.
31. NCI UO1 CA 107948-01 Review Panel “The Pediatric Brain Tumor Consortium” (NCI – ZCA1 GRB-F (J1)): Member, 2003.
32. NCI Subcommittee D — Clinical Studies PO1 CA112359-01 Review Panel “New Approaches to the Treatment of Neuroblastomas” (NCI-D RPRB (S3)): Member, 2004.
33. NCI Subcommittee A — Cancer Centers review panel (NCI-A RTRB-Z (E1)), 2004.
34. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (University of Pennsylvania Comprehensive Cancer Center): Member, 2004.
35. NCI GI/Pancreas Inter-SPORE Meeting: Section of Data Analysis: Chair, Nashville, TN, 2004.
36. NCI GI/Pancreas Inter-SPORE Meeting: Invited Speaker, Nashville, TN, 2004
37. NCI Clinical Oncology Study Section: Ad Hoc Member, 2005.
38. NCI Specialized Programs of Research Excellence (SPORE) in Ovarian — GYN Cancer Review panel: Member, 2005.
39. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (University of Colorado Comprehensive Cancer Center): Member, 2005.
40. NCI Etiologic and Early Marker Studies (EEMS) Review Panel: Member, 2005 – present.
41. NCI Avon Breast Cancer Research Review Panel: Member, 2005.
42. NCI PO1 Experimental Therapeutics Cluster Review Panel: Member, 2005.
43. NCI ZCA1 GRB-S (01) Centers of Cancer Nanotechnology Excellence (CCNE). National Cancer Institute Special Emphasis Panel: Member, 2005.
44. NCI ZRG1 ONC-J (02) M: COX-2 Inhibition of T-Cells in Human Lung Cancer. Center for Scientific Review Special Emphasis Panel: Member, 2005.
45. NCI Translational Research Workshop Group (TRWG): Invited Speaker, 2006.
46. NCI Intramural Program: Biostatistics Branch Review Panel: Member, 2006.
47. NCI SPORE Breast Cancer Research Review Panel: Member, 2006.
48. NCI Avon Breast Cancer Research Review Panel: Member, 2006.
49. NCI Special Emphasis Panel (SEP) L30 and L40: Member, 2006 – 2009.
50. NCI Discovery and Development Special Emphasis Panel (SEP): Member, 2006 – 2007.
51. NCI Specialized Programs of Research Excellence (SPORE) Standing Special Emphasis Panel (SEP): Member, 2007 – present
52. NCI Workshop on Implementation of Biomarkers Evidence in Translational Research Organizing Committee: Member, 2007.
53. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (Kimmel Cancer Center at Thomas Jefferson University): Member, 2007.
54. NCI Avon Progress for Patients Blue Ribbon Panel Advisory Board: Member, 2007.
55. NCI/NIH Cancer Genome Atlas (TCGA) Data Portal Use Workshop: Invited participant, 2008.
56. NCI Special Emphasis Panel on Comprehensive Systems Genetics of Cancer: Member, 2008.
57. NCI P01 Molecular Oncology Special Emphasis Panel: Member, 2008.
58. NCI Translational Science Meeting: Invited Speaker, 2008.
59. NCI Subcommittee J — Population and Patient-Oriented Training Study Section: Member, 2008 – 2009.

60. NCI ZCA1 RTRB-2 Career Development Awards Panel: Member, 2008.
61. NCI P01 Molecular Oncology (Basic, Translational, and Clinical Studies) Special Emphasis Panel: Member, 2009.
62. NCI P01 Molecular Oncology (Basic, Translational, and Clinical Studies) Special Emphasis Panel: Member, 2010.
63. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (Pennsylvania State Cancer Center): Member, 2010.
64. NCI SBIR Phase II, Integrating patient-reported outcomes in hospice and palliative care practices, Study section: Chair, 2010.
65. NCI LRP Review Panel: Member, 2011.
66. NCI Cancer Diagnostics and Treatments SBIR/STTR review panel: Member, 2011.
67. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (Maryland Greenebaum Cancer Center): Member, 2011.
68. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (University of Virginia Cancer Center): Member, 2011.
69. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (Johns Hopkins Kimmel Cancer Center): Member, 2011, 2016.
70. NCI P01 ZCA1 GRB-T (M1) Special Emphasis Panel: Member, 2012.
71. NCI P30 Cancer Center Support Grant (CCSG) Review Panel (New York University Cancer Institute): Member, 2012.
72. NCI P30 Cancer Center Support Grant (CCSG) Review Panel (Kimmel Cancer Center at Thomas Jefferson University): Member, 2012.
73. NCI P30 Cancer Center Support Grant (CCSG) Review Panel (University of Chicago Comprehensive Cancer Center): Member, 2012.
74. NCI Cancer Immunopathology and Immunotherapy (CII) Study Section: Member, 2013-2017.
75. NCI P30 Cancer Center Support Grant (CCSG) Review Panel (Fred Hutchinson/University of Washington Consortium): Member, 2014.
76. NCI P30 Cancer Center Support Grant (CCSG) Review Panel (University of Texas Health Science Center at San Antonio (UTHSCSA)): Member, 2014.
77. NCI P30 Cancer Center Support Grant (CCSG) Review Panel (Cold Spring Harbor Laboratory Cancer Center): Member, 2016
78. NCI P30 Cancer Center Support Grant (CCSG) Review Panel (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University): Member, 2016.
79. NCI ZCA1 RPRB-N (O)1 Special Emphasis Panel; SPORE Review: Member, 2017.
80. NCI P30 Cancer Center Support Grant (CCSG) Review Panel (The Hawaii Cancer Center): Member, 2018.
81. NCI Specialized Programs of Research Excellence (SPORE) Standing Special Emphasis Panel (SEP): Member, 2020.
82. NCI P30 Cancer Center Support Grant (CCSG) Review Panel (University of Pennsylvania Comprehensive Cancer Center): Member, 2020.
83. NCI Developmental Therapeutics (DT) study section: Member, 2021.
84. NCI P30 Cancer Center Support Grant (CCSG) Review Panel (Wake Forest Baptist Medical Center Comprehensive Cancer Center): Member, 2021.

E. Other

1. VICC Clinical Breast Cancer Journal Club: Statistical Commentator, 1998 – present.
2. Vanderbilt University Chinese Student Association: Advisor, 1998 – 2002.
3. 1998 Chinese Youth Goodwill Mission from Taiwan: Co-sponsor, 1998.
4. NIH SRA, MEP Study Section Special Emphasis Panel (ZRG1-MEP-04S): Member, 1999.
5. U.S. Army Medical Research and Materiel Command (USAMRMC) Breast Cancer Research Program (BCRP): Scientist Reviewer, Epidemiology, 1999.
6. International Biometric Conference, Berkeley, California, Section of Correlated Binary Data: Chair, 2000.
7. Vanderbilt University School of Medicine Admission Interview Process: Faculty Interviewer, 2000 – 2001.
8. Joint Statistical Meetings Invited Sessions Program: Section on Statistical Consulting: Organizer, 2001.
9. Joint Statistical Meetings Invited Sessions Program: Invited Speaker, 2001.
10. International Chinese Statistical Association: Section on Recent Statistical Research in Cancer Studies: Invited Speaker, Philadelphia, PA, 2002.
11. American Association for Cancer Research (AACR): Education Session of Array and Gene Expression: Invited Speaker, San Francisco, CA, 2002.
12. International Association for the Study of Lung Cancer: Symposium of Molecular Taxonomy of Lung Cancer: Invited Speaker, Vancouver, BC Canada, 2003.
13. American Association for Cancer Research (AACR) International Conference on “Frontiers in Cancer Prevention Research”: Scientific Committee Member, Phoenix, AZ, 2003.
14. 2004 Targeted Therapies for the Treatment of Lung Cancer Investigators’ Meeting: Invited Speaker, San Diego, CA, 2004.
15. 2004 American Association for Cancer Research/American Society of Clinical Oncology Workshop Methods in Clinical Cancer Research: Invited Faculty Member, Vail, CO, 2004-2013.
16. International Epidemiology Institute 2004 Course on Molecular Epidemiology: Invited Faculty Member, Nashville, TN, 2004.
17. Joint NCI-FDA Workshop on Research Strategies, Study Design and Statistical Approaches to Biomarkers Validation for Cancer Diagnosis and Detection: Invited Faculty, Washington DC, 2004.
18. International Society for Biological Therapy of Cancer 19th Annual Meeting: Invited Speaker, San Francisco CA, 2004.
19. IASLC/ASCO Consensus Conference on Bronchioloalveolar Cell Carcinoma: Invited Panel Discussant, New York, NY, 2004.
20. Targeted Therapies for the Treatment of Lung Cancer Investigators’ Meeting: Invited Faculty, Steamboat Springs, CO, 2005.
21. Mathematical Biosciences Institute (MBI) Workshop — Genomics, Proteomics, and Bioinformatics — Biomarkers in Cancer Research: Invited Faculty, Columbus, OH, 2005.
22. ICSA 2005 Applied Statistics Symposium: Invited Faculty, Washington DC, 2005.
23. Spline and Wavelet Applications in Biostatistics and Actuarial Mathematics, (With Dr. Don Hong). Invited presentation and Minisymposium Organizer, Athens, GA, 2005.
24. 11th World Conference on Lung Cancer, Invited Speaker, Barcelona, Spain, 2005.
25. 47th Anniversary Annual Conference, The American Associate for Chinese Studies: Chair and local organizing committee: Member, Nashville, TN, 2005.
26. NIH National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel: Member, 2005.

27. Workshop on Mathematical Tools and Statistical Techniques for Quantitative Medical Data Analysis. Scientific Committee, Member, 2005.
28. Radiation Therapy Oncology Group (RTOG) Annual Meeting: Invited Speaker, Miami, FL, 2006.
29. 42nd American Society Clinical Oncology (ASCO) Annual Meeting: Invited Faculty Member, Atlanta, GA, 2006.
30. 4th Asia Pacific Bioinformatics Conference, Invited Tutorial Speaker, Taipei, Taiwan, 2006.
31. NSA Workshop on Mathematical Tools and Statistical Techniques for Quantitative Medical Data Analysis, Scientific Committee: Member, Johnson City, TN, 2006.
32. Hawaii International Conference on Statistics, Math, and Related Fields: Abstract Reviewer, Section Chair, Honolulu, HI, 2007.
33. 6th-Sino-Japan-Korea Bioinformatics Training Course: Invited Faculty, Shanghai, China, 2007.
34. FDA Office of Women's Health Intramural Science Program: Expert Reviewer, 2007.
35. 12th World Conference on Lung Cancer, International Association for the Study of Lung Cancer: International Scientific Committee: Member, Seoul, Korea, 2007.
36. NSF Workshop on Quantitative Proteomic Data Analysis: Invited Plenary Speaker, Murfreesboro, TN, November 2007.
37. 2nd Adaptive Designs in Clinical Drug Development: Invited Speaker, London, UK, 2008.
38. Targeted Therapies for the Treatment of Lung Cancer Meeting: Invited Speaker, Santa Monica, CA, February 2008.
39. Susan G. Komen Foundation Promise Grant: Program Reviewer, Washington, DC, 2008.
40. ENAR, Panel on Genomics and Microarray Analyses: Chair, Arlington, VA, 2008.
41. AACR Annual Meeting 2008, "Clinical Trial Design Workshop Part 1: A Journey from Classical to Innovative Approaches": Invited Panel Member, San Diego, 2008.
42. 2008 Biostatistics and Bioinformatics Workshop on High Dimensional Data Analysis: Co-Organizer, Taipei, Taiwan, 2008.
43. Lung Cancer Symposium 2008, Invited Speaker, Niagara-on-the-Lake, Ontario, Canada, 2008.
44. AACR Annual Meeting 2008: Invited Faculty, San Diego, 2008.
45. ASCO 44th Annual Meeting, Educational Section of Advanced Concepts in Clinical Trial Design and Methodology: Invited Speaker, Chicago, IL, May 2008.
46. 13th World Conference on Lung Cancer, International Association for the Study of Lung Cancer: International Scientific Committee: Member, San Francisco, 2008-2009.
47. American Association for Cancer Research (AACR) 2009 Program Committee, Biostatistics in Clinical Trials Section: Chair, 2008.
48. Susan G. Komen for the Cure's Promise Grants Scientific Peer Review Committee: Member, 2008 – 2012.
49. American Society for Clinical Oncology Cancer Research Committee: Member, 2008 – present.
50. Canadian Cancer Society Research Institute Program Project Review Panel: Member, 2009.
51. ASCO 45th Annual Meeting, Educational Section of Advanced Concepts in Clinical Trial Design and Methodology: Invited Speaker, Orlando, FL, 2009.
52. 13th World Conference on Lung Cancer, International Association for the Study of Lung Cancer: International Scientific Committee: Member, San Francisco, 2009.
53. NIH/CSR ZRG1 OTC-X (14) B Experimental Cancer Therapeutics SBIR/STTR study section: Member, 2009.
54. AACR/ASCO Capitol Hill Lobby Day: Member, 2009.

55. American Association for Cancer Research 8th Annual International Conference on Frontiers in Cancer Prevention Research: Scientific Review Committee Member, 2009.
56. NIH/CSR ZRG1 OTC-X (14) B Experimental Cancer Therapeutics SBIR/STTR Study section: Member, 2010.
57. Susan G. Komen for the Cure Targeted Therapies (TT2) grant: Review panel member, Dallas, TX, 2009.
58. NIH Gastrointestinal Cancers Special Emphasis Panel: Member, 2010.
59. Cancer Society Research Institute, Review Panel for the Canadian Breast Cancer Research Alliance Special Research Competition on Predictive Oncology, Member, 2010.
60. 2nd Lung Cancer Symposium, Invited Speaker, Niagara-on-the-Lake, Ontario, Canada, 2010.
61. ASCO 46th Annual Meeting, Educational Section of Advanced Concepts in Clinical Trial Design and Methodology: Invited Speaker, Chicago, IL, May 2010.
62. Susan G. Komen for the Cure Research Programs grant: Review panel member, Dallas, TX, 2011.
63. AACI/AACR/ASCO Capitol Hill Lobby Day: Member, 2010.
64. American College of Radiology Imaging Network Biospecimen Review Committee: Member, 2010 – present.
65. American Society for Clinical Oncology Cancer Foundation Grants Selection Committee: Member, 2010 – present.
66. The 9th International Bioinformatics Workshop (IBW2011): Invited Speaker, Xi'an, China, 2011.
67. 4th International Symposium on Cancer Metastasis and the Lymphovascular System: Basis for Rational Therapy: Biomarkers and Informatics: Session Chair, New York, 2011.
68. 14th World Conference on Lung Cancer, International Association for the Study of Lung Cancer: International Scientific Committee: Member, Amsterdam, Netherlands, 2011.
69. 2012 AACR Annual Meeting Scientific Program Committee: Member, 2011.
70. International Workshop on Cancer Systems Biology (ICSB) Steering Committee: Member, 2011 – present.
71. Aduro BioTech CRS-207 & GVAX Pancreas Vaccine with Cyclophosphamide Study Data and Safety Monitoring Committee: Member, 2011.
72. Immunogen Data Safety and Monitoring Board: Member, 2012.
73. Talent in Oncology Programme (TOP): Invited Speaker, Munich, Germany, 2012.
74. 2012 Chicago Thoracic Symposium: Abstract Reviewer, Program Committee Member, and Chair of Keynote Lectures, 2012.
75. 2012 Methods in Cancer Research Workshop, Scientific Committee: Member, Al-Ahsa, Saudi Arabia, 2012.
76. 2012 AACR Annual Meeting, Clinical Trial Design in the Era of High-Density Data Analysis Session: Chairperson, 2012.
77. International Conference on Intelligent Biology and Medicine: General Chair, Nashville, TN, 2012.
78. Talent in Oncology Programme (TOP): Invited Speaker, Amsterdam, Netherlands, 2013.
79. 11th Annual International Congress on Target Therapies in Cancer: Invited Speaker, Washington, DC, 2013.
80. International Conference on Intelligent Biology and Medicine: General Chair, Nashville, TN, 2013.
81. Brain Tumour Charity, Peer Review Committee: Member, 2013.
82. 2014 AACR Program Committee, Clinical Research Subcommittee: Chairperson of the Biostatistics in Clinical Trials, 2014.

83. Grand Rounds, Roswell Park Cancer Institute: Invited Speaker, Buffalo, NY, 2013.
84. International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer: Invited Speaker, Sydney, Australia, 2013.
85. International Clinical Trials Workshop (ICTW) Working Group: Member, 2014 – 2017.
86. Roche pRED Data Monitoring Committee of the MDM2 phase 2/3 trial in AML patients: Member, 2014.
87. Peking University (PKU) Big Data Brainstorm Workshop: Chair, Beijing, China, 2014.
88. Institute of Medicine (IOM) Committee on Policy Issues in the Clinical Development of Biomarkers for Molecularly Targeted Therapies: Member, 2014 – present.
89. AACR Education Program Committee: Member, 2015 – present.
90. 2015 Joint Statistical Meeting: Joint Presenter, “Two-Stage Modified Toxicity Probability Interval Design for Low Target Toxicity Rate.” Seattle, Washington, 2015.
91. Pacific Rim Cancer Biostatistics Conference: Chair, “Phase III Trials.” Seattle, Washington, 2015.
92. MMY3004 Interim Analysis Meeting, Vienna, Austria, 2015.
93. EITA-Bio 2015: Recent Advances in Biomedical Research Conference: Program Steering Committee: Member, National Taiwan University, Taiwan, 2015.
94. South Big Data Hub Meeting, Georgia Tech Global Learning Center, Atlanta, GA, 2015.
95. ESMO Asia Congress Annual Meeting: Invited Speaker, Marina Square, Singapore, 2015.
96. Roche WO29519 Constitutional Independent Data Monitoring Committee Meeting, Barcelona, Spain, 2016.
97. Cold Spring Harbor Laboratory Cancer Center Site Visit Invitation, Woodbury, New York, 2016.
98. Targeted Therapies for the Treatment of Lung Cancer Meeting: Invited Speaker, Santa Monica, CA, 2016.
99. Canadian Oncology Resident Education Conference: Invited Speaker, Vancouver, British Columbia, 2016.
235. Boehringer Ingelheim Meeting: Invited Speaker, Vancouver, British Columbia, 2016.
236. British Columbia Cancer Agency Grand Rounds: Invited Speaker, Vancouver, British Columbia, 2016.
237. British Columbia Cancer Agency Research Conference: Invited Speaker, Vancouver, British Columbia, 2016.
238. Canadian Oncology Resident Education at the Canadian Lung Cancer Conference: Invited Speaker, Vancouver, British Columbia, 2016.
239. Career Development and Mentor Committee for Early-Stage Faculty, American Association of Cancer Research (AACR) Annual Meeting: Chair, New Orleans, LA, 2016.
240. Chinese Society of Gynecology Oncology Annual Meeting: Invited Speaker, Beijing, China, 2016.
241. Roswell Park Cancer Institute: Methods in Clinical Research Workshop, Invited Lecturer, Fort Lauderdale, FL, 2016.
242. 2016 Barrett’s Esophagus Translational Research Network (BETRNet) Steering Committee Meeting: Speaker, Rockville, MD, 2016.
243. American Association for Cancer Research (AACR) /American Society of Clinical Oncology (ASCO) Workshop Methods in Clinical Cancer Research: Course Director, Vail, CO, 2014-2016.
244. Second International Symposium on Translational Cancer Research, Keynote Speaker, Tianjin, China, 2016.

245. Talent in Oncology Programmes (TOP) Asia Fundamentals Meetings, Invited Speaker, Taipei, Taiwan, 2016.
246. The 75th Annual Meeting of the Japanese Cancer Association (JCA), Invited Speaker, Tokyo, Japan, 2016.
247. The 17th Annual International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, Conference Committee: Trial Design/Statistics, Vienna, Austria, 2016.
248. Ontario Institute for Cancer Research (OICR) Translational Research Initiatives: Hospital for Sick Children, Neurosurgery, Biostatistical Reviewer, Ontario, Canada, 2016
249. Ontario Institute for Cancer Research (OICR) Translational Research Initiatives: Princess Margaret Cancer Centre and Ottawa Hospital Research Institute, Immunology, Biostatistical Reviewer, Ontario, Canada, 2016.
250. European Society for Medical Oncology (ESMO) Asia 2016 Congress, Invited Speaker, Singapore, 2016.
251. American Society of Clinical Oncology (ASCO) International Clinical Trials Workshops (ICTW), Course Director, Luoyang, China, 2017.
252. AACR Annual Meeting Clinical Trials Committee Member, 2017-2019.
253. Roche Hong Kong Young Scientist Forum, Invited Speaker, Hong Kong, China, 2017.
254. McGill University Visiting Speakers Program in Oncology, Invited Speaker, Quebec, Canada, 2017.
255. 2017 AMIA Annual Symposium: Reviewer, 2017.
256. AACR Annual Meeting 2018 Program Committee, Co-Chair, 2017 – 2018.
257. Boehringer Ingelheim Meeting: Invited Speaker, Vancouver, British Columbia, 2017.
258. American Association of Cancer Research (AACR) Annual Meeting: AACR-Minority and Minority-Serving Institution Faculty Scholar, Washington, DC, 2017.
259. ASCO Annual Meeting Scientific Program Committee-Biostatistics, Member, 2017.
260. Global Breast Cancer Conference, Invited Speaker, Jeju Island, South Korea, 2017.
261. Urological Association of Chinese Hospital Association Annual Meeting, Invited Speaker, Wuhan, China, 2017.
262. Talent in Oncology Programmes (TOP) Asia Fundamentals Meetings, Invited Speaker, Guangzhou, China, 2017.
263. Institute of Genetics and Molecular and Cellular Biology (IGBMC), Invited Speaker, Strasbourg, Switzerland, 2017.
264. AACR NextGen Star, Applicant Reviewer, 2017.
265. The 27th Taiwan Statistics Conference, Keynote Speaker, 2017.
266. Shanghai Jiaotong University Summer Institute Statistical Workshop: Course Director, Shanghai, China, 2017.
267. Springer Nature: Beyond Developing Clinical Trials: Successful Communication of Your Research, Invited Faculty, Guangzhou, China, 2017.
268. Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGMBC), ILLKIRCH, Invited Speaker, Cédex, France, 2017.
269. 18th IASLC World Conference on Lung Cancer, Invited Speaker, Yokohama, Japan, 2017.
270. American Society of Clinical Oncology (ASCO) International Clinical Trials Workshop (ICTW), Chairperson and Invited Speaker, Louyang, China, 2017.
271. 2017 San Antonio Breast Cancer Symposium, Invited Speaker.
272. Tamkang University Statistical Workshop, Course Director, Taipei, Taiwan, 2017.

273. The Cancer Institute and Hospital, Chinese Academy of Medical Sciences: The Workshop of the Clinical Research and Statistical Challenges, Invited Speaker, Beijing, China, 2017.
274. 2nd Pacific Rim Cancer Biostatistics Workshop, Co-Chair, Kanazawa, Japan, 2017.
275. 2018 Young Scientists' Forum, Invited Speaker, Hong Kong, Hong Kong.
276. 18th Annual Targeted Therapies of the Treatment of Lung Cancer, Invited Faculty, Santa Monica, California, 2018.
277. 2018 Taiwan Breast Cancer Consortium and German Breast Group Joing Meeting, Invited Speaker, Taipei, Taiwan, 2018.
278. 20th Edition of the ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research, Invited Faculty, Zeist, Netherlands, 2018.
279. Taiwan Statistical Association Annual Meeting, Keynote Speaker, 2018.
280. 2018 Joint Statistical Meetings: Joint Presenter, "p-Value estimation for the Risk Source of a Prediction Model." Vancouver, BC.
281. Barrett's Esophagus Translational Research Network (BETRNet) Steering Committee Annual Meeting, Session leader, Philadelphia, PA, 2018.
282. IASLC 19th World Conference on Lung Cancer, "Which is most important efficacy endpoint in first line trials in advanced NSCLC PFS of OS - Point of view: OS." Toronto, ON, 2018.
283. 19th Annual Targeted Therapies of the Treatment of Lung Cancer, Invited Faculty, Santa Monica, California, 2019.
284. 21th Edition of the ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research, Invited Faculty, Zeist, Netherlands, 2019.
285. IASLC 20th World Conference on Lung Cancer, Invited Speaker, Barcelona, Spain, 2019.
286. Barrett's Esophagus Translational Research Network (BETRNet) Steering Committee Annual Meeting, Session leader & Invited Speaker, Ann Arbor, MI, 2019.
287. Thai Society of Clinical Oncology (TSCO) Annual Meeting, Invited Speaker, Phetchaburi, Thailand, 2019.
288. 2019 Multiomics and Precision Medicine Conference, Invited Speaker, Tainan, Taiwan, 2019.
289. 3rd Pacific Rim Cancer Biostatistics Workshop, Invited Speaker, Portland, OR, 2019.
290. 2019 Asia Super Computing Conference, Invited Speaker, Singapore, 2019.
291. Quanta Smart Medicine Symposium, Invited Speaker, Taipei, Taiwan, 2019.
292. New Precision Healthcare Centennium Forum, Invited Speaker, Taipei, Taiwan, 2019
293. IASLC 2020 Targeted Therapies of Lung Cancer Meeting, Invited Faculty and Speaker, Santa Monica, CA, 2020.
294. 2020 Canadian Lung Cancer Conference Annual Meeting, Invitred Speaker, Vancouver, Canada, 2020.
295. Taiwan: 2020 BioTaiwan Committee (BTC) Meeting, Invited Speaker, Taipei, Taiwan, 2020.
296. Conference of Texas Statisticians 2020, Invited Speaker, virtual meeting, 2020.
297. The 9th International Forum on Multidisciplinary Management of Lung Cancer, Invited Speaker, Beijing, China, 2020.
298. 2020 Annual Meeting of Taiwan Biobank Association, Invited speaker, virtural meeting, 2020.
299. 2020 International Symposium on Application of Big Data in Prevention and Treatment of Cancer, Invited Speaker, virture conference, 2020.
300. 2020 Asia Oncology Day, Invited Speaker, virtual conference,2020.
301. AACR Annual Meeting 2021 Clinical Trials Committee, member 2020 – 2021.

302. 2021 EORTC-ESMO-AACR Workshop on Methods in Clinical Cancer Research Workshop, Program Committee: member, Sint-Michielsgestel, Netherlands, 2021.
303. IASLC 2021 Targeted Therapies of Lung Cancer Meeting, Invited Speaker, virtual conference, 2021.
304. Canadian Lung Cancer Conference Annual Meeting, Invited Speaker, Vancouver, Canada, 2021.
305. AACR Annual Meeting 2022 Program Committee, Vice Chair, 2021 – 2022.
306. 2021 GOG Foundation Symposium - Cancer Immunotherapy: Successes, Challenges and New Frontiers, Invited Speaker, virtual conference, 2021.

COMMITTEES

A. Vanderbilt University

1. Vanderbilt University Faculty Senate, 2004 – 2007.
2. Vanderbilt Community Giving Campaign Allocations Committee: member, 2006 – 2007.
3. Vanderbilt Senate Consultative Committee member, 2007.
4. Vanderbilt Academic Policies and Services Committee (APS): member; 2004 – 2007.
5. Vanderbilt Academy for Excellence in Teaching: member, 2013 – present.
6. Advanced Computing Center for Research and Education (ACCRE): steering committee member, 2015 – present.
7. Vanderbilt Data Science Visions Working Group: Co-Chair, 2017 – 2018.
8. Executive Committee of Executive Faculty, 2018 – 2020.

B. Vanderbilt University School of Medicine

1. Vanderbilt-Ingram Comprehensive Cancer Center Clinical Protocol Review Committee: Member, 1995 – 2001.
2. Vanderbilt-Ingram Comprehensive Cancer Center Clinical Trials Office Steering Committee: Member, 1998 – present.
3. Vanderbilt-Ingram Comprehensive Cancer Center Biostatistics Faculty Search Committee: Chairman, 1998.
4. Information Policy Advisory Committee Database Subcommittee: Member, 1999.
5. Bioinformatics Graduate Programs Admissions Committee: Member, 2001.
6. Data Center for Large Clinical Trials Multidisciplinary Group Committee: Member, 2001 – present.
7. Vanderbilt-Ingram Comprehensive Cancer Center Data Safety and Monitoring Committee: Member, 2001 – present.
8. Vanderbilt-Ingram Comprehensive Cancer Center Clinical Protocol Scientific Review Committee: Member, 2001 – present.
9. Vanderbilt University Faculty Mentoring Committee: Ayumi Shintani, Ph.D., Health Services Research/Biostatistics, 2001 – 2007.
10. Vanderbilt University Faculty Mentoring Committee: Terri Ni, Ph.D., Genetic Medicine/Cardiovascular Medicine, 2003 – 2009.
11. Vanderbilt University Faculty Mentoring Committee: Andrew Yi, Ph.D., Genetic Medicine, 2007 – present.
12. Data Safety and Monitoring Committee: RAAS, Inflammation and Post-Operative Atrial Fibrillation, member, 2003 – present.
13. Vanderbilt University Department of Biostatistics, Promotion and Tenure Committee: Member, 2003 – present.

14. Vanderbilt University Department of Biostatistics, Faculty and Search Committee: Member, 2003 – present.
15. Vanderbilt University Microarray Core Steering Committee: Member, 2006 – 2009.
16. Ayers Institute Steering Committee: Member, 2008 – present.
17. Data Safety and Monitoring Board: Inotropic Drugs and Risk of Postoperative Atrial Fibrillation: Member, 2009 – present.
18. Data Safety and Monitoring Board: Antioxidant Enzyme Induction as a New Approach to Therapy in Patients with Asthma: Member, 2009 – present.
19. Emerging Information and Technical Conference (EITC) Biomedical Technology Steering Committee: Member, 2011 – present.
20. BioVU Steering Committee: Member, 2012 – present.
21. K25 Grant Mentoring Committee: David Smith, Ph.D., Department of Radiology and Radiological Sciences, Vanderbilt University, 2013 - present.
22. Genetics Executive Committee: Member, 2014 – present.
23. Executive Committee of the Executive Faculty: Member, 2014-2015, 2019 - present
24. Faculty Appointments and Promotions Committee of the Vanderbilt School of Medicine, 2015-2017.
25. Faculty Advisory Committee for Research IT: Member, 2015-present.
26. Grant W. Liddle Chair Selection Committee: Chairperson, 2017
27. Vanderbilt Faculty Research Scholars Selection Committee: Member, 2018
28. Donna S. Hall Chair in Breast Cancer Review Committee: Chairperson, 2021

C. Meharry-Vanderbilt Alliance

29. Epidemiology & Statistics Senior Faculty Search Committee: Co-Chair, 2001 – 2002.
30. Statistics Senior Faculty Search Committee: Co-Chair, 2013.

D. University of Alabama at Birmingham Comprehensive Cancer Center

31. External Advisory Board: Ad-Hoc Member, 2003.
32. External Consultant for Bioinformatics, 2003.

E. American Joint Committee on Cancer (AJCC)

33. Statistical Task Force Committee: Member, 2005.
34. Statistical Task Force, Development of the 7th Edition of the AJCC Cancer Staging Manual: Member, 2006.

F. Middle Tennessee State University

35. College of Basic and Applied Science, Master of Science in Professional Science (MS-PS) Advisory Board: Member, 2006 – present.

G. State of Tennessee Department of Health

36. Tennessee Cancer Registry Advisory Committee: Member, 2007 – present.

H. Northwestern University

37. Robert H. Lurie Comprehensive Cancer Center External Advisory Board: Member, 2008 – present.
38. Brest SPORE External Advisory Board: Member, 2020 – present.
- I. SRA International Global Health Sector**
39. External Consulting and Advisory Team: Member, 2008 – present.
- J. US Food and Drug Administration (FDA)**
40. Anti-infective Drugs Advisory Committee: Voting member, 2009 – 2014.
41. Anti-infective Drugs Advisory Committee: Ad hoc voting member, 2015 – present.
- K. Tokai University Institute of Innovative Science and Technology, Isahara, Japan**
42. Tenure Track Faculty Selection Committee: Member, 2010 – present.
- L. Shanghai Center for Bioinformatics Technology, Shanghai, China**
43. Academic Committee Member: Member, 2010 – present.
- M. University of Colorado, Denver**
44. SPORE in Lung Cancer External Scientific Advisory Board Member, 2010 – 2019.
45. Lung Strategic Partnering to Evaluate Cancer Signatures (SPECS) External Advisory Committee: Member, 2011 – 2019.
46. University of Colorado Comprehensive Cancer Center External Scientific Advisory Board Member, 2020 – present.
- N. University of Kentucky Markey Cancer Center, Lexington**
47. Biostatistics Shared Resource Facility External Advisory Board Member, 2010 – present.
- O. American College of Radiology**
48. Imaging Network Biospecimen Review Committee: Member, 2010 – present.
- P. Moffitt Cancer Center**
49. External Advisory Board: Member, 2014 – 2019.
50. Council of Scientific Advisors Ad-Hoc Member, 2010.
51. SPORE in Lung Cancer External Scientific Advisory Board Member, 2010 – 2015.
- Q. Duke University**
52. Institute for Genome Sciences and Policy (Duke IGSP): Data Safety and Monitoring Board-Oversight Committee (DSMB-OC), 2011 – 2012.
- R. Arizona University**
53. Arizona GI SPORE External Advisory Committee: Member, 2011 – 2012.
- S. Dartmouth College**
54. Institute for Quantitative Biomedical Sciences External Advisory Committee: Member, 2012 – present.
- T. Rutgers Cancer Institute of New Jersey**

55. Precision Medicine Initiative External Advisory Board: Member, 2013 – present.
56. Biometrics Shared Resource External Advisory Board: Member, 2019 - present.
- U. Radiation Therapy Oncology Group, American College of Radiology**
57. Brain SPORE External Advisory Board: Member, 2013 – present.
- V. City of Hope Cancer Center**
58. Biostatistics Core External Advisory Board: Member, 2013.
- W. University of California, San Diego**
59. Cancer Center Support Grant: Biostatistics Core External Consultant, 2013.
- X. Mount Sinai School of Medicine**
60. Tisch Cancer Institute External Advisory Board (EAB): Member, 2013 – present.
61. Myeloproliferative Neoplasms – Research Consortium (MPN – RC) External Advisory Board (EAB): Member, 2019 – present.
- Y. United States-Latin America Cancer Research Network**
62. Data Monitoring Committee (DMC) in the Molecular Profiling of Breast Cancer Study, 2013 – present.
- Z. MD Anderson Cancer Center**
63. External Advisory Board (EAB) (Scientist Panel) of the R. Lee Clark Fellows Award, 2014 – present.
- AA. Indiana University**
64. Center for Computational Biology and Bioinformatics (CCBB) External Advisory Board, 2014 – present.
65. Genome Privacy Workshop: Advisory Committee Member, 2015 – present.
- BB. Baylor College of Medicine**
66. Dan L. Duncan Cancer Center External Advisory Committee, 2014 – present.
- CC. Peking University, China**
67. PKU Biobank Advisory Board: Member, 2104 – present.
- DD. University of Texas Southwestern Medical Center**
68. Kidney SPORE External Advisory Board: Member, 2015 – present.
69. Lung SPORE Biostatistics Core External Reviewer, 2017 – present
- EE. Oregon Health and Science University: Knight Cancer Institute**
70. Cancer Biostatistic Advisory Committee: Member, 2015 – present
71. OHSU Knight Cancer Institute EAB Committee: Member, 2019 – present
- FF. American Association for Cancer Research (AACR) Annual Meeting**

- 72. Clinical Trials Committee, Member, 2017 – present
- 73. 2018 Program Committee, Co-Chair, 2017 – 2018
- 74. Career Development Committee, Member, 2017 – present
- 75. Education Committee, Member, 2017 – 2018
- 76. Education Committee, Chairperson, 2018 - Present
- 77. 2018 Annual Meeting, Co-Chairperson
- 78. 2018 Major Symposium: Integrative Data Science for the Precision Medicine Era, Chairperson
- 79. 2018 Educational Session: Common Statistical Errors and Mistakes in Cancer Research: How to Avoid Them, Chairperson and Speaker

GG. Yale School of Medicine: Yale Cancer Center

- 80. DNA Damage Repair SPORE External Advisory Board: Member, 2017 – present

HH. Alliance for Clinical Trials in Oncology

- 81. Alliance Statistics and Data Center (SDC) External Reviewer, 2017 – present

II. James Cancer Center and Moffit Cancer Center

- 82. Lung SPORE External Advisory Board: Member, 2017 – present

JJ. National Cancer Institute

- 83. Special Emphasis Panel: Chairperson, 2018
- 84. CTEP Early Drug Development (EDD) and Investigational Drug Steering Committee (IDSC): Member 2019 – present

KK. International Workshop on Cancer Systems Biology

- 85. Steering Committee Member, 2017

LL. Mayo Clinic

- 86. Lung SPORE External Advisory Board: Member, 2020 – present

LEADERSHIP DEVELOPMENT

- Vanderbilt University School of Medicine Academic Leadership Program, 2007.

CONSULTING

- Vanderbilt University Medical Center — provided consulting services to over 1,000 clients and have reviewed over 2,000 clinical protocols, 1994 – present.

CURRENT RESEARCH AT VANDERBILT

- 1. **U24CA163056 (Shyr)** 03/15/2017 - 02/28/2022
 NCI
 Barrett's Esophagus Translational Research Network Coordinating Center
 Major goal: to provide administrative, leadership, and data management support for BETRNet.
 Role: PI
- 2. **VUMC61566/U24CA213274 (Shyr)** 02/20/2017 – 01/31/2022

NCI
Small Cell Lung Cancer Consortium Coordinating Center
Major goal: to provide coordination for the NCI Small Cell Lung Cancer Consortium.
Role: Site PI

- 3. VUMC66058/U54CA217450 (Shyr)** 04/01/2018-03/31/2021
NCI
Phenotype Heterogeneity and Dynamics in SCLC
Major goal: to identify mechanisms that drive cellular heterogeneity of small cell lung cancer as well as how to target this heterogeneity to improve therapy.
Role: Site PI
- 4. VUMC44233 /CA186689 (LoRusso)** 07/10/2014 – 02/28/2021
NCI
ViKTriY Early Clinical Trials Consortium (ECTC)
The major goal of this project is to develop novel drugs and drug combinations via early clinical trials. The focus is on collaboration between scientists and clinicians to advance drug development, not only looking at response rates, but mechanisms of resistance and response, including use of biomarkers to provide insight.
Role: Biostatistician
- 5. P50CA098131 (Pietenpol)** 08/07/2013-07/31/2024
NCI
SPORE in Breast Cancer
The overall goal of this project is to conduct multidisciplinary, mechanism-based, translational research of the highest possible impact that will contribute meaningfully to measurable progress in breast cancer.
Role: Core Director
- 6. P30CA068485 (Pietenpol)** 09/01/1998 – 08/31/2025
NCI
Cancer Center Support Grant
Major goal: to provide infrastructure support to facilitate research toward our mission to alleviate cancer death and suffering through pioneering research, innovative patient care, evidence-based prevention, and education. Role: Scientific Director
- 7. R01HL133127 (Murray/Shoemaker)** 04/01/2017 - 03/31/2021
NHLBI
Novel Pathophysiological Targets in Atrial Fibrillation Susceptibility
Major goal: to test the hypotheses of mechanistic links between common diseases such as hypertension and obesity with atrial fibrillation.
Role: Collaborator
- 8. U54TR002243 (Bernard)** 06/01/2017 – 02/28/2022
NCATS
Vanderbilt Institute for clinical and Translational Research (VICTR)
Major goal: to ensure the translational science workforce has the skills, knowledge, and resources necessary to advance translation of discoveries.
Role: Co-investigator
- 9. U54CA163072 (Moses/Pal)** 09/22/2016 – 08/31/2021
NCI
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities
Major goal: to provide the environment and focus for the efforts of diverse investigators working across many disciplines to identify the determinants of cancer disparities.
Role: Biostatistics & Bioinformatics Core Director
- 10. P01HL129941 (Harrison)** 08/01/2016 - 07/31/2021
NHLBI
The Role of Inflammation in Cardiovascular Disease

Major goal: to understand how immune cells including macrophages, dendritic cells (DCs) and T cells are activated and contribute to cardiovascular diseases including atherosclerosis and hypertension.

Role: Co-investigator

11. U2CCA233291 (Coffey Jr)

09/20/2018 – 06/30/2023

NCI

Integrative Single-Cell Atlas of Host and Microenvironment in Colorectal Neoplastic Transformation

Major goal: to map spatial relationships across the spectrum of normal colon, early polyps, advanced adenomas, and adenocarcinomas, including unique stromal and microbial microenvironments, to identify these phenotypes for development of precision diagnostics and preventive strategies.

Role: Unit Co-Lead

12. 18FRN342110369 (Roden)

07/01/2018 - 06/30/2022

American Heart Association

Atrial Fibrillation Network, SFRN

Major goal: to advance treatment and prevention of atrial fibrillation.

Role: Biostatistician

13. P01HL108800 (Hemnes)

09/15/2017-06/30/2022

NHLBI

Hormonal, Metabolic and Signaling Interactions in PAH

Major goal: to establish new therapeutic interventions toward the basic molecular etiology of PAH.

Role: Co-investigator

14. P50CA236733 (Coffey)

07/09/2019-05/31/2024

NCI

Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer

Major goal: to: (1) examine whether cancer stem cells represent a tractable therapeutic target, (2) optimize EGFR blockade by targeting glutamine metabolism, and (3) develop a drug to inhibit MYC.

Role: Core Director

15. VUMC82497(P01CA229123) (Coffey)

01/01/2020 - 12/31/2020

NCI

exRNA in Colorectal Carcinoma: Biogenesis and Function

The overall goal of our Program is to understand how extracellular RNA is secreted and taken up by recipient cells to influence the development and aggressiveness of colorectal carcinomas (CRC).

Role: Director, Core 1A

16. VUMC/U54CA260560 (Hirsch)

09/30/2020-08/31/2022

Mt. Sinai/NCI

SARS-CoV-2 Serological Sciences Centers of Excellence (U54)-Data Science Core

he purpose of the Data Science Core (DSC) is to provide professional expertise in biostatistics, bioinformatics and research informatics for all SARS-CoV-2 Serological Sciences Centers of Excellence (U54) projects, investigators and participants.

Role: Core Director

PAST RESEARCH AT VANDERBILT

1. UM1 CA186689 (Vanderbilt PI: Berlin)

10/01/14-02/29/20

NCI/Primary: Yale University

Role: Co-Investigator

ViKTriY Early Clinical Trials Consortium

The ultimate purpose of this project is to define better approaches for the development of novel anticancer agents that capitalize on the ability to characterize tumors molecularly and find appropriate biomarkers to select patients most likely to respond to specific agents.

2. P50 CA095103 (Coffey, Jr.)

05/01/16-06/30/19

NIH/NCI

Role: Core leader

SPORE in GI Cancer - Bridge Funding

The four projects of this study continue to focus on transforming how we diagnose and treat individuals with colorectal cancer and deepening our understanding of the pathobiology of colorectal neoplasia.

3. **P50 CA098131** (Mayer/Pietenpol) 09/01/17-08/31/19
NCI Role: Co-Investigator
Discovery of Targetable Mechanisms of Endocrine
Our overall goal continues to be to conduct multidisciplinary, mechanism-based, translational research of the highest possible impact that will contribute meaningfully to measurable progress in breast cancer.
4. **P30 CA068485** (Pietenpol) 09/10/10-08/31/20
NCI Role: Core leader
Cancer Center Support Grant
This grant provides the infrastructure support to facilitate basic, clinical and population-based research relevant to our mission to alleviate cancer death and suffering.
5. **R01 HL124935** (Knollmann) 06/01/15-03/31/20
NIH Role: Co-Investigator
Toward a Mechanism-Based Approach to Treating Atrial Fibrillation
The major goal of this study is to investigate the molecular mechanisms responsible for atrial fibrillation, the most common form of chronic arrhythmia in the United States.
6. **R01 CA200999** (Yang) 04/30/16-11/30/19
NCI Role: Co-Investigator
Sex Hormones, Phytoestrogens and Lung Cancer in Female Nonsmokers
The major goal of this project is to fill important gaps in our knowledge about whether exposure to endogenous estrogens and plant estrogens (phytoestrogens) in nonsmoking women may relate to lung cancer risk and mortality.
7. **P50 CA098131** (Arteaga) 09/11/08-08/31/19
NCI Role: Core leader
SPORE in Breast Cancer
The overall goal of this project is to conduct multidisciplinary, mechanism-based, translational research of the highest possible impact that will contribute meaningfully to measurable progress in breast cancer.
8. **R01 NS0940941** (DeBaun) 08/01/15 – 07/31/20
NIH/NCI Role: Co-Investigator
Primary Prevention of Stroke in Children with SCA in Sub-Saharan African II
The major goal of this project is to determine if moderate dose hydroxyurea when compared to low dose hydroxyurea can successfully prevent strokes in high risk children with SCA living in Nigeria and Ghana.
9. **P01 HL116263** (Linton) 06/01/14-04/30/19
NHLBI Role: Co-Investigator
HDL Function in Human Disease
The major goal of this project is to define the mechanisms for HDL dysfunction in three distinct diseases associated with increased risk for atherosclerotic cardiovascular disease.
10. **U01 CA196405** (Massion) 09/24/15 – 08/31/20
NIH/NCI Role: Co-Investigator
Cellular, Molecular and Quantitative Imaging Analysis of Screening-Detected Lung Adenocarcinoma
The goal of this project is to improve prediction models of early stage adenocarcinoma (ADC) of the lung by integrating quantitative imaging, molecular and cellular determinants to offer a paradigm-shift in the clinical management of patients with early ADC.
11. **R01 CA034590** (Richmond) 07/01/13-06/30/18
NCI Role: Co-Investigator
Chemokine Signals in the Pre-Metastatic Niche Inhibit Metastasis

The major goal of this project is to evaluate mechanisms of entrainment and to characterize the precise intracellular signal transduction pathways involved in chemokine mediated entrainment of leukocytes associated with progression of breast cancers.

12. **UM1 CA173640** (Shu) 09/18/13-08/31/18
NCI Role: Co-Investigator
Shanghai Men's Health Study
The major goal of this project is to conduct a long-term epidemiological study of cancer and other chronic diseases, with a focus on identifying modifiable protective dietary factors for cancers. The SMHS, with its large sample size, wealth of resources, and unique exposure patterns and disease spectrum, provides exceptional opportunities to address many significant hypotheses that cannot be adequately investigated in any other existing cohort study.
13. **AHA 14 SFRN 20420046** (Harrison) 07/01/14 – 06/30/18
American Heart Association Role: Co-Investigator
Vanderbilt University Strategically Focused Prevention Research Center
The major goal of this project is to establish a prevention research center to expand and extend efforts to goal to reduce coronary heart disease (CHD), stroke and risk.
14. **U01 CA202979** (Blot) 07/21/16-03/31/17
NCI Role: Co-Investigator
Southern Community Cohort Study
Southern Community Cohort Study, a long-term prospective epidemiologic study tracking cancer incidence among approximately 86,000 adults age 40-79, two-thirds African American. Nested case-control studies will utilize baseline questionnaire data and stored biologic specimens to address unanswered questions about the causes of cancer among African Americans and the determinants of health disparities.
15. **R01 CA177372 (EI-Rifai)** 08/01/13-07/31/16
NCI Role: Co-Investigator
The Role of miRNA Network in Gastric Cancer
The goal of this project is to gain further understanding of the role of H. Pylori in shaping the miRNA signature and promoting the multi-step gastric tumorigenesis in order to identify diagnostic, prognostic and possibly therapeutic miRNA targets in gastric cancer.
16. **R21 NS080639** (DeBaun) 09/30/12 – 08/31/14
NINDS Role: Co-Investigator
Primary Prevention of Strokes in Nigerian Children with Sickle Cell Disease
The goal of this project is to determine the acceptability of randomization to HU vs. placebo for primary prevention of strokes in Nigerian children with sickle cell anemia (SCA) in preparation for a NIH sponsored multicenter, phase III Trial.
17. **National Lung Cancer Partnership** (Shyr) 08/01/12-07/31/14
National Lung Cancer Partnership Role: Principal Investigator
Lung Cancer Mutation Consortium Protocol
The major goal of this project is to develop and implement a customized clinical relational database for use by the Lung Cancer Mutation Consortium.
18. **R01 CA102162** (Moses) 12/01/11 – 11/30/13
NCI Role: Co-Investigator
TGF-Beta in Mammary Development and Tumorigenesis
The major goal of this study is to characterize Cre expression pattern, recombination, and phenotype in various TGF-beta recombinant mouse backgrounds.
19. **P50 CA128323** (Gore) 09/22/08 – 08/31/13
NCI Role: Core leader
Vanderbilt in vivo Cellular and Molecular Imaging Center
The major goal of this project is to establish a new *in vivo* cellular and molecular imaging center at Vanderbilt University, which will be dedicated to highly innovative molecular imaging studies of cancer biology.

20. **P50 CA090949** (Carbone) 09/26/07 – 03/31/12
 NIH/NCI Role: Core leader
SPORE in Lung Cancer
 The major goal of this project is to investigate the molecular features of tumors or tumor-host interactions that determine their clinical behavior and represent potential molecular targets for interventions.
21. **RC2 CA14839** (Pao: Colorado) 09/01/09 – 08/31/13
 NIH Role: Core leader
Lung Cancer Mutation Consortium Trial
 The major goal of this project is to establish a Lung Cancer Mutation Consortium (LCMC) consisting of 13 institutions with a major interest in lung cancer and genomic testing of lung cancer as documented by having major NCI grants in lung cancer.
22. **U54 CA091405** (Moses) 09/25/06 – 07/31/12
 NIH/NCI Role: Co-Investigator
MMC and VICC: Partners in Eliminating Cancer Disparities
 A comprehensive cancer research partnership between MMC and VICC.
23. **2R01 CA085492** (Moses) 03/01/11 – 02/29/16
 NCI Role: Co-Investigator
TGF-Beta Suppression and Promotion of Mammary Carcinomas
 The major goal of this project is to delineate the mechanisms of both suppression and promotion of mammary tumors by TGF-beta, using mouse models.
24. **P01 CA116087** (Peek) 01/01/09 – 12/31/13
 NCI Role: Co-Investigator
H. pylori-indn and Gastric Cancer
 The major goal of this project is to delineate the molecular signaling events initiated by *H. pylori*-epithelial cell contact that regulate phenotypes related to gastric carcinogenesis.
25. **U54 CA126505** (Matrisian) 09/25/06 – 08/31/11
 NIH/NCI Role: Co-Investigator
Paracrine TGF-Beta Signaling in Tumor Initiation and Progression
 The major goal of this project is to establish the Vanderbilt University Tumor Microenvironment Network (VUTMEN) to contribute to the generation of a comprehensive understanding of the role of the tumor stroma.
26. **R01 DK058587** (Peek) 09/01/07 – 06/30/11
 NIDDKD Role: Core leader
H. pylori and Gastrointestinal Biology
 The major goal of this project is to investigate effects of *H. pylori* on prostaglandin biology using conditionally immortalized gastric cells.
27. **R01 CA085492** (Moses) 12/15/05 – 11/30/10
 NCI Role: Co-Investigator
TGF-Beta Suppression and Promotion of Mammary Carcinomas
 The specific aim for this gran is to determine the effects of systemic inhibition of TGF-(signaling on mammary tumor formation and metastases from MMTV-c-neu and MMTV-PyVmT-induced mammary tumors in the context Tgfr2 knockout in mammary epithelial cells effected by both MMTV-Cre and WAP-Cre.
28. **U01 CA114771** (Carbone) 09/30/05 – 05/31/10
 NCI Role: Co-Investigator
Molecular Signatures of Lung Cancer
 This team proposes to evaluate the potential clinical usefulness of several molecular signatures already developed using a variety of molecular analysis technologies, including DNA, RNA and protein-based technologies addressing both diagnostic and predictive signatures. Important markers in proteomic profiles will be identified, and together with genomic and cDNA markers, clinically feasible assays will be developed and their robustness tested in prospective studies.
29. **P50 GM015431** (Morrow) 07/03/06 – 06/30/11

- NIGMS
Research Center for Pharmacology and Drug Toxicology
 The focus of the Center is research related to eicosanoid biology and pharmacology
- Role: Co-Investigator
30. **R21 CA099269** (Berlin)
 NCI
PS-341 in Hepatocellular Carcinoma: A Phase II Trial
 Specific aims for this study are 1) Evaluate the antitumor effect of PS-341 in hepatocellular carcinoma patients, 2) Evaluate the effect of PS-341 on 26S proteasome activity in peripheral white blood cells (WBC's) and patient serum. Direct measurement of 26S proteasome activity as well as proteins affected by proteasome 26S and NF-kB will be analyzed, and 3) Evaluate the effect of PS-341 on intratumoral NF-kB activation, on tumor apoptosis and 26S proteasome activity.
- 09/18/03 – 08/31/05
 Role: Co-Investigator
31. **R01 DK73902** (Peek)
 NIDDKD
Mechanisms that Regulate Helicobacter Pylori-Induced Beta-Catenin Activation
 The overarching objective of this program project is delineation of the molecular signaling events initiated by H. pylori:epithelial cell contact that regulate phenotypes related to gastric carcinogenesis.
- 04/01/06 – 12/31/10
 Role: Co-Investigator
32. **P01 CA077839** (DuBois)
 NCI
Mechanisms for Chemoprevention of Cancer
 The overall goal of this PPG is to determine the molecular mechanisms involved in the chemoprevention of cancer by non-steroidal anti-inflammatory drugs (NSAIDS). The studies will specifically test the hypotheses that the cyclooxygenase (COX) pathway and/or its eicosanoid products play a role in certain aspects of breast, cervical, ovarian and colorectal carcinogenesis.
- 05/01/04 – 04/30/2009
 Role: Co-Investigator
33. **P50 CA098131** (Moses)
 NCI
HER (erbB) Inhibitors in Untreated Operable Breast Cancer (SPORE in Breast Cancer Supplement)
 This supplement provides clinical trial, administrative, and correlative studies support for inter-SPORE clinical trials with the University of Alabama (Birmingham), University of North Carolina (Chapel Hill), and Dana-Farber Cancer Institute. The current trial targets 100 patients treated over the next 2 years with 1-2 weeks of the EGF receptor inhibitor erlotinib (OSI-774, 'Tarceva') in patients with operable breast cancer.
- 09/25/06 – 07/31/11
 Role: Co-Investigator
34. **R01 CA080195** (Arteaga)
 NCI
ErbB2-targeted anti-tumor strategies in breast cancer
 The major goal of this project is to identify mechanisms of resistance to anti-HER2 drugs, contributing to the eventual elimination of HER2+ breast cancer.
- 04/01/05 – 03/31/11
 Role: Co-Investigator
35. **R01 CA129961** (Moses)
 NCI
Evaluation of MRI Biomarkers of Breast Cancer Response
 The proposed research will combine several new imaging methods to obtain quantitative information on how breast tumors respond to treatment. We hypothesize that this will let us distinguish responders from non-responders early in the course of treatment.
- 04/01/08 – 03/31/12
 Role: Co-Investigator

STATISTICAL SOFTWARE

R, S-PLUS, SAS, MATLAB, Stata, SPSS, BDMP, SUDAAN, SOLAS, StaXact, Resampling Stats, East, nQuery Advisor, PASS, NCSS, StudySize, SYSTAT, GLIM, Minitab, EGRET, Epicure, PC Cluster, etc.

OPERATING SYSTEMS & LANGUAGES

LINUX, WINDOWS, DOS, UNIX, VAX/VMS, MAC, BASIC, FORTRAN, COBOL, C, C++, C-sharp, HTML, JAVA, etc.

INTERESTS

- Consulting on biomedical problems, designing experiments and data analysis, clinical trials design and analysis.
- Applied multivariate analysis, especially repeated measures procedures and high dimensional data analysis.
- Applied bioinformatic and statistical methods in modern molecular biology: genomics and proteomics research.

BOOKS/BOOK CHAPTERS/BOOK REVIEWS

1. **Shyr Y** (2002). *Statistics with Applications to the Biomedical Science*. Tamkang Chair Lecture Series 132. Tamkang University, Taipei, Taiwan.
2. **Shyr Y** and Kim, KM (2003) *Weighted Flexible Compound Covariate Method for Classifying Microarray Data*. In: A Practical Approach to Microarray Data Analysis (Berrar, D., ed.), pp. 186-201, Kluwer Academic Publishers, Norwell, MA, USA.
3. **Shyr Y** (2006) *Statistical Approaches for High Dimensional Data Derived from High Throughput Assays*. In: Handbook of Statistics in Clinical Oncology 2nd edition (Crowley J, ed.), pp. 457-470, Chapman and Hall/CRC, Boca Raton, FL, USA.
4. Hong D and **Shyr Y** (2007) *Quantitative Medical Data Analysis Using Math Tools and Statistical Techniques*, World Scientific Publication, Singapore, (ISBN: 978-981-270-461-0).
5. Hong D, Li HM, Li M, and **Shyr Y** (2007) *Evolution Algorithm and Recent Progress on Proteomic Data Preprocessing Using*. In: Quantitative Medical Data Analysis Using Math Tools and Statistical Techniques, pp. 155-174. World Scientific Publication, Singapore.
6. Hong D, Yuan X, and **Shyr Y** (2007) *Survival Model and Estimation for Lung Cancer Patients*. In: Quantitative Medical Data Analysis Using Math Tools and Statistical Techniques, pp. 195-216. World Scientific Publication, Singapore.
7. Hong D and **Shyr Y** (2008) *Mathematical Framework and Wavelets Applications in Proteomics for Cancer Study*. In: Handbook of Cancer Models with Applications, (Wai-Yuan Tan and Leonid Hanin eds.), pp. 471-499, World Scientific, New Jersey, USA.
8. **Shyr Y** (2009) *Design and Conduct of Clinical Trials for Breast Cancer*. In: The Breast 4th ed - Comprehensive Management of Benign and Malignant Disorders. (Bland and Copeland, eds.), Elsevier, USA.
9. **Shyr Y** (2010) *Prediction of Antitumor Response*. In: Principles of Anticancer Drug Development 1st ed. (Hidalgo M, ed.), pp. 257-274. Springer, USA.
10. **Shyr Y**. Review of book: Design and Analysis of Clinical Trials with Time-to-Event Endpoint. *Biometrics* 2010; 66:659-660.
11. **Shyr Y** and Ye F (2015) *Statistical Considerations in Predictive and Prognostic Markers*. In: Biomarkers in Cancer Screening and Early Detection 1st edition (Srivastava, ed.). Wiley-Blackwell, New Jersey, USA.

12. Hoskins S, Shyr D, and **Shyr Y**. (2017) *Sample Size Calculation for Differential Expression Analysis of RNA-seq Data*. In: *Frontiers of Biostatistical Methods and Applications in Clinical Oncology*. (Matsui and Crowley, eds.), Springer, USA.
13. Klimberg, VS, **Shyr Y**, and Wells T (2018) *Design and Conduct of Clinical Trials for Breast Cancer*. In: *The Breast 5th ed - Comprehensive Management of Benign and Malignant Disorders*. (Bland and Copeland, eds.), Elsevier, USA.

PUBLICATIONS (h-index = 111)

1. Baliga P, Merion RM, Turcotte JG, Ham JM, Henley KS, Lucey MR, Schork A, **Shyr Y**, Campbell DA, Jr. Preoperative risk factor assessment in liver transplantation. *Surgery* 1992;112(4):704-710; discussion 710-701.
2. Calkins H, **Shyr Y**, Schork A, Kadish A, Morady F. Effects of quinidine and amiodarone on blood pressure during rapid ventricular pacing in coronary artery disease. *Am J Cardiol* 1992;70(13):1206-1209.
3. Levy S, Lauribe P, Dolla E, Kou W, Kadish A, Calkins H, Pagannelli F, Moyal C, Bremond M, Schork A, et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. *Circulation* 1992;86(5):1415-1420.
4. Wang HL, Burgett FG, **Shyr Y**. The relationship between restoration and furcation involvement on molar teeth. *Journal of Periodontology* 1993;64(4):302-305.
5. Wang HL, Yeh CT, Smith F, Burgett FG, Richards P, **Shyr Y**, O'Neal R. Evaluation of ferric oxalate as an agent for use during surgery to prevent post-operative root hypersensitivity. *Journal of Periodontology* 1993;64(11):1040-1044.
6. Wang HL, Burgett FG, **Shyr Y**, Ramfjord S. The influence of molar furcation involvement and mobility on future clinical periodontal attachment loss. *Journal of Periodontology* 1994;65(1):25-29.
7. Wang HL, O'Neal RB, Thomas CL, **Shyr Y**, MacNeil RL. Evaluation of an absorbable collagen membrane in treating Class II furcation defects. *Journal of Periodontology* 1994;65(11):1029-1036.
8. Wang HL, Pappert TD, Castelli WA, Chiego DJ, Jr., **Shyr Y**, Smith BA. The effect of platelet-derived growth factor on the cellular response of the periodontium: an autoradiographic study on dogs. *Journal of Periodontology* 1994;65(5):429-436.
9. Wang HL, Yuan K, Burgett F, **Shyr Y**, Syed S. Adherence of oral microorganisms to guided tissue membranes: an in vitro study. *Journal of Periodontology* 1994;65(3):211-218.
10. Young PC, **Shyr Y**, Schork MA. The role of the primary care physician in the care of children with serious heart disease. *Pediatrics* 1994;94(3):284-290.
11. Calkins H, **Shyr Y**, Frumin H, Schork A, Morady F. The value of the clinical history in the differentiation of syncope due to ventricular tachycardia, atrioventricular block, and neurocardiogenic syncope. *American Journal of Medicine* 1995;98(4):365-373.
12. Chen CC, Wang HL, Smith F, Glickman GN, **Shyr Y**, O'Neal RB. Evaluation of a collagen membrane with and without bone grafts in treating periodontal intrabony defects. *Journal of Periodontology* 1995;66(10):838-847.
13. Herman GE, Schork MA, **Shyr Y**, Elfont EA, Arbit S. Histologists, Microtomy, Chronic Repetitive Trauma, and Techniques to Avoid Injury .1. A Statistical Evaluation of the Job Functions Performed by Histologists. *Journal of Histotechnology* 1995;18(2):139-143.
14. Loder RT, Farley FA, Herring JA, Schork MA, **Shyr Y**. Bone age determination in children with Legg-Calve-Perthes disease: a comparison of two methods. *Journal of Pediatric Orthopaedics* 1995;15(1):90-94.
15. Loder RT, Urquhart A, Steen H, Graziano G, Hensinger RN, Schlesinger A, Schork MA, **Shyr Y**. Variability in Cobb angle measurements in children with congenital scoliosis. *Journal of Bone and Joint Surgery (British Volume)* 1995;77(5):768-770.

16. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, **Shyr Y**, Strauss WE, Oates JA, Roberts LJ, 2nd. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. *New England Journal of Medicine* 1995;332(18):1198-1203.
17. Vrlenich LA, Bozynski ME, **Shyr Y**, Schork MA, Roloff DW, McCormick MC. The effect of bronchopulmonary dysplasia on growth at school age. *Pediatrics* 1995;95(6):855-859.
18. Calkins H, Bahu M, **Shyr Y**, Schork A, Bolling S, Kou W, Kirsch M, Morady F. Relationship of amiodarone to postoperative complications of transthoracic implantation of automatic implantable cardioverter defibrillators. *Panminerva Medica* 1996;38(2):89-97.
19. Chomsky DB, Lang CC, Rayos GH, **Shyr Y**, Yeoh TK, Pierson RN, 3rd, Davis SF, Wilson JR. Hemodynamic exercise testing. A valuable tool in the selection of cardiac transplantation candidates. *Circulation* 1996;94(12):3176-3183.
20. Darbar D, Davidson NC, Gillespie N, Choy AM, Lang CC, **Shyr Y**, McNeill GP, Pringle TH, Struthers AD. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. *American Journal of Cardiology* 1996;78(3):284-287.
21. Johnson DH, Paul DM, Hande KR, **Shyr Y**, Blanke C, Murphy B, Lewis M, De Vore RF, 3rd. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. *Journal of Clinical Oncology* 1996;14(7):2054-2060.
22. Malicky DM, Soslowsky LJ, Blasler RB, **Shyr Y**. Anterior glenohumeral stabilization factors: progressive effects in a biomechanical model. *Journal of Orthopaedic Research* 1996;14(2):282-288.
23. Norris AE, Ford K, **Shyr Y**, Schork MA. Heterosexual experiences and partnerships of urban, low-income African-American and Hispanic youth. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1996;11(3):288-300.
24. Zic JA, Stricklin GP, Greer JP, Kinney MC, **Shyr Y**, Wilson DC, King LE, Jr. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. *Journal of the American Academy of Dermatology* 1996;35(6):935-945.
25. Blanke C, DeVore R, **Shyr Y**, Epstein B, Murray M, Hande K, Stewart S, Johnson D. A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer. *International Journal of Radiation Oncology Biology Physics* 1997;37(1):111-116.
26. Chinery R, Brockman JA, Peeler MO, **Shyr Y**, Beauchamp RD, Coffey RJ. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21(WAF1/CIP1) via C/EBP beta. *Nature Medicine* 1997;3(11):1233-1241.
27. Choy H, DeVore RF, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, **Shyr Y**, LaPorte K, Johnson DH. Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. *Seminars in Oncology* 1997;24(4):21-26.
28. Coomer RW, Schulman G, Breyer JA, **Shyr Y**. Ambulatory blood pressure monitoring in dialysis patients and estimation of mean interdialytic blood pressure. *American Journal of Kidney Diseases* 1997;29(5):678-684.
29. Goral S, Ynares C, **Shyr Y**, Yeoh TK, Johnson HK. Long-term renal function in heart transplant recipients receiving cyclosporine therapy. *Journal of Heart and Lung Transplantation* 1997;16(11):1106-1112.
30. Kemp WE, Jr., Kerins DM, **Shyr Y**, Byrd BF, 3rd. Optimal Alunex dosing for enhancement of Doppler tricuspid regurgitation spectra. *American Journal of Cardiology* 1997;79(2):232-234.
31. May RE, Himmelfarb J, Yenicesu M, Knights S, Ikizler TA, Schulman G, HernanzSchulman M, **Shyr Y**, Hakim RM. Predictive measures of vascular access thrombosis: A prospective study. *Kidney International* 1997;52(6):1656-1662.
32. Metts JC, 3rd, Kotkin L, Kasper S, **Shyr Y**, Adams MC, Brock JW, 3rd. Genital malformations and coexistent urinary tract or spinal anomalies in patients with imperforate anus. *Journal of Urology* 1997;158(3 Pt 2):1298-1300.

33. Nicholson B, Paul D, **Shyr Y**, Garrett M, Hande KR, Johnson DH. Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: A Vanderbilt cancer center phase II trial. *Seminars in Oncology* 1997;24(4):20-23.
34. **Shyr Y**, Kshirsagar AM. A formula for a missing plot in a general incomplete block design, when recovery of interblock information is used. *Communications in Statistics-Theory and Methods* 1997;26(12):2855-2860.
35. **Shyr Y**, Kshirsagar AM. Stepwise canonical analysis in categorical data. *Communications in Statistics-Theory and Methods* 1997;26(7):1575-1583.
36. Venkov CD, Su M, **Shyr Y**, Vaughan DE. Ethanol-induced alterations in the expression of endothelial-derived fibrinolytic components. *Fibrinolysis & Proteolysis* 1997;11(2):115-118.
37. Wang HL, MacNeil RL, Thomas C, **Shyr Y**, Syed S. The effect of an absorbable collagen membrane on the subgingival microflora. *Periodontal Clinical Investigations* 1997;19(1):27-35.
38. Chinery R, Beauchamp RD, **Shyr Y**, Kirkland SC, Coffey RJ, Morrow JD. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells. *Cancer Research* 1998;58(11):2323-2327.
39. Cowen ME, Dusseau DJ, Toth BG, Guisinger C, Zodet MW, **Shyr Y**. Casemix adjustment of managed care claims data using the Clinical Classification for Health Policy Research method. *Medical Care* 1998;36(7):1108-1113.
40. Evanson JA, Himmelfarb J, Wingard R, Knights S, **Shyr Y**, Schulman G, Ikizler TA, Hakim RM. Prescribed versus delivered dialysis in acute renal failure patients. *American Journal of Kidney Diseases* 1998;32(5):731-738.
41. Fitzpatrick JM, Hill DLG, **Shyr Y**, West J, Studholme C, Maurer CR. Visual assessment of the accuracy of retrospective registration of MR and CT images of the brain. *IEEE Transactions on Medical Imaging* 1998;17(4):571-585.
42. Lamps LW, Pinson CW, Raiford DS, **Shyr Y**, Scott MA, Washington MK. The significance of microabscesses in liver transplant biopsies: A clinicopathological study. *Hepatology* 1998;28(6):1532-1537.
43. Neyra NR, Ikizler TA, May RE, Himmelfarb J, Schulman G, **Shyr Y**, Hakim RM. Change in access blood flow over time predicts vascular access thrombosis. *Kidney International* 1998;54(5):1714-1719.
44. Ong MMA, Eber RM, Korsnes MI, MacNeil RL, Glickman GN, **Shyr Y**, Wang HL. Evaluation of a bioactive glass alloplast in treating periodontal intrabony defects. *Journal of Periodontology* 1998;69(12):1346-1354.
45. **Shyr Y**. Applied biostatistical method and models for survival analysis. *Medical Newsletter of Chang Gung Memorial Hospital (Taiwan)* 1998;8:24-27.
46. **Shyr Y**. Applying understanding and not misusing medical biostatistics. *Medical Newsletter of Chang Gung Memorial Hospital (Taiwan)* 1998;8:24-25.
47. **Shyr Y**. A canonical form of Anderson's classification statistic. *Communications in Statistics-Theory and Methods* 1998;27(3):577-587.
48. **Shyr Y**. The limitations and extensions of Cox model. *Medical Newsletter of Chang Gung Memorial Hospital (Taiwan)* 1998;8:26-28.
49. Washington K, Chiappori A, Hamilton K, **Shyr Y**, Blanke C, Johnson D, Sawyers J, Beauchamp D. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. *Modern Pathology* 1998;11(9):805-813.
50. Wolinsky PR, Banit D, Parker RE, **Shyr Y**, Snapper JR, Rutherford EJ, Johnson KD. Reamed intramedullary femoral nailing after induction of an "ARDS-like" state in sheep: Effect on clinically applicable markers of pulmonary function. *Journal of Orthopaedic Trauma* 1998;12(3):169-175.
51. Wolinsky PR, McCarty EC, **Shyr Y**, Johnson KD. Length of operative procedures: reamed femoral intramedullary nailing performed with and without a fracture table. *Journal of Orthopaedic Trauma* 1998;12(7):485-495.

52. Becker BN, Coomer RW, Fotiadis C, Evanson J, **Shyr Y**, Hakim RM. Risk factors for hospitalization in well-dialyzed chronic hemodialysis patients. *American Journal of Nephrology* 1999;19(5):565-570.
53. Chang AC, **Shyr Y**, Groves J, Chomsky DB, Davis SF, Wilson JR, Drinkwater DC, Pierson RN, Merrill WH. The utility of exercise testing after cardiac transplantation in older patients. *Journal of Surgical Research* 1999;81(1):48-54.
54. Choy H, LaPorte K, Knill-Selby E, Mohr P, **Shyr Y**. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. *Seminars in Radiation Oncology* 1999;9(2):90-96.
55. Cmelak AJ, Choy H, **Shyr Y**, Mohr P, Glantz MJ, Johnson DH. National survey on prophylactic cranial irradiation: Differences in practice patterns between medical and radiation oncologists. *International Journal of Radiation Oncology Biology Physics* 1999;44(1):157-162.
56. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, **Shyr Y**, Leach SD. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. *Journal of Nuclear Medicine* 1999;40(11):1784-1791.
57. Evanson JA, Ikizler TA, Wingard R, Knights S, **Shyr Y**, Schulman G, Himmelfarb J, Hakim RM. Measurement of the delivery of dialysis in acute renal failure. *Kidney International* 1999;55(4):1501-1508.
58. Herline AJ, Pinson CW, Wright JK, Debelak J, **Shyr Y**, Harley D, Merrill W, Starkey T, Pierson R, Chapman WC. Acute pancreatitis after cardiac transplantation and other cardiac procedures: Case-control analysis in 24,631 patients. *American Surgeon* 1999;65(9):819-825.
59. Hohenfellner K, Hunley TE, Brezinska R, Brodhag P, **Shyr Y**, Brenner W, Habermehl P, Kon V. ACE I/D gene polymorphism predicts renal damage in congenital uropathies. *Pediatric Nephrology* 1999;13(6):514-518.
60. Holcomb GW, Morgan WM, Neblett WW, Pietsch JB, O'Neill JA, **Shyr Y**. Laparoscopic cholecystectomy in children: Lessons learned from the first 100 patients. *Journal of Pediatric Surgery* 1999;34(8):1236-1240.
61. Hughes CA, O'Gorman LA, **Shyr Y**, Schork MA, Bozynski MEA, McCormick MC. Cognitive performance at school age of very low birth weight infants with bronchopulmonary dysplasia. *Journal of Developmental and Behavioral Pediatrics* 1999;20(1):1-8.
62. Ikizler TA, Wingard RL, Harvell J, **Shyr Y**, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. *Kidney International* 1999;55(5):1945-1951.
63. Lowe LH, Banks WJ, **Shyr Y**. Pyloric ratio: Efficacy in the diagnosis of hypertrophic pyloric stenosis. *Journal of Ultrasound in Medicine* 1999;18(11):773-777.
64. Norgaard P, Law B, Joseph H, Page DL, **Shyr Y**, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. *Clinical Cancer Research* 1999;5(1):35-42.
65. Rehman SU, Pupim LB, **Shyr Y**, Hakim R, Ikizler TA. Intradialytic serial vascular access flow measurements. *American Journal of Kidney Diseases* 1999;34(3):471-477.
66. **Shyr Y**. Statistical strategies for modeling the quasi-sinusoidality of time-qualified data. *Statistical Modeling* 1999;14:664-668.
67. Wolinsky PR, McCarty E, **Shyr Y**, Johnson K. Reamed intramedullary nailing of the femur: 551 cases. *Journal of Trauma-Injury Infection and Critical Care* 1999;46(3):392-399.
68. Zhang JP, Blum MG, Chang AC, **Shyr Y**, Blair KSA, Awwad M, Pierson RN. Immunohistologic evaluation of mechanisms mediating hyperacute lung rejection, and the effect of treatment with K76-COOH, FUT-175, and anti-Gal column immune adsorption. *Xenotransplantation* 1999;6(4):249-261.
69. Chakravarthy A, Nicholson B, Kelley M, Beauchamp D, Johnson D, Frexes-Steed M, Simpson J, **Shyr Y**, Pietenpol J. A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer. *Clinical Breast Cancer* 2000;1(1):68-71.

70. Choy H, Devore RF, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, **Shyr Y**, Johnson DH. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (A Vanderbilt cancer center affiliate network study). *International Journal of Radiation Oncology Biology Physics* 2000;47(4):931-937.
71. Choy H, **Shyr Y**, Cmelak AJ, Mohr PJ, Johnson DH. Patterns of practice survey for nonsmall cell lung carcinoma in the US. *Cancer* 2000;88(6):1336-1346.
72. Franke JJ, Gilbert WB, Grier J, Koch MO, **Shyr Y**, Smith JA. Early post-prostatectomy pelvic floor biofeedback. *Journal of Urology* 2000;163(1):191-193.
73. Hernanz-Schulman M, Foster C, Maxa R, Battles G, Dutt P, Stratton C, Holburn G, Schulman G, Neblett WW, **Shyr Y**, Hakim RR, Vanholder R, Heller RM. Experimental study of mortality and morbidity of contrast media and standardized fecal dose in the peritoneal cavity. *Pediatric Radiology* 2000;30(6):369-378.
74. Komhoff M, Guan YF, Shappell HW, Davis L, Jack G, **Shyr Y**, Koch MO, Shappell SB, Breyer MD. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. *American Journal of Pathology* 2000;157(1):29-35.
75. Lowe LH, Penney MW, Scheker LE, Perez R, Stein SM, Heller RM, **Shyr Y**, Hernanz-Schulman M. Appendicolith revealed on CT in children with suspected appendicitis: How specific is it in the diagnosis of appendicitis? *American Journal of Roentgenology* 2000;175(4):981-984.
76. Mertz H, Morgan V, Tanner G, Pickens D, Price R, **Shyr Y**, Kessler R. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. *Gastroenterology* 2000;118(5):842-848.
77. Mizobata S, Tompkins K, Simpson JF, **Shyr Y**, Primus FJ. Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen. *Cancer Immunology Immunotherapy* 2000;49(6):285-295.
78. Neyra NR, Hakim RM, **Shyr Y**, Ikizler TA. Serum transferrin and serum prealbumin are early predictors of serum albumin in chronic hemodialysis patients. *Journal of Renal Nutrition* 2000;10(4):184-190.
79. Nicholson BP, Paul DM, Hande KR, **Shyr Y**, Meshad M, Cohen A, Johnson DH. Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. *Clinical Breast Cancer* 2000;1(2):136-143; discussion 144.
80. Roberts JR, **Shyr Y**, Christian KR, Drinkwater D, Merrill W. Preemptive gastrointestinal tract management reduces aspiration and respiratory failure after thoracic operations. *Journal of Thoracic and Cardiovascular Surgery* 2000;119(3):449-452.
81. **Shyr Y**. The current challenges and future of bioinformatics. *Proceeding of Taiwan Biotechnology Symposiums* 2000:15-22.
82. **Shyr Y**. The statistical strategies for modeling the relationship between multiple variable and RNA expression data and clinical endpoints. *Proceeding of Taiwan Biotechnology Symposiums* 2000:1-14.
83. Stefansic JD, Herline AJ, **Shyr Y**, Chapman WC, Fitzpatrick JM, Dawant BM, Galloway RL. Registration of physical space to laparoscopic image space for use in minimally invasive hepatic surgery. *IEEE Transactions on Medical Imaging* 2000;19(10):1012-1023.
84. Tingstad EM, Wolinsky PR, **Shyr Y**, Johnson KD. Effect of immediate weightbearing on plated fractures of the humeral shaft. *Journal of Trauma-Injury Infection and Critical Care* 2000;49(2):278-280.
85. Washington K, Wright K, **Shyr Y**, Hunter EB, Olson S, Raiford DS. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. *Human Pathology* 2000;31(7):822-828.
86. Xu XC, Clarke P, Szalai G, Shively JE, Williams LE, **Shyr Y**, Shi EG, Primus FJ. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. *Cancer Research* 2000;60(16):4475-4484.
87. Amorino GP, Lee H, Holburn GE, Paschal CB, Hercules SK, **Shyr Y**, Steffen RP, Choy H. Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13. *Radiation Research* 2001;156(3):294-300.

88. Blanke CD, Stipanov M, Morrow J, Rothenberg M, Chinery R, **Shyr Y**, Coffey R, Johnson DH, Leach SD, Beauchamp RD. A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. *Investigational New Drugs* 2001;19(1):21-27.
89. Choy H, DeVore RF, Hande KR, Porter LL, Rosenblatt PA, Slovis B, Laporte K, **Shyr Y**, Johnson DH. Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. *Lung Cancer* 2001;34(3):441-449.
90. Deane NG, Parker MA, Aramandla R, Diehl L, Lee WJ, Washington MK, Nanney LB, **Shyr Y**, Beauchamp RD. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. *Cancer Research* 2001;61(14):5389-5395.
91. Dowell JE, Garrett AM, **Shyr Y**, Johnson DH, Hande KR. A randomized phase II trial in patients with carcinoma of an unknown primary site. *Cancer* 2001;91(3):592-597.
92. Dowell JE, Johnson DH, Rogers JS, **Shyr Y**, McCullough N, Krozely P, DeVore RF. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy. *Investigational New Drugs* 2001;19(1):85-88.
93. Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, Cohen AG, **Shyr Y**, Carbone DP, DeVore RF. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: A multicenter phase II study. *Clinical Cancer Research* 2001;7(1):68-73.
94. Lowe LH, Penney MW, Stein SM, Heller RM, Neblett WW, **Shyr Y**, Hernanz-Schulman M. Unenhanced limited CT of the abdomen in the diagnosis of appendicitis in children: Comparison with sonography. *American Journal of Roentgenology* 2001;176(1):31-35.
95. McCarley P, Wingard RL, **Shyr Y**, Pettus W, Hakim RM, Ikizler TA. Vascular access blood flow monitoring reduces access morbidity and costs. *Kidney International* 2001;60(3):1164-1172.
96. McCarty EC, Spindler KP, Tingstad E, **Shyr Y**, Higgins M. Does intraarticular morphine improve pain control with femoral nerve block after anterior cruciate ligament reconstruction? *American Journal of Sports Medicine* 2001;29(3):327-332.
97. Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Toledano AY, **Shyr Y**, Washington K. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation. *Human Pathology* 2001;32(4):368-378.
98. Murphy BA, Cmelak A, Burkey B, Netterville J, **Shyr Y**, Douglas S, Smith W. Topoisomerase I inhibitors in the treatment of head and neck cancer. *Oncology (Williston Park)* 2001;15(7 Suppl 8):47-52.
99. Pietrow PK, Parekh DJ, Smith JA, Jr., **Shyr Y**, Cookson MS. Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence. *Journal of Urology* 2001;166(6):2286-2290.
100. Saadeh E, Ikizler TA, **Shyr Y**, Hakim RM, Himmelfarb J. Recombinant human growth hormone in patients with acute renal failure. *Journal of Renal Nutrition* 2001;11(4):212-219.
101. Sofowora GG, Choo EF, Mayo G, **Shyr Y**, Wilkinson GR. In vivo inhibition of human CYP1A2 activity by oltipraz. *Cancer Chemotherapy and Pharmacology* 2001;47(6):505-510.
102. Tham KT, Peek RM, Atherton JC, Cover TL, Perez-Perez GI, **Shyr Y**, Blaser MJ. Helicobacter pylori genotypes, host factors, and gastric mucosal histopathology in peptic ulcer disease. *Human Pathology* 2001;32(3):264-273.
103. Wang HL, Bunyaratavej P, Labadie M, **Shyr Y**, MacNeil RL. Comparison of 2 clinical techniques for treatment of gingival recession. *Journal of Periodontology* 2001;72(10):1301-1311.
104. Washington K, Debelak JP, Gobbell C, Sztipanovits DR, **Shyr Y**, Olson S, Chapman WC. Hepatic cryoablation-induced acute lung injury: Histopathologic findings. *Journal of Surgical Research* 2001;95(1):1-7.
105. Boyd AS, **Shyr Y**, King LE, Jr. Basal cell carcinoma in young women: an evaluation of the association of tanning bed use and smoking. *Journal of the American Academy of Dermatology* 2002;46(5):706-709.

106. Caglar K, Fedje L, Dimmitt R, Hakim RM, **Shyr Y**, Ikizler TA. Therapeutic effects of oral nutritional supplementation during hemodialysis. *Kidney International* 2002;62(3):1054-1059.
107. Chen S-Y, Wang H-L, Glickman GN, **Shyr Y**, MacNeil RL. Multivariate analysis of factors influencing outcomes of regenerative therapy: a retrospective study. *International Chinese Journal of Dentistry* 2002;2:50-59.
108. Hallahan DE, Geng L, **Shyr Y**. Effects of intercellular adhesion molecule 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice. *Journal of the National Cancer Institute* 2002;94(10):733-741.
109. Himmelfarb J, Evanson J, Hakim RM, Freedman S, **Shyr Y**, Ikizler TA. Urea volume of distribution exceeds total body water in patients with acute renal failure. *Kidney International* 2002;61(1):317-323.
110. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, **Shyr Y**, Himmelfarb J. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. *Clinical Nephrology* 2002;58(3):190-197.
111. MacRae R, **Shyr Y**, Johnson D, Choy H. Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. *Journal of the European Society for Therapeutic Radiology and Oncology* 2002; 64(1): 37-40.
112. Miller MF, McDowell T, Small SE, **Shyr Y**, Kemp NR. Hardly used habitats: Dearth and distribution of burrowing in Paleozoic and Mesozoic stream and lake deposits. *Geology* 2002;30(6):527-530.
113. Pietrow PK, Pope JcT, Adams MC, **Shyr Y**, Brock JW, 3rd. Clinical outcome of pediatric stone disease. *Journal of Urology* 2002;167(2 Pt 1):670-673.
114. Pupim LB, Kent P, Caglar K, **Shyr Y**, Hakim RM, Ikizler TA. Improvement in nutritional parameters after initiation of chronic hemodialysis. *American Journal of Kidney Diseases* 2002;40(1):143-151.
115. Washington K, Greenson JK, Montgomery E, **Shyr Y**, Crissinger KD, Polk DB, Barnard J, Lauwers GY. Histopathology of ulcerative colitis in initial rectal biopsy in children. *American Journal of Surgical Pathology* 2002;26(11):1441-1449.
116. Wudel LJ, Jr., Chapman WC, **Shyr Y**, Davidson M, Jeyakumar A, Rogers SO, Jr., Allos T, Stain SC. Disparate outcomes in patients with colorectal cancer: effect of race on long-term survival. *Archives of Surgery* 2002;137(5):550-554; discussion 554-556.
117. Wudel LJ, Jr., Wright JK, Debelak JP, Allos TM, **Shyr Y**, Chapman WC. Prevention of gallstone formation in morbidly obese patients undergoing rapid weight loss: results of a randomized controlled pilot study. *Journal of Surgical Research* 2002;102(1):50-56.
118. Gorska AE, Jensen RA, **Shyr Y**, Aakre ME, Bhowmick NA, Moses HL. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. *American Journal of Pathology* 2003;163(4):1539-1549. PMID: PMC1868288.
119. Kim JC, Kim JS, Saha D, Cao Q, **Shyr Y**, Choy H. Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells. *Radiotherapy and Oncology* 2003;68(3):305-313.
120. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, **Shyr Y**, Edgerton ME, Westfall MD, Roberts JR, Pietsenpol JA, Carbone DP, Gonzalez AL. Significance of p63 amplification and overexpression in lung cancer development and prognosis. *Cancer Research* 2003;63(21):7113-7121.
121. Neyra R, Chen KY, Sun M, **Shyr Y**, Hakim RM, Ikizler TA. Increased resting energy expenditure in patients with end-stage renal disease. *Journal of Parenteral and Enteral Nutrition* 2003;27(1):36-42.
122. **Shyr Y**. Statistical strategies for analyzing the microarray data in human lung cancer. *Lung Cancer* 2003;41(2003):90-91.
123. Tu WH, Thomas TZ, Masumori N, Bhowmick NA, Gorska AE, **Shyr Y**, Kasper S, Case T, Roberts RL, Shappell SB, Moses HL, Matusik RJ. The loss of TGF-beta signaling promotes prostate cancer metastasis. *Neoplasia* 2003;5(3):267-277. PMID: PMC1502411.

124. VanderVeen LA, Hashim MF, **Shyr Y**, Marnett LJ. Induction of frameshift and base pair substitution mutations by the major DNA adduct of the endogenous carcinogen malondialdehyde. *Proceedings of the National Academy of Sciences of the United States of America* 2003;100(24):14247-14252. PMID: PMC283577.
125. Wudel LJ, Jr., Delbeke D, Morris D, Rice M, Washington MK, **Shyr Y**, Pinson CW, Chapman WC. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. *American Surgeon* 2003;69(2):117-124; discussion 124-116.
126. Xie L, Law BK, Aakre ME, Edgerton M, **Shyr Y**, Bhowmick NA, Moses HL. Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. *Breast Cancer Res* 2003;5(6):R187-198. PMID: PMC314403.
127. Yamagata N, **Shyr Y**, Yanagisawa K, Edgerton M, Dang TP, Gonzalez A, Nadaf S, Larsen P, Roberts JR, Nesbitt JC, Jensen R, Levy S, Moore JH, Minna JD, Carbone DP. A training-testing approach to the molecular classification of resected non-small cell lung cancer. *Clinical Cancer Research* 2003;9(13):4695-4704.
128. Yanagisawa K, **Shyr Y**, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone DP. Proteomic patterns of tumour subsets in non-small-cell lung cancer. *Lancet* 2003;362(9382):433-439.
129. Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, **Shyr Y**, Boothby M, Joyce S, Carbone DP, Breyer RM. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. *Journal of Clinical Investigation* 2003;111(5):727-735. PMID: PMC151895.
130. Gonzalez AL, Roberts RL, Massion PP, Olson SJ, **Shyr Y**, Shappell SB. 15-Lipoxygenase-2 expression in benign and neoplastic lung: an immunohistochemical study and correlation with tumor grade and proliferation. *Human Pathology* 2004;35(7):840-849.
131. Ikizler TA, Sezer MT, Flakoll PJ, Hariachar S, Kanagasundaram NS, Gritter N, Knights S, **Shyr Y**, Paganini E, Hakim RM, Himmelfarb J. Urea space and total body water measurements by stable isotopes in patients with acute renal failure. *Kidney International* 2004;65(2):725-732.
132. Jagasia M, Morgan D, Goodman S, Hamilton K, Kinney M, **Shyr Y**, Stein R, Zic J, Greer J. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. *Leukemia & Lymphoma* 2004;45(11):2261-2267.
133. Jennings MT, Cmelak A, Johnson MD, Moots PL, Pais R, **Shyr Y**. Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy. *Pediatric Blood & Cancer* 2004;43(1):46-54.
134. Kimble KM, Eber RM, Soehren S, **Shyr Y**, Wang HL. Treatment of gingival recession using a collagen membrane with or without the use of demineralized freeze-dried bone allograft for space maintenance. *Journal of Periodontology* 2004;75(2):210-220.
135. Lu B, Gonzalez A, Massion PP, **Shyr Y**, Shaktour B, Carbone DP, Hallahan DE. Nuclear survivin as a biomarker for non-small-cell lung cancer. *British Journal of Cancer* 2004;91(3):537-540. PMID: PMC2409840.
136. Massion PP, Taflan PM, **Shyr Y**, Rahman SM, Yildiz P, Shakhtour B, Edgerton ME, Ninan M, Andersen JJ, Gonzalez AL. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. *American Journal of Respiratory and Critical Care Medicine* 2004;170(10):1088-1094.
137. Osusky KL, Hallahan DE, Fu A, Ye F, **Shyr Y**, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. *Angiogenesis* 2004;7(3):225-233.
138. Pupim LB, Caglar K, Hakim RM, **Shyr Y**, Ikizler TA. Uremic malnutrition is a predictor of death independent of inflammatory status. *Kidney International* 2004;66(5):2054-2060.
139. Pupim LB, Himmelfarb J, McMonagle E, **Shyr Y**, Ikizler TA. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. *Kidney International* 2004;65(6):2371-2379.

140. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, Soroko S, Freedman S, Becker K, Spratt D, **Shyr Y**, Ikizler TA. Plasma cytokine levels predict mortality in patients with acute renal failure. *Kidney International* 2004;65(4):1357-1365.
141. Tedesco KL, Thor AD, Johnson DH, **Shyr Y**, Blum KA, Goldstein LJ, Gradishar WJ, Nicholson BP, Merkel DE, Murrey D, Edgerton S, Sledge GW, Jr. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. *Journal of Clinical Oncology* 2004;22(6):1071-1077.
142. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, **Shyr Y**, Matrisian LM, Carbone DP, Lin PC. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. *Cancer Cell* 2004;6(4):409-421.
143. Basi S, Pupim LB, Simmons EM, Sezer MT, **Shyr Y**, Freedman S, Chertow GM, Mehta RL, Paganini E, Himmelfarb J, Ikizler TA. Insulin resistance in critically ill patients with acute renal failure. *American Journal of Physiology - Renal Physiology* 2005;289(2):F259-264.
144. Boyd AS, Wu H, **Shyr Y**. Monster cells in malignant melanoma. *American Journal of Dermatopathology* 2005;27(3):208-210.
145. Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, **Shyr Y**, Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. *FASEB Journal* 2005;19(13):1884-1886.
146. Bui CM, Chen H, **Shyr Y**, Joos KM. Discontinuing nasal steroids might lower intraocular pressure in glaucoma. *J Allergy Clin Immunol* 2005;116(5):1042-1047.
147. Csiki I, Morrow JD, Sandler A, **Shyr Y**, Oates J, Williams MK, Dang T, Carbone DP, Johnson DH. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. *Clinical Cancer Research* 2005;11(18):6634-6640.
148. Frank DB, Abtahi A, Yamaguchi DJ, Manning S, **Shyr Y**, Pozzi A, Baldwin HS, Johnson JE, de Caestecker MP. Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. *Circulation Research* 2005;97(5):496-504.
149. Grau AM, Ata A, Foster L, Ahmed NU, Gorman DR, **Shyr Y**, Stain SC, Pearson AS. Effect of race on long-term survival of breast cancer patients: transinstitutional analysis from an inner city hospital and university medical center. *American Surgeon* 2005;71(2):164-170.
150. Kim DW, **Shyr Y**, Chen H, Akerley W, Johnson DH, Choy H. Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics* 2005;63(4):1029-1036.
151. Kim DW, **Shyr Y**, Shaktour B, Akerley W, Johnson DH, Choy H. Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. *Lung Cancer* 2005;50(2):235-245.
152. Kuhn JE, Huston LJ, Soslowsky LJ, **Shyr Y**, Blasier RB. External rotation of the glenohumeral joint: ligament restraints and muscle effects in the neutral and abducted positions. *Journal of Shoulder and Elbow Surgery* 2005;14(1 Suppl S):39S-48S.
153. Maas K, Chen H, **Shyr Y**, Olsen NJ, Aune T. Shared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease. *Human Molecular Genetics* 2005;14(10):1305-1314.
154. Park YK, Franklin JL, Settle SH, Levy SE, Chung E, Jeyakumar LH, **Shyr Y**, Washington MK, Whitehead RH, Aronow BJ, Coffey RJ. Gene expression profile analysis of mouse colon embryonic development. *Genesis* 2005;41(1):1-12.
155. Rahman SM, **Shyr Y**, Yildiz PB, Gonzalez AL, Li H, Zhang X, Chaurand P, Yanagisawa K, Slovis BS, Miller RF, Ninan M, Miller YE, Franklin WA, Caprioli RM, Carbone DP, Massion PP. Proteomic patterns of preinvasive bronchial lesions. *American Journal of Respiratory and Critical Care Medicine* 2005;172(12):1556-1562. PMID: PMC2718455.

156. Schwartz SA, Weil RJ, Thompson RC, **Shyr Y**, Moore JH, Toms SA, Johnson MD, Caprioli RM. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. *Cancer Research* 2005;65(17):7674-7681.
157. Shinohara ET, Geng L, Tan J, Chen H, **Shyr Y**, Edwards E, Hallbrook J, Kesicki EA, Kashishian A, Hallahan DE. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation sensitizing drugs. *Cancer Research* 2005;65(12):4987-4992.
158. Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, Olson SJ, Andersen JJ, **Shyr Y**, Carbone DP, Johnson DH, Hallahan DE, Lu B. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. *Cancer* 2005;103(8):1685-1692.
159. Tedesco KL, Berlin J, Blanke CD, Teng M, Choy H, Roberts J, Beauchamp RD, Leach S, Wyman K, Tarpley J, **Shyr Y**, Caillouette C, Chakravarthy B. Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer. *International Journal of Radiation Oncology Biology Physics* 2005;61(5):1364-1370.
160. Tedesco KL, Berlin J, Rothenberg M, Choy H, Wyman K, Scott Pearson A, Daniel Beauchamp R, Merchant N, Lockhart AC, **Shyr Y**, Caillouette C, Chakravarthy B. A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. *Radiotherapy and Oncology* 2005;76(1):54-58.
161. Thompson MA, Stumph J, Henrickson SE, Rosenwald A, Wang Q, Olson S, Brandt SJ, Roberts J, Zhang X, **Shyr Y**, Kinney MC. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. *Human Pathology* 2005;36(5):494-504.
162. Xie L, Xu BJ, Gorska AE, **Shyr Y**, Schwartz SA, Cheng N, Levy S, Bierie B, Caprioli RM, Moses HL. Genomic and proteomic analysis of mammary tumors arising in transgenic mice. *Journal of Proteome Research* 2005;4(6):2088-2098.
163. Xu BJ, **Shyr Y**, Liang X, Ma LJ, Donnert EM, Roberts JD, Zhang X, Kon V, Brown NJ, Caprioli RM, Fogo AB. Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. *Journal of the American Society of Nephrology* 2005;16(10):2967-2975.
164. Yi Y, Mirosevich J, **Shyr Y**, Matusik R, George AL, Jr. Coupled analysis of gene expression and chromosomal location. *Genomics* 2005;85(3):401-412.
165. Baker SG, Kramer BS, McIntosh M, Patterson BH, **Shyr Y**, Skates S. Evaluating markers for the early detection of cancer: overview of study designs and methods. *Clinical Trials* 2006;3(1):43-56.
166. Cuneo KC, Geng L, Tan J, Brousal J, Shinohara ET, Osusky K, Fu A, **Shyr Y**, Wu H, Hallahan DE. SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation. *International Journal of Radiation Oncology Biology Physics* 2006;64(4):1197-1203.
167. Dennehy MK, Richards KA, Wernke GR, **Shyr Y**, Liebler DC. Cytosolic and nuclear protein targets of thiol-reactive electrophiles. *Chemical Research in Toxicology* 2006;19(1):20-29.
168. Geng L, Shinohara ET, Kim D, Tan J, Osusky K, **Shyr Y**, Hallahan DE. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. *International Journal of Radiation Oncology Biology Physics* 2006;64(1):263-271.
169. Hong D, **Shyr Y**. Wavelets in biostatistics. *Journal of Concrete and Applicable Mathematics* 2006;4:505-521.
170. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, **Shyr Y**, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. *PLoS Med* 2006;3(12):e486. PMID: PMC1716188.
171. Slebos RJ, Li M, Evjen AN, Coffa J, **Shyr Y**, Yarbrough WG. Mutagenic effect of cadmium on tetranucleotide repeats in human cells. *Mutation Research* 2006;602(1-2):92-99.

172. Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X, **Shyr Y**, Murphy BM, Cmelak AJ, Burkey BB, Netterville JL, Levy S, Yarbrough WG, Chung CH. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. *Clinical Cancer Research* 2006;12(3 Pt 1):701-709.
173. Wetzel JD, Barton ES, Chappell JD, Baer GS, Mochow-Grundy M, Rodgers SE, **Shyr Y**, Powers AC, Thomas JW, Dermody TS. Reovirus delays diabetes onset but does not prevent insulinitis in nonobese diabetic mice. *Journal of Virology* 2006;80(6):3078-3082. PMID: PMC1395416.
174. Wright RW, Boyce RH, Michener T, **Shyr Y**, McCarty EC, Spindler KP. Radiographs are not useful in detecting arthroscopically confirmed mild chondral damage. *Clinical Orthopaedics and Related Research* 2006;442:245-251.
175. Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, **Shyr Y**, Winkquist E, Soulieres D, Chen EX, Squire JA, Marrano P, Kamel-Reid S, Dancey J, Siu LL, Tsao MS. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. *Journal of Clinical Oncology* 2007;25(16):2184-2190.
176. Albert JM, Gonzalez A, Massion PP, Chen H, Olson SJ, **Shyr Y**, Diaz R, Lambright ES, Sandler A, Carbone DP, Putnam JB, Jr., Johnson DH, Lu B. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. *Cancer Epidemiology Biomarkers & Prevention* 2007;16(9):1845-1851.
177. Chen S, Hong D, **Shyr Y**. Wavelet-based procedures for proteomic mass spectrometry data processing. *Computational Statistics & Data Analysis* 2007;52(1):211-220.
178. Cheng N, Chytil A, **Shyr Y**, Joly A, Moses HL. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. *Cancer Research* 2007;67(10):4869-4877.
179. Cmelak AJ, Murphy BA, Burkey B, Douglas S, **Shyr Y**, Netterville J. Taxane-based chemoradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial. *Head Neck* 2007;29(4):315-324.
180. Dai Q, Shrubsole MJ, Ness RM, Schlundt D, Cai Q, Smalley WE, Li M, **Shyr Y**, Zheng W. The relation of magnesium and calcium intakes and a genetic polymorphism in the magnesium transporter to colorectal neoplasia risk. *American Journal of Clinical Nutrition* 2007;86(3):743-751. PMID: PMC2082111.
181. Hoshino A, Yee CJ, Campbell M, Woltjer RL, Townsend RL, van der Meer R, **Shyr Y**, Holt JT, Moses HL, Jensen RA. Effects of BRCA1 transgene expression on murine mammary gland development and mutagen-induced mammary neoplasia. *International Journal of Biological Sciences* 2007;3(5):281-291. PMID: PMC1865089.
182. Jiang A, Pan W, Milbauer LC, **Shyr Y**, Hebbel RP. A practical question based on cross-platform microarray data normalization: are BOEC more like large vessel or microvascular endothelial cells or neither of them? *Journal of Bioinformatics and Computational Biology* 2007;5(4):875-893.
183. Kantrow SM, Boyd AS, Ellis DL, Nanney LB, Richmond A, **Shyr Y**, Robbins JB. Expression of activated Akt in benign nevi, Spitz nevi and melanomas. *Journal of Cutaneous Pathology* 2007;34(8):593-596. PMID: PMC2665272.
184. Kim DW, Blanke CD, Wu H, **Shyr Y**, Berlin J, Beauchamp RD, Chakravarthy B. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. *International Journal of Radiation Oncology Biology Physics* 2007;67(2):397-404.
185. Li JQ, Xu BJ, Shakhtour B, Deane N, Merchant N, Heslin MJ, Washington K, Coffey RJ, Beauchamp RD, **Shyr Y**, Billheimer D. Variability of in situ proteomic profiling and implications for study design in colorectal tumors. *International Journal of Oncology* 2007;31(1):103-111.
186. Lovvorn HN, 3rd, Boyle S, Shi G, **Shyr Y**, Wills ML, Perantoni AO, de Caestecker M. Wilms' tumorigenesis is altered by misexpression of the transcriptional co-activator, CITED1. *Journal of Pediatric Surgery* 2007;42(3):474-481. PMID: PMC3028602.

187. Murff HJ, Shrubsole MJ, Smalley WE, Wu H, **Shyr Y**, Ness RM, Zheng W. The interaction of age and hormone replacement therapy on colon adenoma risk. *Cancer Detection and Prevention* 2007;31(2):161-165. PMID: PMC1949417.
188. Roberts LJ, 2nd, Oates JA, Linton MF, Fazio S, Meador BP, Gross MD, **Shyr Y**, Morrow JD. The relationship between dose of vitamin E and suppression of oxidative stress in humans. *Free Radical Biology & Medicine* 2007;43(10):1388-1393. PMID: PMC2072864.
189. Shin A, Shrubsole MJ, Ness RM, Wu H, Sinha R, Smalley WE, **Shyr Y**, Zheng W. Meat and meat-mutagen intake, doneness preference and the risk of colorectal polyps: the Tennessee Colorectal Polyp Study. *International Journal of Cancer* 2007;121(1):136-142.
190. Shinohara ET, Gonzalez A, Massion PP, Olson SJ, Albert JM, **Shyr Y**, Carbone DP, Johnson DH, Hallahan DE, Lu B. PDGFR-beta expression in small cell lung cancer patients. *International Journal of Radiation Oncology Biology Physics* 2007;67(2):431-437.
191. Sinsakul M, Sika M, Rodby R, Middleton J, **Shyr Y**, Chen H, Han E, Lehrich R, Clyne S, Schulman G, Harris R, Lewis J. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. *American Journal of Kidney Diseases* 2007;50(6):946-951.
192. Tang YW, Li H, Wu H, **Shyr Y**, Edwards KM. Host single-nucleotide polymorphisms and altered responses to inactivated influenza vaccine. *Journal of Infectious Diseases* 2007;196(7):1021-1025.
193. Wall RJ, **Shyr Y**, Smalley W. Nonsteroidal anti-inflammatory drugs and lung cancer risk: a population-based case control study. *Journal of Thoracic Oncology* 2007;2(2):109-114.
194. Willey CD, Murphy BA, Netteville JL, Burkey BB, **Shyr Y**, Shakhtour B, Kish B, Raben D, Chen C, Song JI, Kane MA, Cmelak AJ. A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients. *International Journal of Radiation Oncology Biology Physics* 2007;67(5):1323-1331.
195. Woodhams DC, Vredenburg VT, Simon MA, Billheimer D, Shakhtour B, **Shyr Y**, Briggs CJ, Rollins-Smith LA, Harris RN. Symbiotic bacteria contribute to innate immune defenses of the threatened mountain yellow-legged frog, *Rana muscosa*. *Biological Conservation* 2007;138(3-4):390-398.
196. Wu H, Muscato NE, Gonzalez A, **Shyr Y**. An EGFR and AKT Signaling Pathway was Identified with Mediation Model in Osteosarcomas Clinical Study. *Biomark Insights* 2007;2:469-476. PMID: PMC2717822.
197. Ye F, **Shyr Y**. Balanced two-stage designs for phase II clinical trials. *Clinical Trials* 2007;4(5):514-524.
198. Yildiz PB, **Shyr Y**, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, Gray WH, Chen S, Li M, Roder H, Liebler DC, Bigbee WL, Siegfried JM, Weissfeld JL, Gonzalez AL, Ninan M, Johnson DH, Carbone DP, Caprioli RM, Massion PP. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. *Journal of Thoracic Oncology* 2007;2(10):893-901.
199. Boyd AS, Shakhtour B, **Shyr Y**. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases. *Journal of the American Academy of Dermatology* 2008;58(5):750-754.
200. Cheng N, Chytil A, **Shyr Y**, Joly A, Moses HL. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. *Molecular Cancer Research* 2008;6(10):1521-1533. PMID: PMC2740918.
201. Frangoul H, Al-Jadiry MF, **Shyr Y**, Ye F, Shakhtour B, Al-Hadad SA. Shortage of chemotherapeutic agents in Iraq and outcome of childhood acute lymphocytic leukemia, 1990-2002. *New England Journal of Medicine* 2008;359(4):435-437.
202. Gilbert J, Cmelak A, **Shyr Y**, Netteville J, Burkey BB, Sinard RJ, Yarbrough WG, Chung CH, Aulino JM, Murphy BA. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. *Cancer* 2008;113(1):186-192.
203. Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, **Shyr Y**, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. *Journal of Clinical Oncology* 2008;26(6):897-906.

204. Harris EI, Lewin DN, Wang HL, Lauwers GY, Srivastava A, **Shyr Y**, Shakhtour B, Revetta F, Washington MK. Lymphovascular invasion in colorectal cancer: an interobserver variability study. *American Journal of Surgical Pathology* 2008;32(12):1816-1821. PMID: PMC2605104.
205. Huang T, Tu K, **Shyr Y**, Wei CC, Xie L, Li YX. The prediction of interferon treatment effects based on time series microarray gene expression profiles. *Journal of Translational Medicine* 2008;6:44. PMID: PMC2546378.
206. Lin KC, Chen YJ, **Shyr Y**. A nonparametric smoothing method for assessing GEE models with longitudinal binary data. *Statistics in Medicine* 2008;27(22):4428-4439.
207. Massion PP, Zou Y, Chen H, Jiang A, Coulson P, Amos CI, Wu X, Wistuba I, Wei Q, **Shyr Y**, Spitz MR. Smoking-related genomic signatures in non-small cell lung cancer. *American Journal of Respiratory and Critical Care Medicine* 2008;178(11):1164-1172. PMID: PMC2720147.
208. Ni TT, Lemon WJ, **Shyr Y**, Zhong TP. Use of normalization methods for analysis of microarrays containing a high degree of gene effects. *BMC Bioinformatics* 2008;9:505. PMID: PMC2612699.
209. Shin A, Shrubsole MJ, Rice JM, Cai Q, Doll MA, Long J, Smalley WE, **Shyr Y**, Sinha R, Ness RM, Hein DW, Zheng W. Meat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk. *Cancer Epidemiology Biomarkers & Prevention* 2008;17(2):320-329. PMID: PMC2572782.
210. Shinall MC, Jr., Koehler E, **Shyr Y**, Lovvorn HN, 3rd. Comparing cost and complications of primary and staged surgical repair of neonatally diagnosed Hirschsprung's disease. *Journal of Pediatric Surgery* 2008;43(12):2220-2225.
211. Shrubsole MJ, Wu H, Ness RM, **Shyr Y**, Smalley WE, Zheng W. Alcohol drinking, cigarette smoking, and risk of colorectal adenomatous and hyperplastic polyps. *American Journal of Epidemiology* 2008;167(9):1050-1058.
212. Slebos RJ, Li M, Vadivelu S, Burkey BB, Nettekville JL, Sinard R, Gilbert J, Murphy B, Chung CH, **Shyr Y**, Yarbrough WG. Microsatellite mutations in buccal cells are associated with aging and head and neck carcinoma. *British Journal of Cancer* 2008;98(3):619-626. PMID: PMC2243146.
213. Xu BJ, Gonzalez AL, Kikuchi T, Yanagisawa K, Massion PP, Wu H, Mason SE, Olson SJ, **Shyr Y**, Carbone DP, Caprioli RM. MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer. *Proteomics – Clinical Applications* 2008;2(10-11):1508-1517.
214. Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, **Shyr Y**, Moses HL. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. *Journal of Clinical Investigation* 2009;119(6):1571-1582. PMID: PMC2689133.
215. Buzzell JE, Lutton DM, **Shyr Y**, Neviasser RJ, Lee DH. Reliability and accuracy of templating the proximal humeral component for shoulder arthroplasty. *Journal of Shoulder and Elbow Surgery* 2009;18(5):728-733.
216. Chen S, Li M, Hong D, Billheimer D, Li H, Xu BJ, **Shyr Y**. A novel comprehensive wave-form MS data processing method. *Bioinformatics* 2009;25(6):808-814. PMID: PMC2732299.
217. Davies SS, Traustadottir T, Stock AA, Ye F, **Shyr Y**, Harman SM, Roberts LJ, 2nd. Ischemia/reperfusion unveils impaired capacity of older adults to restrain oxidative insult. *Free Radical Biology & Medicine* 2009;47(7):1014-1018. PMID: PMC2748908.
218. Kan JH, Estrada C, Hasan U, Bracikowski A, **Shyr Y**, Shakhtour B, Hernanz-Schulman M. Management of occult fractures in the skeletally immature patient: cost analysis of implementing a limited trauma magnetic resonance imaging protocol. *Pediatric Emergency Care* 2009; 25(4): 336-30.
219. Li S, Li H, Li M, **Shyr Y**, Xie L, Li Y. Improved prediction of lysine acetylation by support vector machines. *Protein and Peptide Letters* 2009;16(8):977-983.
220. Lovejoy CA, Xu X, Bansbach CE, Glick GG, Zhao R, Ye F, Sirbu BM, Titus LC, **Shyr Y**, Cortez D. Functional genomic screens identify CINP as a genome maintenance protein. *Proceedings of the National Academy of Sciences of the United States of America* 2009;106(46):19304-19309. PMID: PMC2780779.

221. Moretti L, Yu DS, Chen H, Carbone DP, Johnson DH, Keedy VL, Putnam JB, Jr., Sandler AB, **Shyr Y**, Lu B. Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. *The Oncologist* 2009;14(11):1106-1115. PMID: PMC3045762.
222. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, **Shyr Y**, Ye F, Choy H. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. *Clinical Cancer Research* 2009;15(6):2158-2165.
223. Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, **Shyr Y**, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. *Journal of Thoracic Oncology* 2009;4(6):689-696. PMID: PMC3563261.
224. Tennessen JA, Woodhams DC, Chaurand P, Reinert LK, Billheimer D, **Shyr Y**, Caprioli RM, Blouin MS, Rollins-Smith LA. Variations in the expressed antimicrobial peptide repertoire of northern leopard frog (*Rana pipiens*) populations suggest intraspecies differences in resistance to pathogens. *Developmental and Comparative Immunology* 2009;33(12):1247-1257. PMID: PMC2927990.
225. Wu H, Dai Q, Shrubsole MJ, Ness RM, Schlundt D, Smalley WE, Chen H, Li M, **Shyr Y**, Zheng W. Fruit and vegetable intakes are associated with lower risk of colorectal adenomas. *Journal of Nutrition* 2009;139(2):340-344. PMID: PMC2646202.
226. Wu J, Qiu Q, Xie L, Fullerton J, Yu J, **Shyr Y**, George AL, Jr., Yi Y. Web-based interrogation of gene expression signatures using EXALT. *BMC Bioinformatics* 2009;10:420. PMID: PMC2799423.
227. Wujcik D, **Shyr Y**, Li M, Clayton MF, Ellington L, Menon U, Mooney K. Delay in diagnostic testing after abnormal mammography in low-income women. *Oncology Nursing Forum* 2009;36(6):709-715.
228. Xu BJ, Li J, Beauchamp RD, **Shyr Y**, Li M, Washington MK, Yeatman TJ, Whitehead RH, Coffey RJ, Caprioli RM. Identification of early intestinal neoplasia protein biomarkers using laser capture microdissection and MALDI MS. *Molecular & Cellular Proteomics* 2009;8(5):936-945. PMID: PMC2689774.
229. Zhao BB, **Shyr Y**. Discrimination or differing model structures? Alternatives and extensions to Blinder-Oaxaca decomposition. *Journal of Economic and Social Measurement* 2009;34(2,3):159-174.
230. Barton CE, Johnson KN, Mays DM, Boehnke K, **Shyr Y**, Boukamp P, Pietenpol JA. Novel p63 target genes involved in paracrine signaling and keratinocyte differentiation. *Cell Death & Disease* 2010;1(9):e74. PMID: PMC3000738.
231. Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. *Breast Cancer Research* 2010; 12(3): R41.
232. Chong PY, Koehler EA, **Shyr Y**, Watson JT, Weikert DR, Rowland JH, Lee DH. Driving with an arm immobilized in a splint: a randomized higher-order crossover trial. *Journal of Bone and Joint Surgery (American Volume)* 2010;92(13):2263-2269.
233. Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, Netteville J, Sinard R, Yarbrough WG, Cmelak AJ, Slebos RJ, **Shyr Y**, Parker J, Gilbert J, Murphy BA. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. *Annals of Oncology* 2010;21(4):864-870. PMID: PMC2844946.
234. Diaz R, Jaboin JJ, Morales-Paliza M, Koehler E, Phillips JG, Stinson S, Gilbert J, Chung CH, Murphy BA, Yarbrough WG, Murphy PB, **Shyr Y**, Cmelak AJ. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics* 2010;77(2):468-476.
235. Grogan EL, Deppen S, Pecot CV, Putnam JB, Jr., Nesbitt JC, **Shyr Y**, Rajanbabu R, Ory B, Lambright ES, Massion PP. Diagnostic characteristics of a serum biomarker in patients with positron emission tomography scans. *The Annals of Thoracic Surgery* 2010;89(6):1724-1728; discussion 1728-1729. PMID: PMC3026702.

236. Hassanein M, Weidow B, Koehler E, Bakane N, Garbett S, **Shyr Y**, Quaranta V. Development of High-Throughput Quantitative Assays for Glucose Uptake in Cancer Cell Lines. *Molecular Imaging and Biology* 2010.
237. Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, **Shyr Y**, Slebos RJ, Chung CH. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. *PLoS ONE* 2010;5(9):e12702. PMID: PMC2938338.
238. Kobayashi H, Huang J, Ye F, **Shyr Y**, Blackwell TS, Lin PC. Interleukin-32beta propagates vascular inflammation and exacerbates sepsis in a mouse model. *PLoS ONE* 2010;5(3):e9458. PMID: PMC2832764.
239. Li M, Gray W, Zhang H, Chung CH, Billheimer D, Yarbrough WG, Liebler DC, **Shyr Y**, Slebos RJ. Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. *Journal of Proteome Research* 2010;9(8):4295-4305. PMID: PMC2920032.
240. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Gonzalez-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. *Journal of Clinical Cancer Research* 2011; 17(7): 2024-34. PMID: PMC3221728.
241. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, Garcia-Echeverria C, **Shyr Y**, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. *Journal of Clinical Investigation* 2010;120(7):2406-2413. PMID: PMC2898598.
242. Ocak S, Yamashita H, Udyavar AR, Miller AN, Gonzalez AL, Zou Y, Jiang A, Yi Y, **Shyr Y**, Estrada L, Quaranta V, Massion PP. DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. *Oncogene* 2010;29(48):6331-6342.
243. Ogden SR, Noto JM, Allen SS, Patel DA, Romero-Gallo J, Washington MK, Fingleton B, Israel DA, Lewis ND, Wilson KT, Chaturvedi R, Zhao Z, **Shyr Y**, Peek RM, Jr. Matrix metalloproteinase-7 and premalignant host responses in Helicobacter pylori-infected mice. *Cancer Research* 2010;70(1):30-35. PMID: PMC2804939.
244. Perez CA, Chen H, **Shyr Y**, Courtney R, Zheng W, Cai Q, Hwang M, Jaboin J, Schleicher S, Moretti L, Wills M, Smith JA, Lu B. The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer. *Journal of Urology* 2010;183(5):2062-2069.
245. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, **Shyr Y**, Beauchamp RD. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. *Gastroenterology* 2010;138(3):958-968.
246. Woodhams DC, Kenyon N, Bell SC, Alford RA, Chen S, Billheimer D, **Shyr Y**, Rollins-Smith LA. Adaptations of skin peptide defences and possible response to the amphibian chytrid fungus in populations of Australian green-eyed treefrogs, *Litoria genimaculata*. *Diversity and Distributions* 2010;16(4):703-712.
247. Yu DS, Zhao R, Hsu EL, Cayer J, Ye F, Guo Y, **Shyr Y**, Cortez D. Cyclin-dependent kinase 9-cyclin K functions in the replication stress response. *Embo Reports* 2010;11(11):876-882. PMID: PMC2966956.
248. Zheng W, Wen W, Gao YT, **Shyr Y**, Zheng Y, Long J, Li G, Li C, Gu K, Cai Q, Shu XO, Lu W. Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. *Journal of the National Cancer Institute* 2010;102(13):972-981. PMID: PMC2897876.
249. Biswas S, Nyman JS, Alvarez J, Chakravarthi A, Ayers A, Sterling J, Edwards J, Rana T, Johnson R, Perrien DS, Lonning S, **Shyr Y**, Matrisian LM, Mundy GR. Anti-transforming growth factor β antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. *PLoS One* 2011;6(11). PMID: PMC3214031.
250. Borkon MJ, Morrow SE, Koehler EA, **Shyr Y**, Hilmes MA, Miller RS, Neblett WW, Lovvorn HN. Operative Intervention for Complete Pancreatic Transection in Children Sustaining Blunt Abdominal Trauma: Revisiting an Organ Salvage Technique. *American Surgeon* 2011;77(5):612-620.

251. Boutté AM, McDonald WH, **Shyr Y**, Yang L, Lin PC. Characterization of the MDSC proteome associated with metastatic murine mammary tumors using label-free mass spectrometry and shotgun proteomics. *PLoS One* 2011; 6(8):e22446. PMID: PMC3154190.
252. Brantley-Sieders DM, Dunaway CM, Rao M, Short S, Hwang Y, Gao Y, Li D, Jiang A, **Shyr Y**, Wu JY, Chen J. Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium. *Cancer Research* 2011;71(3):976-987. PMID: PMC3032824.
253. Brantley-Sieders DM, Jiang A, Sarma K, Badu-Nkansah A, Walter DL, **Shyr Y**, Chen J. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. *PLoS One* 2011; 6(9): e24426. PMID: PMC3174170.
254. Dexheimer JW, Talbot TR III, Ye F, **Shyr Y**, Jones I, Gregg WM, Aronsky D. A computerized pneumococcal vaccination reminder system in the adult emergency department. *Vaccine* 2011;29:7035-7041. PMID: PMC3168965.
255. Fohn LE, Rodriguez A, Kelley MC, Ye F, **Shyr Y**, Stricklin G, Robbins JB. D2-40 lymphatic marker for detecting lymphatic invasion in thin to intermediate thickness melanomas: association with sentinel lymph node status and prognostic value—a retrospective case study. *Journal of the American Academy of Dermatology* 2011;64(2):336-345.
256. Fox E, Miller T, Balko J, Kuba MG, Sanchez V, Smith A, Liu S, Gonzalez-Angulo A, Mills G, Ye F, **Shyr Y**, Manning HC, Buck E, Arteaga C. A kinome-wide screen identifies the Insulin/IGF1 receptor pathway as a mechanism of escape from hormone dependence in breast cancer. *Cancer Research* 2011;71(21):6773-6784. PMID: PMC3206206.
257. Fu Z, Shrubsole MJ, Smalley WE, Wu H, Chen Z, **Shyr Y**, Ness RM, Zheng W. Association of meat intake and meat-derived mutagen exposure with the risk of colorectal polyps by histologic type. *Cancer Prevention Research* 2011;4(10):1686-1697. PMID: PMC3188364.
258. Funatogawa T, Funatogawa I, **Shyr Y**. Analysis of covariance with pre-treatment measurements in randomized trials under the cases that covariances and post-treatment variances differ between groups. *Biometrical Journal* 2011; 53(3):512-524.
259. Ge L, Smail M, Meng W, **Shyr Y**, Ye F, Fan KH, Li X, Zhou HM, Bhowmick NA. Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. *PLoS One* 2011; 6(11): e27529. PMID: PMC3212574.
260. Horn L, Zhao Z, Sandler A, Johnson D, **Shyr Y**, Wolff S, Devore RF, Laskin J. A Phase II Study of Carboplatin and Irinotecan in Extensive Stage Small-Cell Lung Cancer. *Clinical Lung Cancer* 2011;12(3):161-165.
261. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, **Shyr Y**, Pietersen JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *Journal of Clinical Investigation* 2011;121(7):2750-2767. PMID: PMC3127435.
262. Li M, Chen S, Zhang J, Chen H, **Shyr Y**. Wave-spec: a preprocessing package for mass spectrometry data. *Bioinformatics* 2011;27(5):739-740. PMID: PMC3105479.
263. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Gonzalez-Angulo AM, Mills GB, Miller WR, Wu H, **Shyr Y**, Arteaga CL. A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance. *Clinical Cancer Research* 2011;17(7):2024-2034. PMID: PMC3221728.
264. Miller TW, Fox E, Balko JM, Ghazoui A, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Sánchez V, Maira SM, Manning HC, González-Angulo AM, Mills GB, Higham C, Ye F, Miller WR, **Shyr Y**, Arteaga C. ER α -dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. *Cancer Discovery* 2011;1(4):338-351. PMID: PMC3204388.
265. Murff HJ, Shrubsole MJ, Chen Z, Smalley WE, **Shyr Y**, Ness RM, Zheng W. Non-steroidal anti-inflammatory drug use and risk of adenomatous and hyperplastic polyps. *Cancer Prevention Research* 2011;4(11):1799-1807. PMID: PMC3203989.

266. Novitskiy SV, Pickup MW, Gorska AE, Owens P, Chytil A, Aakre M, Wu H, **Shyr Y**, Moses HL. TGF- β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. *Cancer Discovery* 2011;1(5):430-441. PMID: PMC3297196.
267. Rahman SM, Gonzalez AL, Li M, Seeley EH, Zimmerman LJ, Zhang XJ, Manier ML, Olson SJ, Shah RN, Miller AN, Putnam JB, Miller YE, Franklin WA, Blot WJ, Carbone DP, **Shyr Y**, Caprioli RM, Massion PP. Lung Cancer Diagnosis from Proteomic Analysis of Preinvasive Lesions. *Cancer Research* 2011;71(8):3009-3017. PMID: PMC3110721.
268. Rosenbluth JM, Mays DJ, Jiang A, **Shyr Y**, Pietenpol JA. Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis. *Proceedings of the National Academy of Sciences of the United States of America* 2011;108(5):2076-2081. PMID: PMC3033306.
269. **Shyr Y**. Rigorous quantitative sciences integration — the foundation of the drug approval in the personal genome era. *International Review of Thrombosis* 2011;6(1):36-43.
270. **Shyr Y**, Su P. Statistics in medical research. *Science Development* 2011;463(7):6-11.
271. Su PF, Chi YC, Li CI, **Shyr Y**, Liao YD. Analyzing survival curves at a fixed point in time for paired and clustered right-censored data. *Computational Statistics & Data Analysis* 2011;55(4):1617-1628.
272. Tamboli RA, Hajri T, Jiang A, Marks-Shulman PA, Williams DB, Clements RH, Melvin W, Bown BP, **Shyr Y**, Abumrad NN, Flynn CR. Reducation in inflammatory gene expression in skeletal muscle from Roux-en-Y gastric bypass patients randomized to omentectomy 2011. *PLoS One*; 6(12):e28577. PMID: PMC3241684
273. Villegas R, Xiang YB, Elasy T, Li HL, Yang G, Cai H, Ye F, Gao YT, **Shyr Y**, Zheng W, Shu XO. Fish, shellfish, and long-chain n-3 fatty acid consumption and risk of incident type 2 diabetes in middle-aged Chinese men and women. *American Journal of Clinical Nutrition* 2011;94(2):543-551. PMID: PMC3142729.
274. White RL, Jr, Ayers GD, Stell VH, Ding S, Gershenwald JE, Salo JC, Pockaj BA, Essner R, Faries M, Charney KJ, Avisar E, Hauschild A, Egberts F, Averbok BJ, Garberoglio CA, Vetto JT, Ross MI, Chu D, Trisal V, Hoekstra H, Whitman E, Wanebo HJ, Debonis D, Vezeridis M, Chevinsky A, Kashani-Sabet M, **Shyr Y**, Berry L, Zhao Z, Soong SJ, Leong SP. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. *Annals of Surgical Oncology* 2011;18(13):3593-3600. PMID: PMC3461951.
275. Xing X, Li Q, Sun H, Fu X, Zhan F, Huang X, Li J, Chen C, **Shyr Y**, Zeng R, Li Y, Lu X. The discovery of novel protein-coding features in mouse genome based on mass spectrometry data. *Genomics* 2011;98(5):343-351.
276. Abramson RG, Su PF, **Shyr Y**. Quantitative metrics in clinical radiology reporting: a snapshot perspective from a single mixed academic-community practice. *Magnetic Resonance Imaging* 2012;30(9):1357-1366. PMID: PMC3466403.
277. Baumann JL, Li M, Poulsen A, Chadwick NS, Cai Q, Chung CH, **Shyr Y**, Olsen JH, Zheng W, Slebos RJ. Analysis of microsatellite mutations in buccal cells from a case-control study for lung cancer. *Cancer Epidemiology* 2012;36(1):e33-9. PMID: PMC3259162.
278. Brantley-Sieders DM, Fan KH, Deming-Halverson SL, **Shyr Y**, Cook RS. Local breast cancer spatial patterning: a tool for community health resource allocation to address local disparities in breast cancer mortality. *PLoS One* 2012;7(9):e45238. PMID: PMC3460936.
279. Chen X, Li J, Gray W, Lehmann B, Bauer J, **Shyr Y**, Pietenpol, J. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. *Cancer Informatics* 2012;11:147-156. PMID: PMC3412597.
280. Engelhardt BG, Sengsayadeth SM, Jagasia M, Savani BN, Kassim AA, Lu P, **Shyr Y**, Yoder SM, Rock MT, Crowe JE Jr. Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival. *Experimental Hematology* 2012;40(12):974-982. PMID: PMC3611587.

281. Fu Z, Shrubsole MJ, Li G, Smalley WE, Hein DW, Chen Z, **Shyr Y**, Cai Q, Ness RM, Zheng W. Using gene-environment interaction analyses to clarify the role of well-done meat and heterocyclic amine exposure in the etiology of colorectal polyps. *American Journal of Clinical Nutrition* 2012;96(5):1119-1128. PMID: PMC3471199.
282. Fu Z, Shrubsole MJ, Smalley WE, Wu H, Chen Z, **Shyr Y**, Ness RM, Zheng W. Lifestyle factors and their combined impact on the risk of colorectal polyps. *American Journal of Epidemiology* 2012;176(9):766-776. PMID: PMC3571253.
283. Guo Y, Cai Q, Samuels DC, Ye F, Long J, Li C, Winther JF, Tawn EJ, Stovall M, Lähteenmäki P, Malia N, Levy S, Shaffer C, **Shyr Y**, Shu X, Boice JD Jr. The use of next generation sequencing technology to study the effect of radiation therapy on mitochondrial DNA mutation. *Mutation Research – Genetic Toxicology and Environmental Mutagenesis* 2012;744(2):154-160. PMID: PMC3354959.
284. Guo Y, Li J, Li CI, Long J, Samuels DC, **Shyr Y**. The effect of strand bias in Illumina short-read sequencing data. *BMC Genomics* 2012;13(1):666. PMID: PMC3532123.
285. Hong J, Katsha A, Lu P, **Shyr Y**, Belkhiri A, El-Rifai W. Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma. *Cancer Research* 2012;72(17):4504-4514. PMID: PMC3432752.
286. Huang Y, Zhao Z, Xu H, **Shyr Y**, Zhang B. Advances in systems biology: computational algorithms and applications. *BMC Systems Biology* 2012;6 Suppl 3:S1. PMID: PMC3524016.
287. Kikuchi T, Hassanein M, Amann JM, Liu Q, Slebos RJ, Rahman SM, Kaufman JM, Zhang X, Hoeksema MD, Harris BK, Li M, **Shyr Y**, Gonzalez AL, Zimmerman LJ, Liebler DC, Massion PP, Carbone DP. In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkers. *Molecular & Cellular Proteomics* 2012;11(10):916-932. PMID: PMC3494148.
288. Li X, Sterling JA, Fan K, Vessella RL, **Shyr Y**, Hayward SW, Matrisian LM, Bhowmick NA. Loss of TGF- β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. *Molecular Cancer Research* 2012;10(4):494-503. PMID: PMC3900026.
289. Liu Q, Guo Y, Li J, Long J, Zhang B, **Shyr Y**. Steps to ensure accuracy in genotype and SNP calling from Illumina sequencing data. *BMC Genomics* 2012;13 Suppl 8:S8. PMID: PMC3535703.
290. Pecot CV, Li M, Zhang XJ, Rajanbabu R, Calitri C, Bungum A, Jett JR, Putnam JB, Callaway-Lane C, Deppen S, Grogan EL, Carbone DP, Worrell JA, Moons KGM, **Shyr Y**, Massion PP. Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. *Cancer Epidemiology, Biomarkers & Prevention* 2012;21(5):786-792. PMID: PMC3660018.
291. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, Higginbotham JN, Juchheim A, Prasad N, Levy SE, Guo Y, **Shyr Y**, Aronow BJ, Haigis KM, Franklin JL, Coffey RJ. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. *Cell* 2012;149(1):146-158. PMID: PMC3563328.
292. Rao M, Song W, Jiang A, **Shyr Y**, Lev S, Greenstein D, Brantley-Sieders D, Chen J. VAMP-associated protein B (VAPB) promotes breast tumor growth by modulation of Akt activity. *PLoS One* 2012;7(10):e46281. PMID: PMC3462209.
293. **Shyr Y**. Rigorous quantitative sciences integration: the foundation of high-dimensional genomic research. *Clin Exp Metastasis* 2012;29(7):641-643. PMID: PMC3485411.
294. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JA, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, **Shyr Y**, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *New England Journal of Medicine* 2012;366(8):707-714. PMID: PMC3724515.
295. Stover DG, Reddy VK, **Shyr Y**, Savani BN, Reddy N. Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma. *Bone Marrow Transplant* 2012;47(1):82-87.

296. Su PF, Chen X, Chen H, **Shyr Y**. Statistical aspects of omics data analysis using the random compound covariate. *BMC Systems Biology* 2012;6 Suppl 3:S11. PMID: PMC3524312.
297. Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik-Delmaire T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, **Shyr Y**, Stuart DD, Levy S, Sosman JA, Richmond A. RAF265 inhibits the growth of advanced human melanoma tumors. *Clinical Cancer Research* 2012;18(8):2184-2198. PMID: PMC3724517.
298. Talati M, Seeley E, Ihida-Stansbury K, Delisser H, McDonald H, Ye F, Zhang X, **Shyr Y**, Caprioli R, Meyrick B. Altered expression of nuclear and cytoplasmic histone H1 in pulmonary artery and pulmonary artery smooth muscle cells in patients with IPAH. *Pulmonary Circulation* 2012;2(3):340-351. PMID: PMC3487302.
299. Vlacich G, Diaz R, Thorpe SW, Murphy BA, Kirby W, Sinard RJ, Shakhtour B, **Shyr Y**, Murphy P, Netterville JL, Yarbrough WG, Cmelak AJ. Intensity-modulated radiation therapy with concurrent Carboplatin and Paclitaxel for locally advanced head and neck cancer: toxicities and efficacy. *Oncologist* 2012;17(5):673-681. PMID: PMC3360907.
300. Wentz SC, Zhao ZG, **Shyr Y**, Shi CJ, Merchant NB, Washington K, Xia F, Chakravarthy AB. Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma. *World Journal of Gastrointestinal Oncology* 2012;4(10):207-215. PMID: PMC3581835.
301. Winther JF, Olsen JH, Wu H, **Shyr Y**, Mulvihill JJ, Stovall M, Nielsen A, Schmiegelow M, Boice JD Jr. Genetic disease in the children of Danish survivors of childhood and adolescent cancer. *Journal of Clinical Oncology* 2012;30(1):27-33. PMID: PMC3255559.
302. Xu BJ, An QA, Srinivasa Gowda S, Yan W, Pierce LA, Abel TW, Rush SZ, Cooper MK, Ye F, **Shyr Y**, Weaver KD, Thompson RC. Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma. *International Journal of Oncology* 2012;40(6):1995-2003.
303. Ye F, Bauer JA, Pietenpol JA, **Shyr Y**. Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives. *BMC Genomics* 2012;13 Suppl 8:S3. PMID: PMC3535706.
304. Ye F, **Shyr Y**. Adaptive clinical trial design: From simple dose-finding trials to large-scale personalized medicine trials. *Personalized Medicine Oncology* 2012;1(4).
305. Zeng CH, Le W, Ni Z, Zhang M, Miao L, Luo P, Wang R, Lv Z, Chen J, Tian J, Chen N, Pan X, Fu P, Hu Z, Wang L, Fan Q, Zheng H, Zhang D, Wang Y, Huo Y, Lin H, Chen S, Sun S, Wang Y, Liu Z, Liu D, Ma L, Pan T, Zhang A, Jiang X, Xing C, Sun B, Zhou Q, Tang W, Liu F, Liu Y, Liang S, Xu F, Huang Q, Shen H, Wang J, **Shyr Y**, Phillips S, Troyanov S, Fogo A, Liu ZH. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult Chinese patients. *American Journal of Kidney Disease* 2012; 60(5): 812-20.
306. Zhao Z, Huang Y, Zhang B, **Shyr Y**, Xu H. Genomics in 2012: challenges and opportunities in the next generation sequencing era. *BMC Genomics* 2012;13 Suppl 8:S1. PMID: PMC3535713.
307. Zhuang G, Song W, Amato K, Hwang Y, Lee K, Boothby M, Ye F, Guo Y, **Shyr Y**, Lin L, Carbone DP, Brantley-Sieders DM, Chen J. Effects of cancer-associated EPHA3 mutations on lung cancer. *Journal of the National Cancer Institute* 2012;104(15):1183-1198. PMID: PMC3611812.
308. Al-Greene NT, Means AL, Lu P, Jiang A, Schmidt CR, Chakravarthy AB, Merchant NB, Washington MK, Zhang B, **Shyr Y**, Deane NG, Beauchamp RD. Four jointed box 1 promotes angiogenesis and is associated with poor patient survival in colorectal carcinoma. *PLoS One* 2013;8(7):e69660. PMID: PMC3726759.
309. Ausborn NL, Wang T, Wentz SC, Washington MK, Merchant NB, Zhao Z, **Shyr Y**, Chakravarthy AB, Xia F. 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. *BMC Cancer* 2013;13(1):155. PMID: PMC3636043.
310. Dexheimer JW, Abramo TJ, Arnold DH, Johnson KB, **Shyr Y**, Ye F, Fan KH, Patel N, Aronsky D. An asthma management system in a pediatric emergency department. *International Journal of Medical Informatics* 2013;82(4):230-238. PMID: PMC3646328.

311. Guo Y, Li J, Li CI, **Shyr Y**, Samuels DC. MitoSeek: Extracting mitochondrial information and performing high throughput mitochondria sequencing analysis. *Bioinformatics* 2013;29(9):1210-1211.
312. Guo Y, Li CI, Sheng Q, Winther JF, Cai Q, Boice JD, **Shyr Y**. Very low-level heteroplasmy mtDNA variations are inherited in humans. *Journal of Genetics and Genomics* 2013;40(12):607-615. PMID: PMC4149221
313. Guo Y, Li CI, Ye F, **Shyr Y**. Evaluation of read count based RNAseq analysis methods. *BMC Genomics* 2013;14(Suppl 8):S2. PMID: PMC4092879
314. Guo Y, Samuels DC, Li J, Clark T, Li CI, **Shyr Y**. Evaluation of allele frequency estimation using pooled sequencing data simulation. *The Scientific World Journal* 2013;2013:895496. PMID: PMC3582166.
315. Guo Y, Sheng Q, Li J, Ye F, Samuels DC, **Shyr Y**. Large scale comparison of gene expression levels by microarrays and RNAseq using TCGA data. *PLoS One* 2013;8(8):e71462. PMID: PMC3748065.
316. Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, Pietenpol J, **Shyr Y**. Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. *BioMed Research International* 2013;2013:915636. PMID: PMC3835197.
317. Hansen AG, Freeman TJ, Arnold SA, Starchenko A, Jones-Paris CR, Gilger MA, Washington MK, Fan KH, **Shyr Y**, Beauchamp RD, Zijlstra A. Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome. *Cancer Research* 2013;73(10):2955-2964. PMID: PMC3660148.
318. Han D, Zager JS, **Shyr Y**, Chen H, Berry LD, Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, Messina JL, Vetto JT, White RL, Pockaj B, Mozzillo N, Charney KJ, Avisar E, Krouse R, Kashani-Sabet M, Leong SP. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. *Journal of Clinical Pathology* 2013;31(35):4387-4393.
319. Katsha A, Soutto M, Sehdev V, Peng D, Washington MK, Piazuolo MB, Tantawy MN, Manning HC, Lu P, **Shyr Y**, Ecsedy J, Belkhir A, El-Rifai W. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. *Gastroenterology* 2013;145(6):1312-1322. PMID: PMC3840093.
320. Li C-I, Su P-F, Guo Y, **Shyr Y**. Sample size calculation for differential expression analysis of RNA-seq data under Poisson distribution. *International Journal of Computation Biology and Drug Design* 2013;6(4):358-375. PMID: PMC3874726.
321. Li C-I, Su P-F, **Shyr Y**. Sample size calculation based on exact test for assessing differential expression analysis in RNA-seq data. *BMC Bioinformatics* 2013;14(1):357. PMID: PMC3924199.
322. Liu Q, Halvey PJ, **Shyr Y**, Slebos RJ, Liebler DC, Zhang B. Integrative omics analysis reveals the importance and scope of translational repression in microRNA-mediated regulation. *Mol Cell Proteomics* 2013;12(7):1900-1911. PMID: PMC3708174.
323. Qiu Q, Lu P, Xiang Y, **Shyr Y**, Chen X, Lehmann BD, Viox DJ, George AL Jr, Yi Y. A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer. *PLoS One* 2013;8(1):e54979. PMID: PMC3558433.
324. Rexer BN, **Shyr Y**, Arteaga CL. Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy. *Journal of Clinical Oncology* 2013;31(17):2073-2075.
325. Samuels DC, Han L, Li J, Quangu S, Clark TA, **Shyr Y**, Guo Y. Finding the lost treasures in exome sequencing data. *Trends Genet* 2013;29(10):593-599. PMID: PMC3926691.
326. Udyavar AR, Hoeksema MD, Clark JE, Zou Y, Tang Z, Li Z, Li M, Chen H, Statnikov A, **Shyr Y**, Liebler DC, Field J, Eisenberg R, Estrada L, Massion PP, Quaranta V. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer. *BMC Systems Biology* 2013;7(Suppl 5):S1. PMID: PMC4029366
327. Wang T, Wentz SC, Ausborn NL, Washington MK, Merchant N, Zhao Z, **Shyr Y**, Chakravarthy AB, Xia F. Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinoma. *Pancreas* 2013;42(6):977-982. PMID: PMC4026161.
328. Yan L, Womack B, Wotton D, Guo Y, **Shyr Y**, Dave U, Li C, Hiebert S, Brandt S, Hamid R. Tgif1 regulates quiescence and self-renewal of hematopoietic stem cells. *Molecular and Cell Biology* 2013;33(24):4824-4833. PMID: PMC3889555.

329. Abrams JA, Appelman HD, Beer DG, Berry LD, Chak A, Falk GW, Fitzgerald RC, Ginsberg GG, Grady WM, Joshi BP, Lynch JP, Markowitz S, Richmond E, Rustgi AK, Seibel EJ, Shaheen NJ, **Shyr Y**, Umar A, Wang KK, Wang TC, Wang TD, Yassin R. Barrett's Esophagus Translational Research Network (BETRNet): The pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research. *Gastroenterology* 2014;146(7):1586-1590. PMID: PMC4224108.
330. Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, Lafrance DR, Vnencak-Jones CL, **Shyr Y**, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. *Breast Cancer Res Treat* 2014;145(2):389-399. PMID: PMC4046906.
331. Boyd AS, Su PF, **Shyr Y**, Tang YW. Squamous cell carcinomas in situ arising in seborrheic keratoses: an association with concomitant immunosuppression? *Int J Dermatol* 2014;53(11):1346-1350.
332. Cardin DB, Goff L, Li CI, **Shyr Y**, Winkler C, Devore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. *Cancer Med* 2014. PMID: PMC4101748.
333. Cleveland SM, Goodings C, Tripathi RM, Elliott N, Thompson MA, Guo Y, **Shyr Y**, Dave UP. LIM domain only-2 (Lmo2) induces T-cell leukemia with epigenetic deregulation of CD4. *Exp Hematol* 2014;42(7):581-593. PMID: PMC4241760.
334. Dexheimer JW, Abramo TJ, Arnold DH, Johnson K, **Shyr Y**, Ye F, Fan KH, Patel N, Aronsky D. Implementation and evaluation of an integrated computerized asthma management system in a pediatric emergency department: A randomized clinical trial. *Int J Med Inform* 2014;83(11):805-813.
335. Donahue MJ, Dethrage LM, Faraco CC, Jordan LC, Clemmons P, Singer R, Mocco J, **Shyr Y**, Desai A, O'Duffy A, Riebau D, Hermann L, Connors J, Kirshner H, Strother MK. Routine clinical evaluation of cerebrovascular reserve capacity using carbogen in patients with intracranial stenosis. *Stroke* 2014;45(8):2335-2341. PMID: PMC4118584.
336. Galadanci NA, Abdullahi SU, Tabari MA, Abubakar S, Belonwu R, Salihu A, Neville K, Kirkham F, Inusa B, **Shyr Y**, Phillips S, Kassim AA, Jordan LC, Aliyu MH, Covert BV, DeBaun MR. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): Challenges of conducting a feasibility test. *Pediatr Blood Cancer* 2014. PMID: PMC4304992
337. Guo Y, Bosompem A, Zhong X, Clark T, **Shyr Y**, Kim AS. A comparison of microRNA sequencing reproducibility and noise reduction using mirVana and TRIzol isolation methods. *Int J Comput Biol Drug Des* 2014;7(2-3):102-112.
338. Guo Y, He J, Zhao S, Wu H, Zhong X, Sheng Q, Samuels DC, **Shyr Y**, Long J. Illumina human exome genotyping array clustering and quality control. *Nat Protoc* 2014;9(11):2643-2662.
339. Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, **Shyr Y**. Detection of internal exon deletion with exon Del. *BMC Bioinformatics* 2014;15:332. PMID: PMC4288651
340. Guo Y, Zhao S, Li CI, Sheng Q, **Shyr Y**. RNAseqPS: A web tool for estimating sample size and power for RNAseq experiment. *Cancer Inform* 2014;13(Suppl 6):1-5. PMID: PMC4213196.
341. Guo Y, Zhao S, Sheng Q, Ye F, Li J, Lehmann B, Pietenpol J, Samuels DC, **Shyr Y**. Multi-perspective quality control of Illumina exome sequencing data using QC3. *Genomics* 2014;103(5-6):323-328.
342. Guo Y, Zhao S, Su PF, Li CI, Ye F, Flynn CR, **Shyr Y**. Statistical strategies for microRNAseq batch effect reduction. *Transl Cancer Res* 2014; 3(3):260-265. PMID: PMC4171948.
343. Guo Y, Zhao S, Ye F, Sheng Q, **Shyr Y**. MultiRankSeq: multiperspective approach for RNAseq differential expression analysis and quality control. *Biomed Res Int* 2014;2014:248090. PMID: PMC4058234.
344. Hansen AG, Arnold SA, Jiang M, Palmer TD, Ketova T, Merkel A, Pickup M, Samaras S, **Shyr Y**, Moses HL, Hayward SW, Sterling JA, Zijlstra A. ALCAM/CD166 is a TGF-beta responsive marker and functional regulator of prostate cancer metastasis to bone. *Cancer Research* 2014. PMID: PMC4149913
345. Kaufman JM, Amann JM, Park K, Arasada RR, Li H, **Shyr Y**, Carbone DP. LKB1 loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT. *J Thorac Oncol* 2014;9(6):794-804. PMID: PMC4026179.

346. Kirabo A, Fontana V, de Faria AP, Loperena R, Galindo CL, Wu J, Bikineyeva AT, Dikalov S, Xiao L, Chen W, Saleh MA, Trott DW, Itani HA, Vinh A, Amarnath V, Amarnath K, Guzik TJ, Bernstein KE, Shen XZ, **Shyr Y**, Chen SC, Mernaugh RL, Laffer CL, Elijevich F, Davies SS, Moreno LH, Madhur MS, Roberts J 2nd, Harrison DG. DC isoketal-modified proteins activate T cell and promote hypertension. *J Clin Invest* 2014;124(10):4642-4656. PMID: PMC4220659.
347. Kris MG, Johnson BE, Berry LD, Kwaitkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, **Shyr Y**, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Shiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Using multiplexed assays of oncogenic drivers in lung cancers to select target drugs. *JAMA* 2014;311(19):1998-2006. PMID: PMC4163053.
348. Lammers PE, **Shyr Y**, Li CI, Hutchison AS, Sandler A, Carbone DP, Johnson DH, Keedy VL, Horn L. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. *J Thorac Oncol* 2014;9(4):559-562. PMID: PMC3990869.
349. Liu Q, Su PF, Zhao S, **Shyr Y**. Transcriptome-wide signatures of tumor stage in kidney renal clear cell carcinoma: connecting copy number variation, methylation and transcription factor activity. *Genome Med* 2014;6(12):117. PMID: PMC4293006.
350. Lu X, An H, Jin R, Zou M, Guo Y, Su PF, Liu D, **Shyr Y**, Yarbrough WG. PPM1A is a RelA phosphatase with tumor suppressor-like activity. *Oncogene* 2014;33(22):2918-2927. PMID: PMC3897569.
351. Mikhitarian K, Pollen M, Zhao Z, **Shyr Y**, Merchant NB, Parikh A, Revetta F, Washington MK, Vnencak-Jones C, Shi C. Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. *Modern Pathology* 2014; 27(5):665-674. PMID: PMC4007414.
352. Novitskiy SV, Forrester E, Pickup MW, Gorska AE, Chytil A, Aakre M, Polosukhina D, Owens P, Yusupova DR, Zhao Z, Ye F, **Shyr Y**, Moses HL. Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis. *Breast Cancer Res* 2014; 16(5):425. PMID: PMC4303109
353. Sheng Q, **Shyr Y**, Chen X. DupChecker: a bioconductor package for checking high-throughput genomic data redundancy in meta-analysis. *BMC Bioinformatics* 2014; 15:323. PMID: PCM4261523
354. Shen EZ, Song CQ, Lin Y, Zhang WH, Su PF, Liu WY, Zhang P, Xu J, Zhan C, Wang X, **Shyr Y**, Cheng H, Dong MQ. Mitoflash frequency in early adulthood predicts lifespan in *Caenorhabditis elegans*. *Nature* 2014; 508(7494):128-132.
355. Sidorova TN, Mace LC, Wells KS, Yermalitskaya LV, Su PF, **Shyr Y**, Atkinson JB, Fogo AB, Prinsen JK, Byrne JG, Petracek MR, Greelish JP, Hoff SJ, Ball SK, Glabe CG, Brown NJ, Barnett JV, Murray KT. Hypertension is associated with preamyloid oligomers in human atrium: a missing link in atrial pathophysiology? *J Am Heart Assoc* 2014; 3(6). PMID: PMC4338732.
356. Sidorova T, Mace LC, Wells KS, Yermalitskaya LV, Su PF, **Shyr Y**, Byrne JG, Petracek, MR, Greelish, JP, Hoff SJ, Ball SK, Glabe CG, Brown NJ, Barnett JV, Murray KT. Quantitative imaging of preamyloid oligomers, a novel structural abnormality in human atrial samples. *J Histochem Cytochem* 2014. PMID: PMC4072180.
357. Strother MK, Anderson MD, Singer RJ, Du L, Moore RD, **Shyr Y**, Ladner TR, Arteaga D, Day MA, Clemmons PF, Donahue MJ. Cerebrovascular collaterals correlate with disease severity in adult North American patients with Moyamoya disease. *AJNR Am J Neuroradiol* 2014; 35(7):1318-1324. PMID: PMC4367488.
358. Su PF, Li CI, **Shyr Y**. Sample size determination for paired right-censored data based on the difference of Kaplan-Meier estimates. *Computational Statistics and Data Analysis* 2014; 74:39-51. PMID: PMC3931470.
359. Trott DW, Thabet SR, Kirabo A, Saleh MA, Itani H, Norlander AE, Wu J, Goldstein A, Arendshorst WJ, Madhur MS, Chen W, Li CI, **Shyr Y**, Harrison DG. Oligoclonal CD8+ T cells play a critical role in the development of hypertension. *Hypertension* 2014; 64(5):1108-1115. PMID: PMC4191997.
360. Tu C, Sheng Q, Li J, Shen X, Zhang M, **Shyr Y**, Qu J. ICan: An optimized ion-current-based quantification procedure with enhanced quantitative accuracy and sensitivity in biomarker discovery. *J Proteome Res* 2014; 13(12):5888-5897. PMID: PMC4261937.

361. Vlacich G, Spratt DE, Diaz R, Phillips JG, Crass J, Li CI, **Shyr Y**, Cmelak AJ. Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer. *Radiother Oncol* 2014; 110(3):435-440.
362. Wang J, Raskin L, Samuels DC, **Shyr Y**, Guo Y. Genome measures used for quality control are dependent on gene function and ancestry. *Bioinformatics* 2014. PMID: PMC4308666
363. Weeke P, Mosley JD, Hanna D, Delaney JT, Shaffer C, Wells QS, Van Driest S, Karnes JH, Ingram C, Guo Y, **Shyr Y**, Norris K, Kannankeril PJ, Ramirez AH, Smith JD, Mardis ER, Nickerson D, George AL Jr, Roden DM. Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. *J Am Coll Cardiol* 2014; 63(14):1430-1437. PMID: PMC4018823.
364. Zhao S, Guo Y, Sheng Q, **Shyr Y**. Advanced heat map and clustering analysis using heatmap3. *Biomed Res Int* 2014; 2014:986048. PMID: PMC4124803.
365. Boyd AS, Chen SC, **Shyr Y**. Intra-dermal nevi with atypical nuclei in the elderly: The senescent nevus. *J Am Acad Dermatol* 2015; 73(3): 500-6. PMID: 26188628.
366. Cohen DN, Lawson SK, Shaver AC, Du L, Nguyen HP, He Q, Johnson DB, Lumbang WA, Moody BR, Prescott JL, Chandra PK, Boyd AS, Zwerner JP, Robbins JB, Tying SK, Rady PL, Chappell JD, **Shyr Y**, Infante JR, Sosman JA. Contribution of beta-HPV infection and UV-damage to rapid-onset cutaneous squamous cell carcinoma during BRAF-inhibition therapy. *Clin Cancer Res* 2015. PMID: PMC4452444.
367. Deng X, Han D, Dezert J, Deng Y, **Shyr Y**. Evidence combination from an evolutionary game theory perspective. *IEEE Trans Cybern* 2015. PMID: N/A
368. Erickson JJ, Lu P, Wen S, Hastings AK, Gilchuk P, Joyce S, **Shyr Y**, Williams JV. Acute viral respiratory infection rapidly induces a CD8+ T cell exhaustion-like phenotype. *J Immunol* 2015; 195(9):4319-30. PMID: PMC4733528.
369. Fata CR, Seeley EH, Desouki MM, Du L, Gwin K, Hanley KZ, Hecht JL, Jarboe EA, Liang SX, Parkash V, Quick CM, Zheng W, **Shyr Y**, Caprioli RM, Fadare O. Are clear cell carcinomas of the ovary and endometrium phenotypically identical? A proteomic analysis. *Hum Pathol* 2015; 46(10): 1427-36.
370. Galadanci NA, Abdullahi SU, Tabari MA, Abubakar S, Belonwu R, Salihu A, Neville K, Kirkham F, Inusa B, **Shyr Y**, Phillips S, Kassim AA, Jordan LC, Aliyu MH, Covert BV, DeBaun MR. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial. *Pediatr Blood Cancer* 2015;62(3):395-401. PMID: PMC4304992.
371. Goodings C, Smith E, Mathias E, Elliot N, Cleveland SM, Tripathi RM, Layer JH, Chen X, Guo Y, **Shyr Y**, Hamid R, Du Y, Dave UP. Hhex is required at multiple stages of adult hematopoietic stem and progenitor cell differentiation. *Stem Cells* 2015. PMID: PMC4641572.
372. Goodings C, Tripathi R, Cleveland SM, Elliott N, Guo Y, **Shyr Y**, Dave UP. Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias. *Leuk Res* 2015;39(1):100-109. PMID: PMC4277943.
373. Guo Y, Zhao S, Sheng Q, Guo M, Lehmann B, Pietenpol J, Samuels DC, **Shyr Y**. RNAseq by total RNA library identifies additional RNAs compared to poly(A) RNA library. *Biomed Res Int* 2015; 2015: 862130. PMID: PMC4620295
374. Hoek KL, Samir P, Howard LM, Niu X, Prasad N, Galassie A, Liu Q, Allos TM, Floyd KA, Guo Y, **Shyr Y**, Levy SE, Joyce S, Edwards KM, Link AJ. A cell-based systems biology assessment of human blood to monitor immune responses after influenza vaccination. *PLoS One* 2015;10(2):e0118528. PMID: PMC4338067.
375. Kummerow KL, Du L, Penson DF, **Shyr Y**, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. 2015;150(1):9-16.
376. Lammers PE, Lu B, Horn L, **Shyr Y**, Keedy V. nab-Paclitaxel in combination with weekly carboplatin with concurrent radiotherapy in stage III non-small cell lung cancer. *Oncologist* 2015;20(5):491-192. PMID: PMC4425395.

377. Liu Q, Su PF, Zhao S, **Shyr Y**. Transcriptome-wide signatures of tumor stage in kidney renal clear cell carcinoma: connecting copy number variation, methylation and transcription factor activity. *Genome Med* 2015;6(12):117. PMID: PMC4293006.
378. Liu Q, Zhong X, Madison B, Rustig A, **Shyr Y**. Assessing Computational Steps for CLIP-Seq Data Analysis. *Biomed Res Int* 2015; 2015: 196082. PMID: PMC4619761.
379. Lockney NA, Zhang M, Lu Y, Sopha SC, Washington MK, Merchant N, Zhao Z, **Shyr Y**, Chakravarthy AB, Xia F. Pyruvate kinase muscle isoenzyme 2 (PKM2) expression is associated with overall survival in pancreatic ductal adenocarcinoma. *J Gastrointest Cancer* 2015; 46(4): 390-8.
380. Samuelson LE, Scherer RL, VanSaun MN, Fan KH, Dozier EA, Carter KJ, Koyama T, **Shyr Y**, Aschner M, Stanwood GD, Bornhop DJ, Matrisian LM, McIntyre JO. New tools for the quantitative assessment of prodrug delivery and neurotoxicity. *Neurotoxicology* 2015;47:88-98. PMID: PMC4501381.
381. Sheng Q, Li R, Dai J, Li Q, Su Z, Guo Y, Li C, **Shyr Y**, Zeng R. Preprocessing significantly improves the peptide/protein identification sensitivity of high resolution isobarically labeled tandem mass spectrometry data. *Mol Cell Proteomics* 2015;14(2):405-417. PMID: PMC4350035.
382. **Shyr Y**, Horn L, Berry L. Are we making progress in lung cancer using progression-free survival as a surrogate end point? *JAMA Oncology* 2015; 1(2): 202-03.
383. Tu C, Sheng Q, Li J, Ma D, Shen X, Wang X, **Shyr Y**, Yi Z, Qu J. Optimization of search engines and postprocessing approaches to maximize peptide and protein identification for high-resolution mass data. *J Proteome Res* 2015; 14(11): 4662-73.
384. Vilgelm AE, Johnson CA, Prasad N, Yang J, Chen SC, Ayers GD, Pawlikowski JS, Raman D, Sosman JA, Kelley M, Ecsedy JA, **Shyr Y**, Levy SE, Richmond A. Connecting the Dots: Therapy-induced senescence and tumor-suppressive immune microenvironment. *J Natl Cancer Inst* 2015; 108(6).
385. Wang J, Liu Q, **Shyr Y**. Dysregulated transcription across diverse cancer types reveals the importance of RNA-binding protein in carcinogenesis. *BMC Genomics* 2015; 16 Suppl 7:S5. PMID: PMC4474540.
386. Wang J, Raskin L, Samuels DC, **Shyr Y**, Guo Y. Genome measures used for quality control are dependent on gene function and ancestry. *Bioinformatics* 2015; 31(3):318-23. PMID: PMC4308666.
387. Zhang P, Samuels DC, Lehmann B, Stricker T, Pietenpol J, **Shyr Y**, Guo Y. Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data. *Brief Bioinform* 2015.
388. Zhong X, Yang H, Zhao S, **Shyr Y**, Li B. Network-based stratification analysis of 13 major cancer types using mutations in panels of cancer genes. *BMC Genomics* 2015; 16 Suppl 7: S7. PMID: PMC4474538.
389. Assad TR, Hemnes AR, Larkin EK, Glazer AM, Xu M, Wells QS, Farber-Eger EH, Sheng Q, **Shyr Y**, Harrell FE, Newman JH, Brittain EL. Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension. *Journal of American College of Cardiology* 2016; 68(23): 2525-2536. PMID: PMC5157701
390. Blum A, Venkitachalam S, Guo Y, Kieber-Emmons AM, Ravi L, Chandar AK, Iyer PG, Canto MI, Wang JS, Shaheen NJ, Barnholtz-Sloan JS, Markowitz SD, Willis JE, **Shyr Y**, Chak A, Varadan V, Guda K. RNA Sequencing Identifies Transcriptionally-Viable Gene Fusions in Esophageal Adenocarcinomas. *Cancer Research* 2016; 76(19):5628-5633. PMID: PMC5050127
391. Eilertson B, Maruri F, Blackman A, Guo Y, Herrera M, van der Heijden Y, **Shyr Y**, Sterling TR. A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis. *Journal of Antimicrobial Chemotherapy* 2016; 71(9): 2419-27. PMID: PMC4992850.
392. Gilchuk P, Hill TM, Guy C, McMaster SR, Boyd KL, Rabacal WA, Lu P, **Shyr Y**, Kohlmeier JE, Sebzda E, Green DR, Joyce S. A Distinct Lung-Interstitial-Resident Memory CD8⁺ T Cell Subset Confers Enhance Protection to Lower Respiratory Tract Infection. *Cell Reports* 2016; 16(7): 1800-9. PMID: PMC5021515
393. Iams WT, Yu H, **Shyr Y**, Patil T, Horn L, McCoach C, Kelly K, Doebele R, Camidge DR. PS01.68: Heterogeneous Clinical Syndromes Existing Within Patients with Stage IV KRAS Mutant Non-Small Cell Lung Cancer: Topic: Medical Oncology. *Journal of Thoracic Oncology* 2016; 11(11):S313

394. Jamshedur Rahman S.M., Ji X, Zimmerman L, Li I, M, Harris B, Hoeksema M, Trenary I, Zou Y, Qian J, Slebos R, Beane J, Spira A, **Shyr Y**, Eisenberg R, Liebler D, Young J, Massion P. The airway epithelium undergoes metabolic reprogramming in individuals at high risk for lung cancer. *Journal of Clinical Investigation* 2016; 1(19):e88814 PMID: PMC5111517
395. Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, **Shyr Y**, Miller V, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM. Targeted next generation sequencing identifies markers of response to PD-1 blockade. *Cancer Immunol Res* 2016; 4(11):959-967. PMID: PMC5134329
396. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, **Shyr Y**, Sullivan RJ, Puzanov I, Sosman JA, Balko JM. Melanoma-specific MHC-II expression represents a tumor-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. *Nat Commun* 2016; 2016: 10582. PMID: PMC4740184
397. Jordan LC, Gindville MC, Scott AO, Juttukonda MR, Strother MK, Kassim AA, Chen SC, Lu H, Pruthi S, **Shyr Y**, Donahue MJ. Non-invasive imaging of oxygen extraction fraction in adults with sickle-cell anaemia. *Brain* 2016; 139(Pt. 3): 738-50.
398. Kavanagh G, Williams J, Morris AS, Nickels ML, Walker R, Koglin N, Stephens AW, Washington MK, Geevarghese SK, Liu Q, Ayers D, **Shyr Y**, Manning HC. Utility of [18F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population. *Mol Imaging Biol* 2016; 18(6): 924-934.
399. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, **Shyr Y**, Moses HL, Sanders ME, Pietersen JA. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. *PLoS One* 2016; 11(6). PMID: PMC4911051.
400. Li CI, **Shyr Y**. Sample size calculation based on generalized linear models for differential expression analysis in RNA-seq data. *Stat Appl Genet Mol Bio* 2016; 15(6): 491-505.
401. Marshall CB, Mays DJ, Beeler JS, Rosenbluth JM, Boyd KL, Santos Guasch GL, Shaver TM, Tang LJ, Liu Q, **Shyr Y**, Venters BJ, Magnuson MA, Pietersen JA. p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network. *Cell Rep* 2016; 14(10): 2289-300. PMID: PMC4794393.
402. Matsushita K, Yang HC, Mysore MM, Zhong J, **Shyr Y**, Ma LJ, Fogo AB. Effects of combination PPAR γ agonist and angiotensin receptor blocker on glomerulosclerosis. *Lab Invest* 2016; 96(6):602-9. PMID: 26999660.
403. Samuels DC, Wang J, Ye F, He J, Levinson RT, Sheng Q, Zhao S, Capra JA, **Shyr Y**, Zheng W, Guo Y. Heterozygosity Ratio, a Robust Global Genomic Measure of Autozygosity and Its Association with Height and Disease Risk. *Genetics* 2016; 204(3):893-904. PMID: PMC5105867
404. Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, **Shyr Y**, Pietersen JA. Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. *Cancer Research* 2016; 76(15): 4305-4306.
405. Sheng Q, Vickers K, Zhao S, Wang J, Samuels DC, Koues O, **Shyr Y**, Guo Y. Multi-perspective quality control of Illumina RNA sequencing data analysis. *Brief Funct Genomics* 2016; 103(5-6):323-8. PMID: 24703969
406. Sheng Q, Zhao S, Li CI, **Shyr Y**, Guo Y. Practicability of detecting somatic point mutation from RNA high throughput sequencing data. *Genomics* 2016; 107(5):163-9.
407. Tu C, Li J, Shen S, Sheng Q, **Shyr Y**, Qu J. Performance Investigation of Proteomic Identification by HCD/CID Fragmentations in Combination with High/Low-Resolution Detectors on a Tribrid, High-Field Orbitrap Instrument. *PLoS One* 2016; 11(7). PMID: PMC4966894.
408. Wang J, Liu Q, Sun J, **Shyr Y**. Disrupted cooperation between transcription factors across diverse cancer types. *BMC Genomics* 2016; 17:560. PMID: PMC4975902.

409. Zhang P, Samuels DC, Lehmann B, Stricker T, Pietenpol J, **Shyr Y**, Guo Y. Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data. *Brief Bioinform* 2016; 17(2): 224-32.
410. Zhang P, Samuels DC, Wang J, Zhao S, **Shyr Y**, Guo Y. Mitochondria single nucleotide variation across six blood cell types. *Mitochondrion* 2016; 28: 16-22.
411. Zhang P, Samuels DC, Zhao S, **Shyr Y**, Guo Y. Practicability of mitochondrial heteroplasmy detection through an Illumina genotyping array. *Mitochondrion* 2016; 31:75-78.
412. Arnold Egloff SA, Du L, Loomans HA, Starchenko A, Su PF, Ketova T, Knoll PB, Wang J, Haddad AQ, Fadare O, Cates JM, Lotan Y, **Shyr Y**, Clark PE, Zijlstra A. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. *Oncotarget* 2017; 8(1):722-741.
413. Chen Z, Soutto M, Rahman B, Fazili MW, Peng D, Piazuolo MB, Chen H, Washington MK, **Shyr Y**, El-Rifai W. Integrated expression analysis identifies transcription networks in mouse and human gastric neoplasia. *Genes Chromosomes Cancer* 2017; 56(7):535-547.
414. Galadanci N, Abdullahi SU, Vance LD, Tabari AM, Ali S, Belonwu R, Salihu A, Galadanci AA, Jibir BW, Bello-Manga H, Neville K, Kirkham FJ, **Shyr Y**, Phillips S, Covert BV, Kassim AA, Jordan LC, Aliyu MH, DeBaun MR. Feasibility Trial for Primary Stroke Prevention in Children with Sickle Cell Anemia in Nigeria (SPIN Trial). *Am J Hematol* 2017; 92(8):780-788.
415. Giltane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, Gómez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, **Shyr Y**, Meszoely I, Balko JM, Arteaga CL. Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. *Sci Transl Med* 2017; 9(402): pii: eaai7993.
416. Guise NB, Koonce TY, Kusnoor SV, Prather AA, Gottlieb LM, Huang LC, Phillips SE, **Shyr Y**, Adler NE, Stead WW. Institute of Medicine Measures of Social and Behavioral Determinants of Health: A Feasibility Study. *Am J Prev Med* 2017; 52(2):199-206.
417. Guo Y, Dai Y, Yu H, Zhao S, Samuels DC, **Shyr Y**. Improvements and impacts of GRCh38 human reference on high throughput sequencing data analysis. *Genomics* 2017; 109(2):83-90.
418. Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, Pietenpol J, **Shyr Y**. Comparative Study of Exome Copy Number Variation Estimation Tools Using Array Comparative Genomic Hybridization as Control. *Biomed Res Int.*; 2017:7409598. PMID: PMC5540237.
419. Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders M, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KN, Sanchez V, Rosenbluth JM, Dillon PM, Ferrero-Torres A, Chang JC, Meszoely I, Grau A, Lehmann BD, **Shyr Y**, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC). *Clin Cancer Res* 2017. PMID: PMC5540799
420. Li Cl, Samuels DC, Zhao YY, **Shyr Y**, Guo Y. Power and sample size calculations for high-throughput sequencing-based experiments. *Brief Bioinformatics* 2017; [E-pub ahead of print]
421. Liu Q, Wang J, Zhao Y, Li Cl, Stengel KR, Acharya P, Johnston G, Hiebert SW, **Shyr Y**. Identification of active miRNA promoters from nuclear run-on RNA sequencing. *Nucleic Acids Res* 2017; 45: 13. PMID: 28460090.
422. Peng D, Guo Y, Chen H, Zhao S, Washington K, Hu T, **Shyr Y**, El-Rifai W. Integrated molecular analysis reveals complex interactions between genomic and epigenomic alterations in esophageal adenocarcinomas. *Scientific Reports* 2017; 7:40729.
423. Schulte ML, Hight MR, Ayers GD, Liu Q, **Shyr Y**, Washington MK, Manning HC. Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo. *Mol Imaging Biol* 2017; 19(3):421-428. PMID: 27770401

424. Esbenshade AJ, Zhao Z, Aftandilian C, Saab R, Wattier RL, Beauchemin M, Miller TP, Wilkes JJ, Kelly MJ, Fernbach A, Jeng M, Schwartz CL, Dvorak CC, **Shyr Y**, Moons KGM, Sulis ML, Friedman DL. Multisite external validation of a risk prediction model for the diagnosis of blood stream infection in febrile pediatric oncology patients without severe neutropenia. *Cancer* 2017; [E-pub ahead of print]
425. Su PF, Mau YL, Guo Y, Li CI, Liu Q, Boice JD, **Shyr Y**. Bivariate Poisson models with varying offsets: an application to the paired mitochondrial DNA dataset. *Stat Appl Genet Mol Biol* 2017; 16(1):47-58.
426. Thomas, CR Jr, **Shyr Y**. Determining Penetration of Prostate-Specific Antigen Screening Recommendations. *Jama Oncology* 2017; 3(5):707.
427. Tu C, Shen S, Sheng Q, **Shyr Y**, Qu J. A peptide-retrieval strategy enables significant improvement of quantitative performance without compromising confidence of identification. *J Proteomics* 2017; 152:276-282.
428. Vlacich G, Stavas MJ, Pendyala P, Chen SC, **Shyr Y**, Cmelak AJ. A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer. *Radiation Oncology* 2017; 12(1):13. PMID: PMC5237132.
429. Wang J, Samuels DC, **Shyr Y**, Guo Y. StrandScript: Evaluation of Illumina Genotyping Array Design and Strand Correction. *Bioinformatics* 2017; Aug 1;33(15):2399-2401. PMID: 28402386.
430. Wang YA, Sun Y, Palmer JD, Solomides C, Huang LC, **Shyr Y**, Dicker AP, Lu B. IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling. *Mol Cancer Res* 2017; 15(7):896-904.
431. Zhang P, Lehmann BD, Samuels DC, Zhao S, Zhao YY, **Shyr Y**, Guo Y. Estimating relative mitochondrial DNA copy number using high throughput sequencing data. *Genomics* 2017; [E-pub ahead of print].
432. Zhang P, Lehmann BD, **Shyr Y**, Guo Y. The Utilization of Formalin Fixed-Paraffin-Embedded Specimens in High Throughput Genomic Studies. *Int J Genomics* 2017; 2017:1926304. PMID: 5299160.
433. Zhao S, Jing W, Samuels DC, Sheng Q, **Shyr Y**, Guo Y. Strategies for processing and quality control of Illumina genotyping arrays. *Brief Bioinform* 2017; [E-pub ahead of print]
434. Wang J, Samuels DC, **Shyr Y**, Guo Y. StrandScript: evaluation of Illumina genotyping array design and strand correction. *Bioinformatics* 2017; 33(15):2399-2401. PMID: 28402386.
435. Galadanci NA, Umar Abdullahi S, Vance LD, Musa Tabari A, Ali S, Belonwu R, Salihu A, Amal Galadanci A, Wudil Jibir B, Bello-Manga H, Neville K, Kirkham FJ, **Shyr Y**, Phillips S, Covert BV, Kassim AA, Jordan LC, Aliyu MH, DeBaun MR. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN Trial). *Am J Hematol* 2017; 92(8):780-788. PMID: 28539953.
436. Liu Q, Wang J, Zhao Y, Li CI, Stengel KR, Acharya P, Joshnston G, Hiebert SW, **Shyr Y**. Identification of active miRNA promoters from nuclear run-on RNA sequencing. *Nucleic Acids Res* 2017; 45(13):e121. PMID: 28460090.
437. Esbenshade AJ, Zhao Z, Aftandilian C, Saab R, Wattier RL, Beauchemin M, Miller TP, Wilkes JJ, Kelly MJ, Fernbach A, Jeng M, Schwartz CL, Dvorak CC, **Shyr Y**, Moons KGM, Sulis ML, Friedman DL. Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia. *Cancer* 2017; 123(19):3781-3790. PMID: 28542918.
438. Li CI, Samuels DC, Zhao YY, **Shyr Y**, Guo Y. Power and sample size calculations for high-throughput sequencing-based experiments. *Brief bioinform* 2017; [Epub ahead of print].
439. Zhang P, Lehmann BD, Samuels DC, Zhao S, Zhao YY, **Shyr Y**, Guo Y. Estimating relative mitochondrial DNA copy number using high throughput sequencing data. *Genomics* 2017; 109(5-6). PMID: 28734953.
440. Giltneane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, Gómez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, **Shyr Y**, Meszoely I, Balko JM, Arteaga CL. Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. *Sci Transl Med* 2017; 9(402). PMID: 28734953.

441. Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, Pietenpol J, **Shyr Y**. Corrigendum to “Comparative Study of Exome Copy Number Variation Estimation Tools Using Array Comparative Genomic Hybridization as Control. *Biomed Res Int* 2017; 2017:7409598. PMID: 28804721.
442. Guo Y, Zhao S, Sheng Q, Samuels DC, **Shyr Y**. The discrepancy among single nucleotide variants detected by DNA and RNA high throughput sequencing data. *BMC Genomics* 2017; 18(Suppl6):690. PMID: 28984205.
443. Sun HC, Xie L, Yang XR, Li W, Yu J, Zhu XD, Xia Y, Zhang T, Xu Y, Hu B, Du LP, Zeng LY, Ouyang J, Zhang W, Song TQ, Li Q, Shi YH, Zhou J, Qiu SJ, Liu Q, Li YX, Tang ZY, **Shyr Y**, Shen F, Fan J. Shanghai Score: A Prognostic and Adjuvant Treatment-evaluating System Constructed for Chinese Patients with Hepatocellular Carcinoma after Curative Resection. *Chin Med J* 2017; 130(22):2650-2660. PMID: 291133751.
444. Almodovar K, Iams WT, Meador CB, Zhao Z, York S, Horn L, Yan Y, Hernandez J, Chen H, **Shyr Y**, Lim LP, Raymond CK, Lovly CM. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. *J Thorac Oncol* 2018; 13(1):112-123. PMID: 28951314.
445. Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, **Shyr Y**, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations – The Lung Cancer Mutation Consortium (LCMC2). *Clin Cancer Res* 2018 24(5): 1038-1047. PMID: 29217530.
446. Ma D, Tu C, Sheng Q, Yang Y, Kan Z, Guo Y, **Shyr Y**, Scott IC, Lou X. Dynamics of Zebrafish Heart Regeneration Using an HPLC-ESI-MS/MS Approach. *J Proteome Res* 2018 17(3): 1300-1308. PMID: 29369637.
447. Galadanci NA, Umar Abdullahi S, Vance LD, Musa Tabari A, Ali S, Belonwu R, Saliyu A, Amal Galadanci A, Wudil Jibir B, Bello-Manga H, Neville K, Kirkham FJ, **Shyr Y**, Phillips S, Covert BV, Kassim AA, Jordan LC, Aliyu MH, DeBaun MR. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN Trial). *Am J Hematol* 2018; 93(3):E83. PMID: 29411418.
448. Greenplate A, Wang K, Tripathy RM, Palma N, Ali SM, Stephenson PJ, Miller VA, **Shyr Y**, Guo Y, Reddy NM, Kozhaya L, Unutmaz D, Chen X, Irish JM, Dave UP. Genomic Profiling of T-Cell Neoplasms Reveals Frequent *JAK1* and *JAK3* Mutations with Clonal Evasion from Targeted Therapies. *JCO Precision Oncology* 2018 [Online]. PMID: 30079384.
449. Gelbard A, **Shyr Y**, Berry L, Hillel AT, Ekbohm DC, Edell ES, Kasperbauer JL, Lott DG, Donovan DT, Garrett CG, Sandhu G, Daniero JJ, Nettekville JL, Schindler JS, Smith ME, Bryson PC, Lorenz RR, Francis DO. Treatment options in idiopathic subglottic stenosis: protocol for a prospective international multicenter pragmatic trial. *BMJ Open* 2018; 8(4):e022243. PMID: 29643170.
450. Ye F, Sheng Q, Feuerer ID, Zhao Z, Fan R, Teng J, Rega SA, Hanto DW, **Shyr Y**, Karp SJ. Directed solutions to address differences in access to liver transplantation. *Am J Transplant* 2018 18(11): 2670-2678. PMID: 29689125.
451. Zhao S, Li CI, Guo Y, Sheng Q, **Shyr Y**. RNASeqSampleSize: real data based sample size estimation for RNA sequencing. *BMC Bioinformatics* 2018; 19(1): 191. PMID: 29843589.
452. Allen RM, Zhao S, Ramirez Solano MA, Zhu W, Michell DL, Wang Y, **Shyr Y**, Sethupathy P, Linton MF, Graf GA, Sheng Q, Vickers KC. Bioinformatic analysis of endogenous and exogenous small RNAs on lipoproteins. *J Extracell Vesicles* 2018 Aug 13;7(1): 1506198. PMID: 30128086.
453. Iams WT, Yu H, **Shyr Y**, Patil T, Horn L, McCoach C, Kelly K, Doebele RC, Camidge DR. First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer with Different Prognostic Significance. *Clin Lung Cancer* 2018. PMID: 30197261.
454. Wang J, Zhao Y, Zhou X, Hiebiert SW, Liu Qi, & **Shyr Y**. Nascent RNA sequencing analysis provides insights into enhancer-mediated gene regulation. *BMC Genomics* 2018 19(1): 633. PMID: 30139328.

455. Wang J, Dai X, Berry LD, Cogan JD, Liu Q, **Shyr Y**. HACER: an atlas of human active enhancers to interpret regulatory variants. *Nucleic Acids Research* 2018 47(D1): D106-D112. PMID: PMC6323890.
456. Laroumanie F, Korneva A, Bersi MR, Alexander MR, Xiao L, Zhong X, Van Beusecum JP, Chen Y, Saleh MA, McMaster WG, Gavulic KA, Dale BL, Zhao S, Guo Y, **Shyr Y**, Perrien DS, Cox NJ, Curci JA, Humphrey JD, Madhur MS. LNK deficiency promotes acute aortic dissection and rupture. *JCI Insight* 2018 3(20): e122558. PMID: PMC6237478.
457. Liu Q, Herring CA, Sheng Q, Ping J, Simmons AJ, Chen B, Baberjee A, Li W, Gu G, Coffey RJ, **Shyr Y**, Lau KS. Quantitative assessment of cell population diversity in single-cell landscapes. *PLOS Biology* 2018 16(10): e2006687. PMID: PMC6211764.
458. Liu B, **Shyr Y**, Cai J, Liu Q. Interplay between miRNAs and host genes and their role in cancer. *Brief Funct Genomics*. 2018 Jul 22;18(4):255-266. doi: 10.1093/bfgp/elz002. PMID: 30785618; PMID: PMC6609535.
459. Hemnes AR, Luther JM, Rhodes CJ, Burgess JP, Carlson J, Fan R, Fessel JP, Fortune N, Gerszten RE, Halliday SJ, Hekmat R, Howard L, Newman JH, Niswender KD, Pugh ME, Robbins IM, Sheng Q, Shibao CA, **Shyr Y**, Sumner S, Talati M, Wharton J, Wilkins MR, Ye F, Yu C, West J, Brittain EL. Human PAH is characterized by a pattern of lipid-related insulin resistance. *JCI Insight*. 2019 Jan 10;4(1):e123611. doi: 10.1172/jci.insight.123611. Epub ahead of print. PMID: 30626738; PMID: PMC6485674.
460. Blum AE, Venkitachalam S, Ravillah D, Chelluboyina AK, Kieber-Emmons AM, Ravi L, Kresak A, Chandar AK, Markowitz SD, Canto MI, Wang JS, Shaheen NJ, Guo Y, **Shyr Y**, Willis JE, Chak A, Varadan V, Guda K. Systems biology analyses reveal hyperactivation of transforming growth factor beta and JNK signaling pathways in esophageal cancer. *Gastroenterology* 2019. 156(6):1761-1774.
461. Yu H, Wang J, Sheng Q, Liu Q, **Shyr Y**. beRBP: binding estimation for human RNA-binding proteins. *Nucleic Acids Res*. 2019 Mar 18;47(5):e26. doi: 10.1093/nar/gky1294. PMID: 30590704; PMID: PMC6411931.
462. Sweeting RS, Du L, **Shyr Y**, Hooks MA. Income, costs, and health care utilization may influence surgical choice in early stage breast cancer. *The Breast Journal* 2019 25(2): 334-337. PMID: 30803098.
463. Feld E, Singhi EK, Phillips S, Huang LC, **Shyr Y**, Horn L. Palliative care referrals for advanced non-small-cell lung cancer (NSCLC): patient and provider attitudes and practices. *Clinical Lung Cancer* 2019 20(3):e291-e298.
464. Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, **Shyr Y**, Mayer IA, Balko JM, Arteaga CL. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. *Nature Communications* 2019 10(1):1373. PMID: 30914635.
465. Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sanchez V, **Shyr Y**, Sanders ME, Pietenpol JA. Identification of targetable recurrent MAP3K8 rearrangements in melanomas lacking known driver mutations. *Molecular Cancer Research* 2019 17(9):1842-1853.
466. Cunningham I, Hamele-Bena D, Guo Y, Shiomi T, Papp AC, Chakvarti B, Yang J, **Shyr Y**, Fisher RA. Extramedullary leukemia behaving as solid cancer: Clinical, histologic, and genetic clues to chemoresistance in organ sites. *American Journal of Hematology* 2019 94(11):1200-1207.
467. Wood M, George TJ, Manochakian R, Polansky M, Baer A, Grupe A, **Shyr Y**, Wang C, Horn L. Quantitative Assessment of Learning Behaviors for Oncology Providers. *J Cancer Educ*. 2019 Aug 3. doi: 10.1007/s13187-019-01593-4. Epub ahead of print. PMID: 31377987.
468. Liu Q, Sheng Q, Ping J, Ramirez MA, Lau KS, Coffey RJ, **Shyr Y**. scRNABatchQC: multi-samples quality control for single cell RNA-seq data. *Bioinformatics* 2019 35(24): 5306–5308.
469. Gelbard A, Anderson C, Berry LD, Amin MR, Benninger MS, Blumin JH, Bock JM, Bryson PC, Castellanos PF, Chen SC, Clary MS, Cohen SM, Crawley BK, Dailey SH, Daniero JJ, de Alarcon A, Donovan DT, Edell ES, Ekblom DC, Fernandes-Taylor S, Fink DS, Franco RA, Garrett CG, Guardiani EA, Hillel AT, Hoffman HT, Hogikyan ND, Howell RJ, Huang LC, Hussain LK, Johns MM 3rd, Kasperbauer JL, Khosla SM, Kinnard C, Kupfer RA, Langerman AJ, Lentz RJ, Lorenz RR, Lott DG, Lowery AS, Makani SS, Maldonado F, Mannion K, Matrka L, McWhorter AJ, Merati AL, Mori MC, Netterville JL, O'Dell K,

- Ongkasuwan J, Postma GN, Reder LS, Rohde SL, Richardson BE, Rickman OB, Rosen CA, Rutter MJ, Sandhu GS, Schindler JS, Schneider GT, Shah RN, Sikora AG, Sinard RJ, Smith ME, Smith LJ, Soliman AMS, Sveinsdóttir S, Van Daele DJ, Veivers D, Verma SP, Weinberger PM, Weissbrod PA, Wootten CT, **Shyr Y**, Francis DO. Comparative Treatment Outcomes for Patients With Idiopathic Subglottic Stenosis. *JAMA Otolaryngol Head Neck Surg*. 2019 Oct 31;146(1):1-10. doi: 10.1001/jamaoto.2019.3022. Epub ahead of print. PMID: 31670805; PMCID: PMC6824232.
470. Manochakian R, George TJ, Wood M, Polansky M, Baer A, Grupe A, **Shyr Y**, Wang C, Horn L. Establishing and Evaluating an ASCO Learning Cohort: a Longitudinal Project Assessing the Learning Needs and Behaviors of Oncology Professionals. *J Cancer Educ*. 2019 Nov 18. doi: 10.1007/s13187-019-01649-5. Epub ahead of print. PMID: 31741200.
471. Teng J, Abdygametova A, Du J, Ma B, Zhou R, **Shyr Y**, Ye F. Bayesian Inference of Lymph Node Ratio Estimation and Survival Prognosis for Breast Cancer Patients. *IEEE J Biomed Health Inform*. 2020 Feb;24(2):354-364. doi: 10.1109/JBHI.2019.2943401. Epub 2019 Sep 24. PMID: 31562112.
472. Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, **Shyr Y**, Arteaga CL, Wolff AC, Pietenpol JA; Translational Breast Cancer Research Consortium. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. *Clin Cancer Res*. 2020 May 1;26(9):2111-2123. doi: 10.1158/1078-0432.CCR-19-2170. Epub 2019 Dec 10. PMID: 31822498; PMCID: PMC7196503.
473. Lai CH, Huang LC, Holby SN, Lai YJ, Su PF, Cheng YS, **Shyr Y**, Hsi RS. Kidney Stone History and Adverse Outcomes After Percutaneous Coronary Intervention. *Urology*. 2020 Feb;136:75-81. doi: 10.1016/j.urology.2019.10.009. Epub 2019 Nov 4. PMID: 31697954; PMCID: PMC7008077.
474. Das S, Ciombor KK, Haraldsdóttir S, Pumpalova Y, Sahin IH, Pineda G, **Shyr Y**, Lin EP, Hsu CY, Chu SK, Goff LW, Cardin DB, Bilen MA, Fisher GA, Wu C, Berlin J. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. *Oncologist*. 2020 Jan 14. doi: 10.1634/theoncologist.2019-0637. Epub ahead of print. PMID: 31943525.
475. George TJ, Manochakian R, Wood M, Polansky M, Baer A, Grupe A, **Shyr Y**, Wang C, Williams J, Horn L. Quantitative Analysis of Oncology Professional Learning Preferences. *JCO Oncol Pract*. 2020 Feb;16(2):e155-e165. doi: 10.1200/JOP.18.00731. Epub 2020 Jan 7. PMID: 32045553.
476. Schafer JM, Lehmann BD, Gonzalez-Ericsson PI, Marshall CB, Beeler JS, Redman LN, Jin H, Sanchez V, Stubbs MC, Scherle P, Johnson KN, Sheng Q, Roland JT, Bauer JA, **Shyr Y**, Chakravarthy B, Mobley BC, Hiebert SW, Balko JM, Sanders ME, Liu PCC, Pietenpol JA. Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. *Sci Transl Med*. 2020 Mar 11;12(534):eaaw8275. doi: 10.1126/scitranslmed.aaw8275. PMID: 32161105.
477. Wang M, Lin EP, Huang LC, Li CY, **Shyr Y**, Lai CH. Mortality of Cardiovascular Events in Patients With COPD and Preceding Hospitalization for Acute Exacerbation. *Chest*. 2020 Mar 14:S0012-3692(20)30443-8. doi: 10.1016/j.chest.2020.02.046. Epub ahead of print. PMID: 32184108.
478. Kuderer* NM, Choueiri* TK, Shah* DP, **Shyr* Y**, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet*. 2020 Jun 20;395(10241):1907-1918. doi: 10.1016/S0140-6736(20)31187-9. Epub 2020 May 28. PMID: 32473681; PMCID: PMC7255743.
479. Lai CH, Hsieh CY, Barnado A, Huang LC, Chen SC, Tsai LM, **Shyr Y**, Li CY. Outcomes of acute cardiovascular events in rheumatoid arthritis and systemic lupus erythematosus: a population-based study. *Rheumatology (Oxford)*. 2020 Jun 1;59(6):1355-1363. doi: 10.1093/rheumatology/kez456. PMID: 31600392.

480. Price^{*} CC, Altice^{*} FL, **Shyr Y^{*}**, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients: Survival and Clinical Outcomes. *Chest*. 2020 Jun 15:S0012-3692(20)31670-6. doi: 10.1016/j.chest.2020.06.006. Epub ahead of print. PMID: 32553536.
481. Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, Rubinstein SM, Lee BJ, Choueiri TK, de Lima Lopes G, Grivas P, Painter CA, Rini BI, Thompson MA, Arcobello J, Bakouny Z, Doroshow DB, Egan PC, Farmakiotis D, Fecher LA, Friese CR, Galsky MD, Goel S, Gupta S, Halfdanarson TR, Halmos B, Hawley JE, Khaki AR, Lemmon CA, Mishra S, Olszewski AJ, Pennell NA, Puc MM, Revankar SG, Schapira L, Schmidt A, Schwartz GK, Shah SA, Wu JT, Xie Z, Yeh AC, Zhu H, **Shyr Y^{*}**, Lyman GH^{*}, Warner JL^{*}. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study. *Cancer Discov*. 2020 Jul 22:CD-20-0941. doi: 10.1158/2159-8290.CD-20-0941. Epub ahead of print. PMID: 32699031.
482. **Shyr Y**, Shyr D. What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials? *JAMA Oncol*. 2020 Jul 23. doi: 10.1001/jamaoncol.2020.1847. Epub ahead of print. PMID: 32701117.
483. Li C, Sun YD, Yu GY, Cui JR, Lou Z, Zhang H, Huang Y, Bai CG, Deng LL, Liu P, Zheng K, Wang YH, Wang QQ, Li QR, Wu QQ, Liu Q, **Shyr Y**, Li YX, Chen LN, Wu JR, Zhang W, Zeng R. Integrated Omics of Metastatic Colorectal Cancer. *Cancer Cell*. 2020 Aug 25:S1535-6108(20)30413-X. doi: 10.1016/j.ccell.2020.08.002. Epub ahead of print. PMID: 32888432.
484. Strayer N, Shirey-Rice JK, **Shyr Y**, Denny JC, Pulley JM, Xu Y. PheWAS-ME: a web-app for interactive exploration of multimorbidity patterns in PheWAS. *Bioinformatics*. 2020 Oct 14:btaa870. doi: 10.1093/bioinformatics/btaa870. Epub ahead of print. PMID: 33051675.
485. COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org; COVID-19 and Cancer Consortium. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. *Cancer Cell*. 2020 Oct 29:S1535-6108(20)30553-5. doi: 10.1016/j.ccell.2020.10.022. Epub ahead of print. PMID: 33176160; PMCID: PMC7598547.
486. Alvarado-Cruz I, Mahmoud M, Khan M, Zhao S, Oeck S, Meas R, Clairmont K, Quintana V, Zhu Y, Porciuncula A, Wyatt H, Ma S, **Shyr Y**, Kong Y, LoRusso PM, Laverty D, Nagel ZD, Schalper KA, Krauthammer M, Sweasy JB. Differential immunomodulatory Effect of PARP Inhibition in BRCA1 deficient and competent tumor cells. *Biochem Pharmacol*. 2020 Dec 4:114359. doi: 10.1016/j.bcp.2020.114359. Epub ahead of print. PMID: 33285109.
487. **Shyr Y**, Berry LD, Hsu CY. Scientific Rigor in the Age of COVID-19. *JAMA Oncol*. 2020 Dec 10. doi: 10.1001/jamaoncol.2020.6639. Epub ahead of print. PMID: 33300984.
488. Shyr D, **Shyr Y**. The design and analysis of non-randomized studies: a case study of off-label use of hydroxychloroquine in the COVID-19 pandemic. *Expert Opin Investig Drugs*. 2020 Dec 29:1-7. doi: 10.1080/13543784.2021.1868435. Epub ahead of print. PMID: 33353432.
489. Ou FS, Michiels S, **Shyr Y**, Adjei AA, Oberg AL. Biomarker Discovery and Validation: Statistical Considerations. *J Thorac Oncol*. 2021 Feb 2:S1556-0864(21)01663-4. doi: 10.1016/j.jtho.2021.01.1616. Epub ahead of print. PMID: 33545385.
490. Osarogiagbon RU, Smeltzer MP, Faris NR, Ray MA, Fehnel C, Ojeabulu P, Akinbobola O, Meadows-Taylor M, McHugh LM, Halal AM, Levy P, Sachdev V, Talton R, Wiggins L, Shu XO, **Shyr Y**, Robbins ET, Klesges LM. Outcomes Following Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study. *J Thorac Oncol*. 2021 Feb 16:S1556-0864(21)01658-0. doi: 10.1016/j.jtho.2020.12.025. Epub ahead of print. PMID: 33607311.
491. Lee J, Huang LC, Berry LD, Anderson C, Amin MR, Benninger MS, Blumin JH, Bock JM, Bryson PC, Castellanos PF, Chen SC, Clary MS, Cohen SM, Crawley BK, Dailey SH, Daniero JJ, de Alarcon A, Donovan DT, Edell ES, Ekbohm DC, Fink DS, Franco RA, Garrett CG, Guardiani EA, Hillel AT, Hoffman HT, Hogikyan ND, Howell RJ, Hussain LK, Johns MM, Kasperbauer JL, Khosla SM, Kinnard C, Kupfer RA, Langerman AJ, Lentz RJ, Lorenz RR, Lott DG, Lowery AS, Makani SS, Maldonado F, Mannion K, Matrka L, McWhorter AJ, Merati AL, Mori M, Netterville JL, O'Dell K, Ongkasuwan J, Postma GN, Reder

- LS, Rohde SL, Richardson BE, Rickman OB, Rosen CA, Rutter MJ, Sandhu GS, Schindler JS, Schneider GT, Shah RN, Sikora AG, Sinard RJ, Smith ME, Smith LJ, Soliman AMS, Sveinsdóttir S, Van Daele DJ, Veivers D, Verma SP, Weinberger PM, Weissbrod PA, Wootten CT, **Shyr Y**, Francis DO, Gelbard A. Association of Social Determinants of Health with Time to Diagnosis and Treatment Outcomes in Idiopathic Subglottic Stenosis. *Ann Otol Rhinol Laryngol*. 2021 Feb 25;3489421995283. doi: 10.1177/0003489421995283. Epub ahead of print. PMID: 33629608.
492. Kim J, Cardin D, Vaishampayan U, Kato S, Grossman S, Glazer P, **Shyr Y**, Ivy S, LoRusso P. Clinical activity and safety of cediranib and olaparib combination in patients with metastatic pancreatic ductal adenocarcinoma without BRCA mutation. *Oncologist*. 2021 Mar 20. doi: 10.1002/onco.13758. Epub ahead of print. PMID: 33742489.
493. Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, **Shyr Y**, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilan MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshov DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes GD Jr. Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium. *Ann Oncol*. 2021 Mar 18:S0923-7534(21)00874-7. doi: 10.1016/j.annonc.2021.02.024. Epub ahead of print. PMID: 33746047; PMCID: PMC7972830.
494. Hsu CY, Lin EP, **Shyr Y**. Development and Evaluation of a Method to Correct Misinterpretation of Clinical Trial Results With Long-term Survival. *JAMA Oncol*. 2021 Apr 15. doi: 10.1001/jamaoncol.2021.0289. Epub ahead of print. PMID: 33856410.
495. Fang WB, Sofia Acevedo D, Smart C, Zinda B, Alissa N, Warren K, Fraga G, Huang LC, **Shyr Y**, Li W, Xie L, Staggs V, Hong Y, Behbod F, Cheng N. Expression of CCL2/CCR2 signaling proteins in breast carcinoma cells is associated with invasive progression. *Sci Rep*. 2021 Apr 22;11(1):8708. doi: 10.1038/s41598-021-88229-0. PMID: 33888841.
496. Guo Y, Yu H, Song H, He J, Oyebamiji O, Kang H, Ping J, Ness S, **Shyr Y**, Ye F. MetaGSCA: A tool for meta-analysis of gene set differential coexpression. *PLoS Comput Biol*. 2021 May 4;17(5):e1008976. doi: 10.1371/journal.pcbi.1008976. Epub ahead of print. PMID: 33945541.
497. Yang J, Zhao S, Wang J, Sheng Q, Liu Q, **Shyr Y**. Immu-Mela: An open resource for exploring immunotherapy-related multidimensional genomic profiles in melanoma. *J Genet Genomics*. 2021 May 14:S1673-8527(21)00101-6. doi: 10.1016/j.jgg.2021.03.016. Epub ahead of print. PMID: 34127402.
498. Wilfong EM, Lovly CM, Gillaspie EA, Huang LC, **Shyr Y**, Casey JD, Rini BI, Semler MW. Severity of illness scores at presentation predict ICU admission and mortality in COVID-19. *J Emerg Crit Care Med*. 2021 Jan;5:7. doi: 10.21037/jeccm-20-92. Epub 2021 Jan 25. PMID: 34179689; PMCID: PMC8232354.
499. Li A, Kuderer NM, Hsu CY, **Shyr Y**, Warner JL, Shah DP, Kumar V, Shah S, Kulkarni AA, Fu J, Gulati S, Zon RL, Li M, Desai A, Egan PC, Bakouny Z, Kc D, Hwang C, Akpan IJ, McKay RR, Girard J, Schmidt AL, Halmos B, Thompson MA, Patel JM, Pennell NA, Peters S, Elshoury A, de Lima Lopes G, Stover DG, Grivas P, Rini BI, Painter CA, Mishra S, Connors JM, Lyman GH, Rosovsky RP; CCC19 consortium. The CoVID-TE Risk Assessment Model for Venous Thromboembolism in Hospitalized Patients with Cancer and COVID-19. *J Thromb Haemost*. 2021 Jul 14. doi: 10.1111/jth.15463. Epub ahead of print. PMID: 34260813.
500. Von Hoff DD, Clark GM, Coltman CA, Disis ML, Eckhardt SG, Ellis LM, Foti M, Garrett-Mayer E, Gonen M, Hidalgo M, Hilsenbeck SG, Littlefield JH, LoRusso PM, Lyerly HK, Meropol NJ, Patel JD, Piantadosi S, Post DA, Regan MM, **Shyr Y**, Tempero MA, Tepper JE, Von Roenn J, Weiner LM, Young DC, Vu NV.

A grant-based experiment to train clinical investigators: the AACR/ASCO methods in clinical cancer research workshop. *Clin Cancer Res.* 2021 Jul 26;clincanres.1799.2021. doi: 10.1158/1078-0432.CCR-21-1799. Epub ahead of print. PMID: 34312215.

501. Chen HC, Wang J, Liu Q, **Shyr Y**. A domain damage index to prioritizing the pathogenicity of missense variants. *Hum Mutat.* 2021 Aug 5. doi: 10.1002/humu.24269. Epub ahead of print. PMID: 34350656.
502. Liu B, **Shyr Y**, Liu Q. Pan-Cancer Analysis Reveals Common and Specific Relationships between Intragenic miRNAs and Their Host Genes. *Biomedicines.* 2021 Sep 18;9(9):1263. doi: 10.3390/biomedicines9091263. PMID: 34572448; PMCID: PMC8471046.

PAPERS DELIVERED AT PROFESSIONAL MEETINGS AND ABSTRACTS — MORE THAN 545